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General introduction
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Eric (21): “Since a couple of weeks, whenever I go outside of my house, I get the feeling 
that I am being watched by someone through cameras. I do not know who is watching 
me or why I am being watched, but it makes me very uncomfortable. Although I am not a 
100% sure about it and when I am at home again I think I am being silly for thinking this, 
it prevents me from going outside of my house unless I really need to.”
Eric also reported he was feeling more down and less energetic over the last couple of 
months. He was spending less time on his studies because he found it more difficult 
to focus. He also spent less time with his friends, because he felt uncomfortable when 
leaving his house, although when he was with his friends he could enjoy spending time 
with them.
Lisa (16): “When I am alone a male voice starts talking and sometimes even shouting at 
me… The voice is telling me I am dumb and ugly and that I have to hurt myself. The voice 
never stops when I am alone, the volume goes down a bit when I put music on very loud 
but it never goes away completely. It makes me very anxious and depressed, I can hardly 
sleep because of it and I cannot focus on anything else.”
Lisa had been treated for over a year for depressive symptoms, she was failing in school, 
having dropped out in the last 4 weeks before the summer holiday and now sat alone in 
her room for most of the time. She had contact with one friend, although only via text 
messages. She had shared with her parents and her therapist that she had as a young 
girl been a victim of sexual abuse. However, she was very afraid to tell her parents and 
therapist about these frightening experiences that had slowly developed after her de-
pressive symptoms had started.
These are just two examples of the many different (subclinical) psychotic symptoms re-
ported by young people who shared their personal stories with me during the clinical 
diagnostic interviews I conducted in search for individuals at ‘clinical high risk’ for psy-
chosis (CHR-P) and individuals who (had) experienced a first episode of psychosis (FEP). 
In addition to their psychotic experiences, both are reporting reduced social and role 
functioning. Lisa was experiencing an almost continuous auditory hallucination (state-
ment 2) and was suffering from a psychotic episode. In contrast, Eric’s suspicious beliefs 
(statement 1) were not fully crystallised and had not crossed the psychosis threshold. 
His symptoms were still at a ‘subclinical’ or ‘attenuated’ level that met criteria for being 
‘at clinical high risk’ for the development of a psychotic episode. These statements illus-
12  |  Chapter 1
trate that both full-blown and subclinical psychotic symptoms are often associated with 
distress and a drop in social and role functioning.
From psychotic-like experiences and subclinical symptoms to psychotic disorder
Psychotic disorders are associated with a high burden for patients themselves as well 
as for their family members and friends. This is directly due to significant impairments 
in academic performance and occupational functioning, difficulties with interpersonal 
relationships and substantially compromised subjective quality of life, as well as a high fi-
nancial burden due to costs for providing care and indirectly by loss of productivity1. It is 
therefore important to gain more insight in the developmental mechanisms of psychotic 
disorders, which will help to optimize early interventions targeting both symptom reduc-
tion and improvement of functioning and quality of life. The goal of early intervention 
is to prevent transition to full blown psychotic symptoms in CHR-P individuals as well as 
preventing the development of recurrent symptoms in those who have experienced a 
first psychotic episode.
In order to elucidate the complex and multi-factorial aetiology of psychotic disorder, in 
which genetic and environmental factors including obstetric complications, urbanization, 
migration, cannabis use, and childhood trauma as well as their interactions are implicat-
ed2, 3, focus has shifted from the population of psychotic disorder patients, especially 
schizophrenic patients, to individuals with subclinical expressions of positive psychotic 
symptoms at the lower end of the psychosis continuum. These include psychotic-like ex-
periences (PLEs, based on self-report measures) or true subclinical psychotic symptoms 
reported by individuals from the general population, CHR-P patients and unaffected 
first-degree relatives of psychotic patients. Investigation of subclinical symptoms allows 
examination of factors that precede transition to psychosis and more importantly impact 
on functioning, irrespective of an eventual specific psychotic disorder diagnosis.  
From a research perspective using general population samples has the important ad-
vantage that subclinical psychotic symptoms are much more prevalent than psychotic 
disorders and inclusion does not dependent on help-seeking. This allows for true popu-
lation-based epidemiological research into the pathophysiology, course and treatment 
of subclinical symptoms in representative population-based contexts. The advantage of 
studying CHR-P patients and unaffected first-degree relatives is that average transition 
rates of 22-36%4 and 10%6  respectively, are much higher than the transition rate of 0.6% 
in the general population4, 5. This allows for investigation of factors related to transition 
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as well as protective factors in non-converters. First-degree relatives of psychotic dis-
order patients also show an increased risk of developing psychotic disorder compared 
to individuals from the general population (respectively 10% compared to 0.6%)5, 6. Ad-
ditionally, these first-degree relatives also report more subclinical psychotic symptoms 
than healthy controls7-9 and they share both a genetic vulnerability and environmental 
risk factors with their affected relative. Investigation of PLEs and subclinical psychotic 
symptoms will help to determine the pathway from early expression on towards clinical 
needs, especially in longitudinal studies in which these samples are repeatedly assessed 
over time. This allows prospective investigation of psychosocial risk factors for psychotic 
illness development and the role of comorbid psychopathology in the progression to-
ward psychosis. Another important benefit of studying individuals with PLEs and subclin-
ical psychotic symptoms is that there is no confounding due to antipsychotic treatments 
or chronicity effects. 
The first part of this thesis therefore focusses on the lowest end of the psychosis con-
tinuum: PLEs and subclinical psychotic symptoms reported by individuals of the general 
population and unaffected first-degree relatives of psychosis spectrum patients. As these 
can be assessed through measures of (‘subjective’) self-report and (‘objective’) clinical 
interviews, the studies in this first part focus on the distinction between self-reported 
psychotic experiences versus ‘clinically validated’ psychotic symptoms. 
The second part of this thesis focusses on the group of help-seeking individuals with 
subclinical psychotic symptoms meeting the criteria for being ‘at clinical high risk’ for the 
development of psychosis (hereinafter: CHR-P). Studies using the Experience Sampling 
Method (ESM) in psychotic disorder patients have provided important information on 
the prevalence and phenomenology of psychotic symptoms in daily life and have shown 
that psychotic patients are characterised by increased emotional and symptomatic stress 
reactivity in response to small daily life hassles. Studies in CHR-P patients and patients 
with a first episode of psychosis will reveal whether these specific processes precede the 
onset of psychosis or if they are the result of illness progression. Specifically, studies in 
this part of the thesis investigate differences in emotional and symptomatic stress reac-
tivity, phenomenology and temporal dynamics of emotional and psychotic symptoms 
between CHR-P and (first episode) psychotic patients in the context of daily life. 
Phenomenology of psychosis
Psychotic disorders constitute a multidimensional syndrome that is expressed in a spec-
14  |  Chapter 1
trum of related diagnostic categories including schizophrenia, schizophreniform disor-
der, schizoaffective disorder, delusional disorder, brief psychotic disorder, depression/bi-
polar disorder with psychotic features, substance-induced psychotic disorder, psychotic 
disorder not otherwise classified, which affect around 3.5% of the population10. Psycho-
sis rarely occurs before the age of 14 years, but there is a sharp increase in its prevalence 
between the ages of 15-17 year11. Overall, about 50% of people who develop a psychotic 
disorder will do so by the time they are in their early 20s. The mean age of onset tends 
to be a little younger in males (18-25 years) than females (25-35 years)11, 12.
Psychotic disorders are characterised by problems recognizing and understanding real-
ity. The positive psychotic symptoms can be distinguished into (1) delusions, bizarre or 
non-bizarre in nature; (2) hallucinations, visual, auditory, tactile, gustatory and/or ol-
factory in nature; and (3) disorganised behaviour. While these positive symptoms are 
thought of as specific characteristics or ‘phenotypes’, individuals with psychotic disor-
ders often also experience other general symptoms in varying degrees across the diag-
nostic categories (i.e. transdiagnostic) forming the clinical psychosis spectrum. These 
are negative symptoms (i.e. restricted affect, anhedonia and motivational problems), 
affective dysregulation (depressive and/or (hypo) manic affect) and cognitive problems 
with regard to memory, attention, executive functioning and social cognition. Psychotic 
disorders are therefore characterised by high clinical heterogeneity and presence of psy-
chotic symptoms typically waxes and wanes, with variety in severity of symptoms and 
symptom-free periods even in chronic patients13-15.
This high clinical heterogeneity is also found at the level of subclinical or attenuated 
psychotic symptoms. The “transdiagnostic and extended psychosis phenotype”16, 17 has 
been proposed to account for the finding that (subclinical) psychotic symptoms are com-
monly reported by non-help seeking individuals from the general population, predom-
inantly during adolescence and early adulthood18-20, with a prevalence of ~7%17, 21. In 
~80% these are transient in nature, persistence occurs in the remaining ~20% and ~7% 
of individuals develop a psychotic disorder, with an annual transition rate below 1%16, 22, 
23. In this model, at any phenomenological or temporal stage along the psychosis contin-
uum may individuals become help seeking and meet CHR-P criteria, of which some will 
develop psychotic disorder. The model can account for the high comorbidity of symp-
toms24, especially anxiety and affective disturbances at clinical and subclinical level25-27. 
Importantly, this model is proposed to underlie the diagnostic categories of schizophre-
nia spectrum and bipolar disorders17, thereby overcoming the limitations of the current 
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psychiatric classification systems which consider psychiatric disorders as separate enti-
ties that do not overlap.
Although population studies have consistently reported that subclinical psychotic 
symptoms are relatively common, prevalence rates seem to be dependent upon the 
assessment strategy used. Prevalence rates in studies that rely on self-report measures 
are more than three times higher than those of studies using interview-based assess-
ments16. Furthermore, studies in which self-reported psychotic experiences (SRPE) were 
reassessed by clinical interview, only about 40% of those were then confirmed as truly 
psychotic in nature11, 12. SRPE not confirmed by clinical interview are referred to as ‘false 
positive’ (FP) SRPE. These findings highlight an important discrepancy between ‘subjec-
tive’ self-report of psychotic experiences and the ‘objective’ evaluations of clinicians. 
Van Nierop and colleagues used data from the second Netherlands Mental Health Sur-
vey and Incidence Study (NEMESIS-2)28 and found that, compared to individuals from the 
general population who had never had a psychotic experience, individuals with FP SRPE 
were characterised by higher levels of non-psychotic psychopathology and neuroticism, 
had experienced more childhood adversity and were functioning less well physically, 
socially and mentally. However, associations with psychopathology, social functioning, 
psychosocial factors as well as help seeking in general and specifically for SRPE were 
generally less strong than for those with confirmed psychotic symptoms. FP SRPE were 
therefore suggested to represent the mildest form of risk along the extended psychosis 
continuum28. However, very little is known about the course and development of FP 
SRPE over time and which psychopathological and psychosocial factors are predictive for 
possible differential outcomes.
Genetics of psychosis
The high clinical heterogeneity of psychotic disorders is mirrored by high genetic het-
erogeneity29. Although the high heritability estimates of 70-85% for schizophrenia and 
60-85% for bipolar disorder30 indicate that about 60-85% of the observed individual dif-
ferences in these patients are attributable to genetic individual differences while the 
remaining part is related to the environment, genetic studies have been unable to find 
‘the’ psychosis gene. Genome-wide association studies (GWAS) in schizophrenia patients 
have led to the discovery of large numbers (100 thousand–1 million) of genetic variants 
called ‘single nucleotide polymorphisms’ (SNPs), each associated with very small effect 
sizes that even cumulatively explain only a modest proportion of the genetic predispo-
sition for psychotic disorder31. However, the combined effect of these individual SNPs is 
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captured in a Polygenic Risk Score (PRS) calculated for each individual, which can be used 
as an index for genetic risk in studies examining the complex interactions between ge-
netic and environmental (GxE) factors underlying psychosis development. Furthermore, 
a genetic overlap between schizophrenia and affective disorders has been suggested by 
recent results of molecular genetic studies32, 33.
The clinical high risk for psychosis state
As the statement of Eric at the start of this chapter in which he describes his feelings 
of being watched and the distress and disruption in normal function he is experiencing 
illustrates, some individuals with subclinical psychotic symptoms are help-seeking and 
meet criteria for being at clinical high risk for psychosis (CHR-P), also known as the “at-
risk mental state” (ARMS), “prodromal” and ultra-high-risk (UHR) state. This construct of 
a clinical high-risk state for psychosis has been proposed in order to capture the pre-psy-
chotic phase, describing people presenting with potentially prodromal symptoms, as 
retrospective studies showed that in around three-quarter of first admitted psychotic 
disorder patients the disorder began with a prodromal phase, which lasted, on average, 
5 years34, 35. 
The CHR-P state can be diagnosed using CHR-P and/or basic symptoms (BS) criteria36 
and requires the presence of 1 or more of the following: (i) subclinical or “attenuated” 
psychotic symptoms (unusual thought content, non-bizarre ideas, perceptual abnormal-
ities and/or disorganised speech); (ii) brief limited intermittent psychotic episode (BLIP); 
(iii) trait vulnerability plus a marked decline in psychosocial functioning (i.e. genetic risk 
and deterioration syndrome [GRD]). The Comprehensive Assessment of At-Risk Men-
tal State (CAARMS)37 and the Structured Interview for Prodromal Symptoms (SIPS) (in-
cluding the companion Scale of Prodromal Symptoms [SOPS])38 are the most often used 
semi-structured interviews to determine CHR-P status. Basic symptoms are subjectively 
experienced disturbances of different domains, including perception, thought process-
ing, language, and attention, that are distinct from classic psychotic symptoms in that 
they are independent of abnormal thought content and reality testing and insight into 
the symptoms psychopathologic nature is intact39. BS are assessed with the Schizophre-
nia Proneness Instrument, adult version (SPI-A)40. 
Many individuals with psychotic experiences meeting CHR-P criteria have clinically de-
bilitating symptoms of comorbid diagnoses. Most often reported are anxiety, depression 
and substance use disorders. Similar to psychotic disorder patients, CHR-P patients are 
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often characterised by high neuroticism and high levels of negative symptoms. Signif-
icant impairments in academic performance and occupational functioning, difficulties 
with interpersonal relationships and a substantially compromised subjective quality of 
life are often observed41-46. A large meta-analysis has shown that transition risk from 
CHR-P to clinical psychosis is ~22% after 1 year, which increases to 36% after 3 years4. 
Meta-analytic results also show that CHR-P state is heterogeneous in terms of longitudi-
nal diagnoses, with 73% of transitions resulting in ‘schizophrenic’ psychoses and 11% in 
‘affective’ psychosis, so current CHR-P diagnostic criteria appear to be strongly biased to-
ward an identification of early phases of schizophrenic rather than affective psychoses47. 
Overall, the majority of CHR-P studies have focussed on transition risk, although recent 
studies of outcome in non-converters show that while the majority of individuals do not 
convert to psychosis, full remission of CHR-P status occurs in less than half of non-con-
verters, with the others still reporting subclinical psychotic symptoms48-52. Furthermore, 
nonpsychotic disorders have been found to co-occur with diagnosis of CHR-P status in 
most cases, and remain highly prevalent, in terms of incidence of new non-psychotic dis-
order and recurrence of previous disorder48, 49. The CHR-P state is therefore predictive of 
broad psychopathology in addition to transition to psychotic disorder and fits well within 
the broad model of clinical staging in psychiatry53-57. This model uses the high risk para-
digm in a broad context in which relatively non-specific sub diagnostic mental distress 
predicts not only psychotic but also non-psychotic outcome. Focus lies on early mental 
distress and non-specific interventions which can help prevent development of more 
severe, specific and relatively treatment-resistant psychiatric syndromes. This allows for 
stage-specific treatment, varying from non-specific non-pharmacological self-manage-
ment approaches in the early stages to more active treatments in the advanced stages. 
The affective pathway to psychosis: evidence from experiences sampling method studies
It has long been suggested that stress plays an important role in the emergence and 
course of psychotic disorder58-62. The vulnerability-stress model states that whenever 
a stressor exceeds the individuals’ vulnerability level psychotic symptoms will emerge. 
The individual’s vulnerability level is assumed to be a stable within-person character-
istic based on genetic predisposition. There is overwhelming epidemiological evidence 
that stressful life events63, childhood adversity64 and small everyday hassles65, 66 are 
associated with the formation and progression of psychotic symptoms. These findings 
highlight the role that environmental stress-exposure plays in both the development 
of PE in the general population21 and the trajectory towards psychotic disorders61. 
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Furthermore, poor self-esteem and neuroticism, a personality trait characterized by 
increased affective reactivity and sensitivity to stress67, often characterise psychotic 
patients and CHR-P individuals46, 68 and have been found to predict onset of psychotic 
symptoms69. 
A promising approach to help elucidate the role of stress as a potential causal factor 
for psychosis development is to zoom into the microenvironment of everyday life. 
The Experience Sampling Method (ESM) is an excellent tool to capture subtle, mo-
ment-to-moment emotions and symptomatology and their dynamics and associations 
with contextual factors in the flow of daily life70-73. It is a structured within-day momen-
tary self-assessment technique that provides frequent assessment of current mood, 
thoughts, symptoms imbedded in their context (e.g. location, company, activity), and 
these repetitive momentary assessments are ecologically valid and free of cognitive bi-
ases that hamper retrospective questionnaires71, 74. Most of the ESM research in the last 
three decades has been performed by providing subjects with a digital wristwatch and 
a set of ESM self-assessment forms collected in a booklet for each day. Advancements 
in technology now allow electronic or digital ESM assessments by means of a PDA or 
mobile phone app. The ESM device (wristwatch, PDA or mobile phone) emits a signal 
(beep) at ten unpredictable moments in a semi-random schedule of 90-minute time 
blocks between 07:30 and 22:3071.  
ESM has several advantages in comparison to conventional research methods in the 
field of psychopathology75. First, ESM studies are ecologically valid as they allow study-
ing individuals within their own real-life environment. Second, in contrast to traditional 
retrospective assessment approaches, ESM assesses momentary experiences elicited by 
simple and straightforward questions that are less prone to biases and forgetting. Third, 
questionnaires and most interviews do not focus how contextual factors impact on the 
variation in symptoms, mood or other constructs in daily life. ESM on the other hand is 
situated in the complex context of daily life and is able to measure the variation in symp-
toms and mood in response to environmental factors present in daily life. Fourth, ques-
tionnaires and interviews require patients to be aware of the dynamics of symptoms and 
their interactions with other factors. However, as different constructs like symptoms, 
mood, stress and social company are measured separately from each other and only 
associated to each other in the analyses conducted by the researcher, ESM provides 
information of which the participant is not aware and therefore not influenced by an 
individual’s own expectations. Fifth, ESM allows for cross-sectional (chapter 4) as well as 
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longitudinal study (chapter 5) of variation and dynamic relationships as data collection 
results in multiple assessments over time. 
Previous ESM studies have shown that when confronted with everyday small stressors 
psychotic disorder patients display increased emotional and symptomatic responses76, 
77. Increased reactivity to stress in daily life is especially found in patients with high lev-
els of positive psychotic symptoms and low levels of negative symptoms78. Unaffected 
first-degree relatives of psychotic patients also display elevated emotional and behav-
ioural responses in the face of everyday life stress76. Subsequent studies have shown 
that increased stress-reactivity clusters within families and a genetic correlation be-
tween increased stress reactivity and the positive psychotic dimension have been shown 
for clinical79 and subclinical symptoms80. Furthermore, there is a role for environmental 
factors as environmental exposures to stress in the form of life events81 and childhood 
trauma82 have been found to explain the elevations in stress reactivity in part. Taken 
together, these results suggest that increased emotional and symptomatic reactivity to 
stress, also referred to as ‘behavioural sensitization’83, reflects an affective pathway to 
psychosis that is suggested to underlie a more reactive, episodic type of psychosis that 
characterises a subgroup of patients with predominantly positive psychotic symptoms59.
Examination of emotional and symptomatic stress reactivity in those at CHR-P will help 
determine if behavioural sensitization occurs before the onset of psychotic disorder 
and an elevated level of stress reactivity is a mechanism underlying psychosis devel-
opment. Palmier-Claus and colleagues84 have examined stress-reactivity in a sample of 
CHR-P patients, psychotic disorder patients and healthy controls. Interestingly, it was the 
CHR-P group that showed significantly elevated emotional stress reactivity for stress-
ful activities and social situations compared to healthy controls and psychotic patients. 
Intensity of symptomatic stress reactivity was comparable to psychotic patients. These 
results suggest that stress sensitization occurs before onset of psychotic disorder. Very 
recently, the study of Reininghaus and colleagues85 examined emotional and sympto-
matic stress-reactivity in CHR-P and FEP patients. Results echoed and expanded those of 
Palmier-Claus and colleagues84.
Phenomenology and temporal dynamics of psychotic experiences in daily life
The prospective, longitudinal character of ESM assessments allows for examination of 
the phenomenology and temporal dynamics of psychotic experiences in daily life71, 74. 
Prevalence rates of hallucinations in daily life in psychotic disorder patients were be-
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tween 40-73%86-88. Visual and auditory hallucinations were found to often co-occur. 
Oorschot and colleagues87 investigated the temporal dynamics of hallucinations and 
the relationships with emotions and delusions. Their results suggested that delusional 
ideation might precede hallucinatory episodes in daily life, rather than result from a 
hallucination. Additionally, affective dysregulation might not play a primary role in hal-
lucination onset. 
Prevalence rates of paranoia or persecutory delusions in daily life are between 49-67% in 
psychosis spectrum patients88, 89. Results of studies across the psychosis continuum have 
indicated an important role for emotions, especially anxiety and low levels of self-esteem 
in triggering or contributing to the maintenance of paranoid symptoms90-94. Self-esteem 
is not constantly low but fluctuates in paranoid patients95. Furthermore, self-esteem 
instability was found to be specifically related to paranoid symptoms and not positive 
psychotic symptoms in general96. One ESM study of psychotic disorder patients demon-
strated that an increase in the level of anxiety and a decrease in the level of self-esteem 
were predictive of the onset of a paranoid episode. Furthermore, negative emotions and 
a low level of self-esteem were associated with paranoid episodes97. 
Outline and aims and of the thesis
The overall aim of this thesis is to identify risk factors for the development of psychotic 
disorder by examining the phenomenology of psychotic symptoms at a macro-level and 
at micro-level of daily life in those at the lower end of the psychosis continuum. The 
studies in this thesis examine (subclinical) psychotic symptoms and associated factors 
in individuals from the general population, unaffected first-degree relatives of psychot-
ic disorder patients, CHR-P patients, FEP patients and long-term psychotic disorder pa-
tients, allowing for comparisons across different stages of the continuum. The first part 
of this thesis focusses on subclinical psychotic symptoms reported in the general popu-
lation and unaffected first-degree relatives of psychotic disorder patients. 
This thesis starts with an investigation of FP SRPE by individuals of the general popula-
tion, using uses baseline and 3-year follow-up data from the second Netherlands Mental 
Health and Incidence Study (NEMESIS-2, n=4683), a longitudinal study of mental disor-
ders in a representative cohort of Dutch adults. FP SRPE are proposed to represent the 
lowest risk for transition to psychosis along the extended psychosis continuum, as they 
are not confirmed as true psychotic symptoms through objective clinical evaluation. The 
study in chapter 2 is a prospective follow-up study of the previously investigated sample 
General introduction  |  21
1
of individuals with FP SRPE at baseline28. We examine if baseline FP SRPE predict reduced 
psychosocial functioning and the occurrence of psychopathology at 3-year follow-up. 
Furthermore, we investigate which psychopathological and psychosocial factors predict 
the differential outcomes of persistence of FP SPRE and transition to validated psychotic 
symptoms.
The high expression of subclinical psychotic symptomatology in unaffected first-degree 
relatives of psychotic patients7, 8 is likely attributable to both shared genes and envi-
ronment with the patient relative. In contrast, the expression of subclinical psychotic 
symptomatology in general population samples is more likely to be associated with en-
vironmental effects16, 98, 99. As PRS reflects the influence of the genetic component on 
the clinical expression of the diverse psychotic symptoms, positive associations are as-
sumed to exist between PRS as an index of genetic risk and self-report and clinical in-
terview measures of subclinical psychotic symptoms. However, early reports on these 
associations were inconclusive100-102. Therefore, in chapter 3 the associations between 
PRS and subclinical psychotic symptoms assessed with a (subjective) self-report measure 
and an (objective) interview measure are examined in unaffected first-degree relatives 
of patients with psychotic disorders and healthy comparison subjects from the general 
population. Given that siblings of psychotic disorder patients have more genetic overlap 
with these patients than individuals from the general population, it is hypothesized that 
the association between PRS and measures of psychosis proneness will be stronger in 
relatives of patients than in individuals from the general population. Associations with 
affective episodes are also investigated as psychotic patients often show affective dys-
regulation and GWAS studies showing considerable overlap between schizophrenia and 
other psychiatric disorders including affective psychoses. 
The second part of this thesis focusses on examination of psychotic symptoms in daily 
life in CHR-P patients, patients with a first episode of psychosis and long-term psychotic 
disorder patients. The study in chapter 4 investigates emotional and symptomatic stress 
reactivity in daily life in individuals at CHR-P, chronic psychotic disorder patients and 
healthy controls to further examine the role of elevated emotional and symptomatic 
stress-reactivity in the onset of psychotic disorder. Previous ESM studies with psychotic 
patients reported that elevation of the level of negative affect was associated with the 
occurrence of momentary psychotic symptoms88, 103, 104. We therefore examine the asso-
ciation between momentary psychotic symptoms and negative affect as a measure of 
distress in CHR-P individuals and long-term psychotic patients. 
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To date no study has investigated prevalence of perceptual abnormalities or hallucina-
tions and suspiciousness in daily life specifically in CHR-P or first episode psychosis pa-
tients, whereas this has been done previously in psychotic disorder patients. Similarly, 
the temporal dynamics of hallucinations and suspiciousness in daily life and the rela-
tionships with emotional processes, anxiety and self-esteem are unknown. The study in 
Chapter 5 is the first to examine the phenomenology of hallucinations and delusions in 
the realm of daily life and their temporal relationship to emotion, anxiety and self-es-
teem in CHR-P and FEP patients. Results of this study will help to further elucidate fac-
tors involved in the onset and maintenance of suspicious and hallucinatory symptoms. 
We compare current findings with previous findings in psychotic disorder patients.
Lastly, in chapter 6, the main results of the work presented in this thesis are integrated 
and discussed. In addition, clinical implications and future perspectives are addressed. 
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ABSTRACT
Aims. Self-reported psychotic experiences (SRPE) by individuals from the general pop-
ulation are often unconfirmed by clinical interview and referred to as ‘false positive’ 
(FP) SRPE. FP SRPE have been suggested to represent the mildest form of risk along the 
extended psychosis continuum. However, little is known about their (clinical) outcome 
and evolution over time. Aims of this study were to prospectively examine, in individuals 
with FP SRPE, (1) the prevalence of remission, persistence and transition to validated PE 
at 3-year follow-up; (2) potential baseline psychopathological and psychosocial predic-
tors of persistence of FP SRPE and transition to validated PE, and (3) whether those with 
persistent FP SRPE and validated PE already differed on psychopathology and psychoso-
cial factors at baseline. We tested the hypotheses that (i) individuals with FP SRPE would 
be more likely to have SRPE and validated PE at follow-up, and (ii) that FP SRPE would be 
predictive of lower functioning and more psychopathology and help-seeking behaviour 
at follow-up.
Methods. Baseline (n=6646) and 3-year follow-up (n=5303) data of the second Neth-
erlands Mental Health Survey and Incidence Study (NEMESIS-2), a general population 
research project on prevalence, incidence, course, and consequences of psychiatric dis-
orders was used. Self-report of PE was followed by clinical interview to determine clinical 
validity. Presence of mood, anxiety and substance use disorders, childhood adversity, 
help-seeking and functioning as well as PE characteristics (number, frequency, distress 
and impact) were used in the analyses which included only individuals with complete 
data for both assessments waves (n=4683).
Results. At baseline, 454 participants had any FP SRPE; of these 372 participants had 
complete follow-up data available. Those with baseline FP SRPE were significantly more 
likely to report SRPE (OR=3.58; 95% CI 2.38-5.40, p<0.001) and validated PE (OR=6.26; 
95% CI 3.91-10.02, p<0.001) at follow-up. Baseline FP SRPE also predicted presence of 
mood and anxiety disorders, reduced functioning and help-seeking at follow-up. Several 
baseline psychopathological, psychosocial and PE characteristics were predictive for the 
persistence of SRPE. These factors also differentiated groups with FP SRPE or validated 
PE from those with remitted FP SRPE at follow-up.
Conclusions. ‘False positive SRPE’, are not truly ‘false’ as they index risk for development 
of clinically relevant psychotic symptoms, development of mood and anxiety disorders 
and reduced functioning. Self-reported PE, even unconfirmed, warrant ‘watchful wait-
ing’ and follow-up over time especially when they are reported by individuals with re-
duced psychosocial functioning and general psychiatric problems.
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INTRODUCTION
There is evidence that the psychosis phenotype is expressed along a continuum, ranging 
from mild, subclinical psychotic experiences (PE) to full-blown psychotic disorder, also 
referred to as the “extended psychosis phenotype”1-3. The prevalence of PE of 5.8-7.2% 
in the general population4, 5 is much higher than the lifetime prevalence of 0.4%-0.7% 
for psychotic disorder in the schizophrenia spectrum6, 7. Even though a large percentage 
of PE are not associated with distress and most are transitory in nature4, 8, PE do predict 
transition to clinical psychotic disorder and hospital admission for psychosis, especially 
when PE are more severe in terms of frequency, number and persistence over time2, 
3, 9. Furthermore, PE have been found to be associated with (childhood) traumatic ex-
periences, neuroticism, substance use and/or dependence, as well as global, cognitive, 
social, and role impairment and are often reported by individuals with non-psychotic 
illness10-16. Furthermore, the associations between PE and other mental disorders have 
been found to be bidirectional in nature17.
Although general population studies consistently report that PE are relatively common, 
there are substantial differences in reported prevalence rates. In their systematic re-
views of prevalence and incidence of PE, Linscott and Van Os4, 18 reported that PE were 
most prevalent in studies using self-reports of participants, with rates were more than 
three times larger than in studies using interview-based assessments. Two studies in 
which self-reports were followed by clinical reassessment reported that ~40% of self-re-
ported psychotic experiences (SRPE) were confirmed by clinical interview19, 20.
Little is known about the progression of PE over time and the characteristics of individ-
uals who report SRPE that cannot be confirmed by clinical interview, also referred to as 
‘false positive’ (FP) SRPE. Only one prospective population-based study examined risk for 
future psychotic disorder in those with FP SRPE and validated PE21. Both types of PE were 
associated with risk for psychotic disorder at 3-year follow-up, with greater risk for those 
with confirmed PE than those with FP SRPE. More recently, van Nierop et al.20 specifically 
compared cross-sectional psychopathological and psychosocial characteristics of groups 
with FP SRPE, clinically validated PE and controls without SRPE. Their results showed that, 
compared to individuals reporting no PE, those with at least one FP SRPE were more like-
ly to have a lifetime mood, anxiety or substance use disorder, reported higher levels of 
neuroticism, were more likely to be characterized by psychosocial risk indicators including 
childhood adversity, bullying, recent negative life events as well as cannabis use. This group 
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was also characterized by worse social, physical and mental functioning, assessed over the 
last month. However, when those with FP SRPE were compared to those with validated 
SRPE, associations with psychopathology, social functioning, psychosocial factors as well as 
help seeking in general and specifically for SRPE were generally less strong.
This evidence may suggest that FP SRPE are not ‘truly’ false-positive but represent the 
mildest expression of psychosis proneness along the extended psychosis continuum20. 
However, further investigation of the characteristics, course and outcomes of FP SRPE as 
well as examination of the impact of psychopathological and psychosocial factors on the 
outcomes of persistence and progression to validated PE is needed before such conclusion 
can be substantiated. Additionally, further examination of the impact of FP SRPE on later 
psychological and psychosocial functioning is necessary to determine the clinical relevance 
of FP SRPE in terms of the development of functional impairment and need for care.
In the present study, we therefore aimed to prospectively examine the development and 
clinical significance of FP SRPE at baseline over a 3-year follow-up period. We examined 
(1) rates of remission, persistence of FP SRPE and transition to validated PE; (2) if indi-
viduals with baseline FP SRPE were more likely to report new PE, both self-reported as 
well as clinically validated PE, than individuals without FP SRPE; and (3) the predictive 
value of FP SRPE on current mental, social, general functioning, the occurrence of recent 
mood, anxiety and/or substance disorders as well as need for care. Furthermore, we 
aimed to examine (4) which psychopathological and psychosocial characteristics meas-
ured at baseline were predictive of persistence of FP SRPE and transition to validated PE; 
and (5) if those with persistent FP SRPE and those who made the transition to validated 
PE at follow-up differed regarding the expression of psychopathological and psychosocial 
factors present at baseline compared to those with remitted FP SPRE at follow-up.
In line with the psychosis continuum model in which FP SRPE are suggested to be the mild-
est expression of risk for psychotic disorder20, we hypothesized that (1) individuals with 
baseline FP SRPE would be significantly more likely to report PE at follow-up, both FP SRPE 
and validated PE, than individuals without SRPE at baseline; (2) the presence of FP SRPE at 
baseline would be predictive of reduced functioning and presence of mood- anxiety and 
substance use disorders at follow-up; and (3) psychopathological and psychosocial factors, 
previously found to distinguish those with FP SRPE from those without SRPE and known to 
be associated with (transition to) psychotic disorder, would predict both the persistence of 
FP SRPE as well as the progression towards validated PE over the follow-up period.
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METHODS
Study cohort
This study used data from the first wave (baseline), performed from November 2007 to 
July 2009 and second wave collected three years later from November 2010 to June 2012, 
of the second Netherlands Mental Health Survey and Incidence Study (NEMESIS-2), ver-
sion 2.0. This is a longitudinal study of prevalence, incidence, course, and consequences 
of psychiatric disorders in the Dutch general population aged 18 to 64 years. The study 
was approved by a Medical Ethics committee. After having been informed about the study 
aims, respondents provided written informed consent. For a more detailed description of 
the NEMESIS-2 methods see de Graaf et al.22, 23. At baseline 6646 persons were interviewed 
(response rate: 65.1%). All baseline respondents were approached for follow-up and 5303 
persons could be interviewed again (response rate 80.4%, with those deceased excluded). 
Attrition was not related to any 12-month mental disorder  at baseline, after controlling 
for sociodemographic characteristics 24. For the current analyses, only participants with 
complete data for both baseline and follow-up measurements were selected, which had 
to include clinical re-interview when PE were reported.
Instruments
Assessment of PE
Studies on earlier Composite International Diagnostic Interview (CIDI) versions conclud-
ed that the CIDI assesses common mental disorders with generally acceptable reliability 
and validity, with the exception of psychosis25, 26. Therefore, a psychosis add-on instru-
ment was constructed, based on the section of psychotic symptoms in CIDI versions 1 
and 2. It consisted of 20 PE, each rated ‘yes’, ‘no’, ‘don’t know’ or ‘refuse to answer’, 
each assessed by a lay interviewer. As clinical relevance of PE may be difficult to diagnose 
by lay interviewers 27 and interviewers made no clinical judgment about participants’ 
answers, reported experiences may be considered an extension of ‘self-report’. At base-
line, the assessment period spanned the entire lifetime of a participant, at follow-up the 
assessment period spanned the time between baseline and follow-up. Whenever a PE 
was endorsed, the subject was asked to state, on a 1 (rarely) to 4 (almost always) scale, 
how often this experience occurred (Frequency), how much it bothered them (Distress), 
to what extent the experience had an influence on their daily professional and social 
activities (Impact) and at which age it first occurred. The age of first onset, number of 
SRPE, the averages of Frequency, Distress and Impact at baseline were used as predic-
tors in the analyses. 
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Individuals who endorsed at least one SRPE at baseline and/or one SRPE at follow-up 
at the respective initial interview were contacted within eight weeks for clinical re-in-
terview over the telephone by an experienced clinician at the level of psychologist or 
psychiatrist. Re-interviews were conducted using questions from the Structured Clinical 
Interview for DSM-IV SCID-I, 28 and all findings were discussed with a second clinician. 
At baseline, 1081 participants (16.3%) endorsed at least one PE. Of these, 794 partici-
pated in clinical re-interview (73.5%). For 454 (58.2%) SRPE were determined as FP. At 
follow-up, 440 out of the total 5303 (8.3%) participants reported that at least one SRPE 
had occurred since baseline. Of these, 367 (83.4%) participants were available for re-in-
terview.
For the analyses six relevant groups were selected (Figure 1). The 372 (of 454) partici-
pants with FP SRPE at baseline and all data available at follow-up were divided over three 
subgroups based on PE status at follow-up: (1) at least one SRPE confirmed by clinical 
re-interview: the ‘Transition to validated PE’ group; (2) one or more SRPE, all determined 
FP by clinical re-interview: the ‘Persistent FP SRPE’ group; (3) no SRPE: the ‘Remitted FP 
SRPE’ group. Given the small number of participants who made the transition to vali-
dated PE in the current study (n=28) we chose not to examine transition to psychotic 
disorder as an outcome, as was done previously by Bak et al.21.
Participants without SRPE at baseline were similarly divided over subgroups based on 
PE status at follow-up: (4) one or more SRPE, with at least one confirmed PE by clinical 
re-interview: the ‘Validated incident PE’ group; (5) one or more SRPE, all non-confirmed 
by clinical re-interview: the ‘FP incident SRPE’ group; (6) absence of SRPE: the ‘control’ 
group.
Demographics, risk factors and psychopathology at baseline
Participants were interviewed at home by trained interviewers who were not clinicians 
with the CIDI version 3.029. Neuroticism was assessed using the Eysenck Personality 
Questionnaire (EPQ-revised short scale)30, 31. Four types of childhood adversity (phys-
ical, emotional, sexual and psychological) and peer victimization were assessed using 
a questionnaire based on NEMESIS-1, and dichotomized (yes or no). Sexual abuse was 
assessed as ‘yes’ when it had happened at least once, physical, emotional and psycho-
logical abuse when it had happened sometimes or more often, and bullying when it had 
happened regularly before the age of 16. Presence of ten possible negative life events in 
the previous twelve months was measured, based on the Brugha Life events section and 
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dichotomized (yes or no)32. Cannabis use was assessed in the section Illegal Substance 
Use of the CIDI 3.0 and analysed as a dichotomous variable indicating regular use (≥ 1 
time per week during the last year. Continuous ratings of general, mental and physical 
health and social functioning over the past month were assessed by the Medical Out-
comes Study Short-form Health Survey (SF-36)33, 34. Help seeking in the past 12 months 
from psychiatrists or psychologists for any psychiatric problem including drug or alcohol 
problems was also assessed.
Fig. 1. Sample distribution at baseline and 3-year follow-up.
Analyses
All analyses were performed in STATA, version 1335. Logistic regression was used to test 
the hypothesis that individuals with baseline FP SRPE are significantly more likely to re-
port PE at follow-up than individuals without baseline SRPE (hypothesis 1). The associ-
ation between presence of baseline FP SRPE as the independent variable and presence 
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of SRPE at follow-up as dependent variable was examined, a priori controlling for age 
and sex. As SRPE were either confirmed or rejected by clinical re-interview at follow-up 
we ran two models reflecting both outcomes as the dependent variables: (1) any  SRPE 
(FP and validated PE combined); and (2) clinically validated PE only. Logistic regression 
was also used to test if baseline FP SRPE predicted presence of any mood, anxiety or 
substance use disorder in the last year before follow-up assessment and help-seeking in 
general and specifically for PE. Linear regression was used to test if baseline FP SRPE pre-
dicted reduced mental, social, physical and general health functioning in the last month 
at follow-up (hypothesis 2).
In order to test the hypothesis that risk indicators known to be associated with (transi-
tion to) psychotic disorder would predict continued self-report of PE (i.e. persistence of 
SRPE) over the follow-up period within the group with baseline FP SRPE (hypothesis 3), 
logistic regression was applied, a priori controlling for age and sex. Presence of SRPE (re-
gardless if these were validated at clinical re-interview) as compared to absence of SRPE 
at follow-up, served as the dependent variable. Psychopathological and psychosocial risk 
indicators as well as PE characteristics served as independent variables. Furthermore, 
multinomial logistic regression, a priori controlling for age and sex, was applied to ex-
amine if associations with risk indicators would be more pronounced in individuals who 
persist in reporting FP SRPE and those who display progression towards validated PE, 
compared to individuals with remitted FP SRPE. In all regression models predictors were 
entered in separate analyses.
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RESULTS
Sample
The mean age of the total sample (n=4683) with complete data available at baseline and 
follow-up was 44.8 (SD=12.3, range 18-68), with comparable mean ages in the subgroups 
(table 1). The groups differed significantly on gender distributions (χ2=17.0, p=0.004), 
education level (χ2=38.2, p<0.001) and job status (χ2=20.6, p=0.001). At baseline, partic-
ipants available for clinical re-interview did not differ from non-responders with regard 
to age, lifetime psychiatric disorders, sex, or employment status, while educational at-
tainment was significantly lower (χ2=8.1, p=0.045). Non-responders were characterized 
by more SRPE than participants (t(1079)=5.14, p<0.001). At follow-up participants avail-
able for clinical re-interview did not differ from non-responders with regard to age, life-
time anxiety and substance use disorder, sex, educational level or employment status as 
measured at baseline. However, non-responders had more SRPE (t(438)=3.49, p<0.001) 
and lifetime mood disorders (χ2=5.7, p=0.02) at baseline.
Psychotic experiences
FP SRPE at baseline and PE at follow-up
Sixty of the 372 participants with baseline FP SRPE (16.1%) had at least one SRPE at 
follow-up. These were clinically validated at re-interview for 28 participants (46.7%). Par-
ticipants with baseline FP SRPE were significantly more likely to have any SRPE as well 
as clinically validated PE at follow-up than participants without baseline SRPE (Table 2).
FP SRPE at baseline and psychopathology and functioning at follow-up
The presence of baseline FP SRPE was significantly associated with the presence of any 
mood or anxiety disorder in the previous year, reduced current general mental, social, 
physical and overall health functioning, as well as general help-seeking at follow-up 
(Table 2).
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Table 1. NEMESIS-2 Baseline Sample and Prevalence Characteristics
Total sample Controls Remitted FP SRPE Persistent FP SRPE Transition to validated PE Incident FP SRPE Incident validated PE
N (%) N (%) N (%) N (%) N (%) N (%) N (%)
Total group 4683 (100) 4147 (88.6) 312 (6.7) 32 (0.7) 28 (0.6) 110 (2.3) 54 (1.1)
Mean age 44.8 Mean age 44.9 Mean age 44.7 Mean age 45.8 Mean age 45.9 ) Mean age 44.7 Mean age 43.0
(SD 12.3) (SD 12.3) (SD 12.2) (SD 12.5) (SD 10.3 (SD 12.4) (SD 12.9)
Men 2141 (45,7) 1931 (46.6) 119 (38.1) 17 (53.1) 6 (21.4) 45 (40.9) 23 (42.6)
Mean age 45.1 Mean age 45.2 Mean age 44.2 Mean age 43.5 Mean age 49.5 Mean age 44.2 Mean age 42.2
(SD 12.3) (SD 12.2) (SD 12.7) (SD 13.9) (SD 11.6) (SD 12.0) (SD 11.6)
Women 2542 (54.9) 2216 (53.4) 193 (61.9) 15 (46.9) 22 (78.6) 65 (59.1) 31 (57.4)
Mean age 44.7 Mean age 44.6 Mean age 45.0 Mean age 48.4 Mean age 44.9 Mean age 45.1 Mean age 43.6
(SD 12.3) (SD 12.4) (SD 11.9) (SD 10.4) (SD 10.0) (SD 12.7) (SD 11.9)
Paid job 3588 (76.6) 3205 (77.3) 233 (74.7) 26 (81.2) 16 (57.1) 76 (69.1) 32 (59.3)
No Job 1095 (23.4) 942 (22.7) 79 (25.3) 6 (18.8) 12 (42.9) 34 (30.9) 22 (40.7)
Education 
   Primary education 
   Lower sec. education 
   Higher sec. education 
   Higher professional/ 
   university education
191 (4.1)
1200 (25.6)
1511 (32.3)
1781 (38.0)
162 (3.9)
1028 (24.8)
1330 (32.1)
1627 (39.2)
14 (4.5)
97 (31.1)
105 (33.6)
96 (30.8)
2 (6.2)
10 (31.3)
14 (43.8)
6 (18.7)
4 (14.3)
7 (25)
10 (35.7)
7 (25)
5 (4.5)
38 (34.6)
34 (30.9)
33 (30.0)
4 (7.4)
20 (37.0)
18 (33.3)
12 (22.2)
FP, false positive; SRPE, self-reported psychotic experiences; PE, psychotic experiences
Table 2. Results of logistic and linear regression analyses: associations between presence of baseline FP SRPE 
and presence of SRPE and validated PE, current functioning, presence of psychopathology and help-seeking 
at follow-up, as compared to no baseline SRPE, adjusted for sex and age
Dichotomous variable OR 95% int. P Continuous variable B 95% int. P
SRPE at follow-up 3.58 2.38 - 4.40 <0.001 General mental functioning -2.37 -3.68 -  -1.06 <0.001
Validated PE at follow-up 6.26 3.91 - 10.02 <0.001 General social functioning -3.74 -5.67 -  -1.82 <0.001
Any mood disordera 2.62 1.77 - 3.86 <0.001 General physical functioning -2.55 -4.37 -  -.74 <0.01
Any anxiety disordera 2.56 1.81 - 3.64 <0.001 General health functioning -4.37 -6.21 -  -2.52 <0.001
Any substance disordera 1.60 .90 - 2.85 ns
Help seeking, generala,b 2.05 1.56 -2.69 <0.001
Help seeking, specifica,c 1.44 .54 - 3.82 ns
ns, not significant; OR, odds ratio; B, beta coefficient. a Presence in the last year before follow-up assess-
ment;  b General: psychiatric problems, including drug- or alcohol-related help seeking; c Specific: psychotic 
experiences
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Table 2. Results of logistic and linear regression analyses: associations between presence of baseline FP SRPE 
and presence of SRPE and validated PE, current functioning, presence of psychopathology and help-seeking 
at follow-up, as compared to no baseline SRPE, adjusted for sex and age
Dichotomous variable OR 95% int. P Continuous variable B 95% int. P
SRPE at follow-up 3.58 2.38 - 4.40 <0.001 General mental functioning -2.37 -3.68 -  -1.06 <0.001
Validated PE at follow-up 6.26 3.91 - 10.02 <0.001 General social functioning -3.74 -5.67 -  -1.82 <0.001
Any mood disordera 2.62 1.77 - 3.86 <0.001 General physical functioning -2.55 -4.37 -  -.74 <0.01
Any anxiety disordera 2.56 1.81 - 3.64 <0.001 General health functioning -4.37 -6.21 -  -2.52 <0.001
Any substance disordera 1.60 .90 - 2.85 ns
Help seeking, generala,b 2.05 1.56 -2.69 <0.001
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ment;  b General: psychiatric problems, including drug- or alcohol-related help seeking; c Specific: psychotic 
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Table 3. Results of logistic regression analyses: associations between baseline psychopathological, psychoso-
cial and PE factors and persistence of SRPE at follow-up as compared to remission, adjusted for sex and age
Dichotomous variable OR 95% int. P Continuous variable OR 95% int. P
Lifetime mood disorder 1.91 1.08 - 3.39 0.03 General mental functioning 0.98 0.965 - 0.996 0.02
Lifetime anxiety disorder 2.08 1.16 - 3.70 0.01 General social functioning 0.98 0.97 - 0.995 0.007
Lifetime substance disorder 1.56 0.82 - 2.97 ns General physical functioning 0.99 0.99 - 1.01 ns
Neuroticism 3.02 1.65 - 5.52 <0.001 General health functioning 0.98 0.97 - 0.996 0.01
Sexual abuse < 16 1.40 0.65 - 3.04 ns Onset of SRPE (age in years)  1.00 0.98 - 1.03 ns
Physical abuse < 16 1.58 0.73 - 3.42 ns Number of SRPE 1.43 1.09 - 1.87 0.01
Emotional abuse <16 1.75 0.96 - 3.20 ns Frequency of SRPE 1.48 1.05 - 2.09 0.03
Psychological abuse <16 1.93 1.08 - 3.44 0.03 Distress of SRPE 1.15 0.87 - 1.52 ns
Regular bullying <16 1.23 0.60 - 2.52 ns Impact of SRPE 1.25 0.87 - 1.77 ns
Negative life events past year 1.45 0.79 - 2.68 ns
Regular cannabis use (≥1/wk, last year) 1.55 0.39 - 6.11 ns
Help seeking, generala 1.97 1.06 - 3.66 0.03
Help seeking, specificb 1.08 0.35 - 3.30 ns
ns, not significant; OR, odds ratio. a General: psychiatric problems, including drug- or alcohol-related help 
seeking; b Specific: psychotic experiences
Table 4. Results of multinomial logistic regression showing the effect of baseline psychopathological and 
psychosocial characteristics on PE status at follow-up, adjusted for sex and age
Persistent FP SRPE vs. Remitted FP SRPE (ref) Transition to validated PE vs. Remitted FP SRPE (ref) Transition to validated PE vs. Persistent FP SRPE (ref)
Dichotomous variable RRR 95% int. P RRR 95% int. P RRR 95% int. P
Lifetime mood disorder 1.59 0.74 - 3.44 ns 2.32 1.05 - 5.10 0.04 1.45 0.51 - 4.15 ns
Lifetime anxiety disorder 1.68 0.77 - 3.67 ns 2.60 1.18 - 5.73 0.02 1.54 0.54 - 4.42 ns
Lifetime substance disorder 1.35 0.59 - 3.12 ns 1.88 0.76 - 4.66 ns 1.39 0.43 - 4.49 ns
Neuroticism (high/low) 2.97 1.34 - 6.58 0.007 3.08 1.31 - 7.28 0.01 1.04 0.34 - 3.22 ns
Sexual abuse < 16 1.62 0.57 - 4.62 ns 1.24 0.44 - 3.49 ns 0.76 0.19 - 3.11 ns
Physical abuse < 16 0.74 0.21 - 2.61 ns 2.94 1.14 - 7.54 0.03 3.96 0.88 - 17.72 0.07
Emotional abuse <16 1.22 0.51 - 2.88 ns 2.45 1.10 - 5.44 0.03 2.01 0.66 - 6.15 ns
Psychological abuse <16 2.02 0.94 - 4.33 0.07 1.83 0.82 - 4.08 ns 0.90 0.31 - 2.59 ns
Regular bullying <16 1.26 0.48 - 3.30 ns 1.20 0.45 - 3.19 ns 0.96 0.26 - 3.55 ns
Negative life events past year 1.78 0.77 - 4.14 ns 1.17 0.51 - 2.69 ns 0.66 0.21 - 2.06 ns
Regular cannabis use (≥1/wk, last year) 0.83 0.10 -7.07 ns 2.70 0.51 - 14.24 ns 3.27 0.25 - 42.47 ns
Help seeking, generala 1.81 0.78 - 4.19 ns 2.15 0.94 - 4.93 0.07 1.19 0.39 - 3.64 ns
Help seeking, specificb na 2.45 0.77 - 7.85 ns na
na, not available; ns, not significant; RRR, relative risk ratio. a General: psychiatric problems, including drug- 
or alcohol-related help seeking; b Specific: psychotic experiences
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Help seeking, specificb na 2.45 0.77 - 7.85 ns na
na, not available; ns, not significant; RRR, relative risk ratio. a General: psychiatric problems, including drug- 
or alcohol-related help seeking; b Specific: psychotic experiences
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Risk factors for persistence of any SRPE at follow-up
Results of logistic regression analyses showed several risk indicators measured at base-
line to be predictive for the continued presence or ‘persistence’ of SRPE at follow-up 
(Table 3). These included the occurrence of a lifetime mood disorder, a lifetime anxie-
ty disorder, lower general health, social and mental functioning assessed over the last 
month, high level of neuroticism, the occurrence of psychological abuse before the age 
of 16 years and help seeking for general psychological problems. Moreover, persistence 
of SRPE was predicted by the number and frequency of baseline SRPE. More information 
about prevalence rates and other characteristics of the examined psychopathological 
and psychosocial variables can be found in supplementary tables S1 and S2.
Persistence of FP SRPE and transition to validated PE
Results of multinomial logistic regression analyses showed that persistence of FP SRPE, 
as compared to remission of FP SRPE at follow-up, was significantly predicted by pres-
ence of high neuroticism and lower general mental functioning. The occurrence of psy-
chological abuse before the age of 16 years just failed to reach statistical significance 
(Tables 4 and 5).
Table 5. Results of multinomial logistic regression showing the effect of baseline psychopathological and 
SRPE characteristics on PE status at follow-up, adjusted for sex and age
Persistent FP SRPE vs. Remitted FP SRPE (ref) Transition to validated PE vs. Remitted FP SRPE (ref) Transition to validated PE vs. Persistent FP SRPE (ref)
Continuous variable B 95% int. P B 95% int. P B 95% int. P
General mental functioning -0.02 -0.04 - 0.0001 0.05 -0.02 -0.04 - 0.003 ns 0.003 -0.03 - 0.03 ns
General social functioning -0.01 -0.03 - 0.003 ns -0.02 -0.03 - -0.004 0.01 -0.006 -0.03 - 0.01 ns
General physical functioning -0.003 -0.02 - 0.02 ns -0.007 -0.03 - 0.01 ns -0.004 -0.03 - 0.02 ns
General health -0.01 -0.03 - 0.01 ns -0.03 -0.04 - -0.01 0.004 -0.02 -0.04 - 0.006 ns
Onset of SRPE (age in years) 0.01 -0.03 - 0.05 ns -0.005 -0.04 - 0.03 ns -0.02 -0.07 - 0.03 ns
Number of SRPE 0.12 -0.30 - 0.54 ns 0.54 0.21 - 0.86 0.001 0.41 -0.08 - 0.90 ns
Frequency of SRPE 0.35 -0.11 - 0.80 ns 0.44 -0.03 - 0.91 0.07 0.09 -0.53 - 0.71 ns
Distress of SRPE 0.06 -0.33 - 0.44 ns 0.22 -0.15 - 0.58 ns 0.16 -0.35 - 0.66 ns
Impact of SRPE 0.29 -0.15 - 0.74 ns 0.15 -0.34 - 0.64 ns -0.14 -0.76 - 0.48 ns
b, beta coefficient
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Transition to validated PE at follow-up was significantly predicted by presence of a life-
time anxiety disorder, a lifetime mood disorder, high neuroticism, the occurrence of 
physical and/or emotional abuse before age 16 and lower health in general. A greater 
number of baseline SRPE was also associated with transition to validated symptoms, 
while an increased frequency of these experiences just failed to reach significance. Fur-
thermore, in general, effect sizes were larger than those of the group with persistent FP 
SRPE, although none reached statistical significance when directly compared (Tables 4 
and 5).
Table 5. Results of multinomial logistic regression showing the effect of baseline psychopathological and 
SRPE characteristics on PE status at follow-up, adjusted for sex and age
Persistent FP SRPE vs. Remitted FP SRPE (ref) Transition to validated PE vs. Remitted FP SRPE (ref) Transition to validated PE vs. Persistent FP SRPE (ref)
Continuous variable B 95% int. P B 95% int. P B 95% int. P
General mental functioning -0.02 -0.04 - 0.0001 0.05 -0.02 -0.04 - 0.003 ns 0.003 -0.03 - 0.03 ns
General social functioning -0.01 -0.03 - 0.003 ns -0.02 -0.03 - -0.004 0.01 -0.006 -0.03 - 0.01 ns
General physical functioning -0.003 -0.02 - 0.02 ns -0.007 -0.03 - 0.01 ns -0.004 -0.03 - 0.02 ns
General health -0.01 -0.03 - 0.01 ns -0.03 -0.04 - -0.01 0.004 -0.02 -0.04 - 0.006 ns
Onset of SRPE (age in years) 0.01 -0.03 - 0.05 ns -0.005 -0.04 - 0.03 ns -0.02 -0.07 - 0.03 ns
Number of SRPE 0.12 -0.30 - 0.54 ns 0.54 0.21 - 0.86 0.001 0.41 -0.08 - 0.90 ns
Frequency of SRPE 0.35 -0.11 - 0.80 ns 0.44 -0.03 - 0.91 0.07 0.09 -0.53 - 0.71 ns
Distress of SRPE 0.06 -0.33 - 0.44 ns 0.22 -0.15 - 0.58 ns 0.16 -0.35 - 0.66 ns
Impact of SRPE 0.29 -0.15 - 0.74 ns 0.15 -0.34 - 0.64 ns -0.14 -0.76 - 0.48 ns
b, beta coefficient
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DISCUSSION
3-year outcomes of baseline FP SRPE: remission, persistence and transition
Our study setup allowed us to collect information about PE in an adult general popu-
lation sample through self-report and interview-based clinical assessment at baseline 
and 3-year follow-up. The distinction between ‘false positive’ and validated PE could 
therefore be made at both baseline and follow-up. This allowed for an investigation of 
the prognostic value of baseline FP SRPE on the continued report of PE, psychopathology 
and functioning at follow-up as well as examination of the association between possible 
risk indicators assessed at baseline and the differential outcomes of baseline FP SRPE at 
follow-up.
Discontinuity or remission of PE (83.9%) was the most prevalent outcome, as previously 
reported4. However, results also confirmed the hypothesis that individuals with baseline 
FP SRPE were more likely to again report SPRE at follow-up. They were ~3.5 times more 
likely to report any SRPE at follow-up and more importantly, ~6 times more likely to re-
port clinically validated PE than participants without baseline SRPE.
Clinical implications of FP SRPE: current functioning, psychopathology and help-seeking
Presence of baseline FP SRPE predicted lower current mental and social functioning as 
well as physical and general health functioning at follow-up. Additionally, presence of 
any current (in the previous year) mood or anxiety disorder and help-seeking behaviour 
were predicted by FP SRPE. Combined with a previous finding that FP SRPE were pre-
dictive of transition to psychotic disorder21, our results confirm the suggestion by van 
Nierop and colleagues20 that individuals reporting FP PE represent a subgroup with the 
mildest subthreshold expression of psychosis along the psychosis continuum, in which 
PE are more likely to remain subclinical although need for care may eventually develop. 
Therefore, SRPE not confirmed by clinical interview, also referred to as ‘false positive 
SRPE’, are not truly ‘false’ as they still index risk for validated psychosis as well as future 
presence of mood- and/or anxiety disorder and reduced functioning. In clinical practice, 
even false positive SRPE thus warrant a ‘watchful waiting’ approach, especially when 
they co-occur with additional psycho(social) problems, in order to intervene promptly 
when PE do become more crystallized and distressing and therefore clinically relevant.
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Predictors of persistence of SRPE
Our study extends the findings of previous general population studies that did not make 
a distinction between validated and FP SRPE and reported an effect of persistence of 
SPRE on help-seeking and impairment at follow-up8, 36. It also extends the findings of Bak 
et al21, who found baseline FP SRPE to be associated with transition to psychotic disorder 
while not examining possible associated psychopathological and psychosocial factors. 
More and more frequent baseline SRPE, a diagnosis of mood disorder, anxiety disorder, 
high neuroticism, lower social and mental functioning and general health in the previ-
ous month, childhood adversity (psychological abuse) and help seeking for psychological 
problems were identified as significant predictors for persistence of SRPE.
Not unexpected, more and more frequent baseline FP SRPE were found to predict per-
sistence of SRPE, as both have been previously associated with risk of transition to psy-
chotic disorder9. Previous studies have found an increase in help-seeking and need for 
subsequent mental health service use in individuals with SRPE37, 38, especially when re-
porting multiple PE. In contrast, distress and impact did not predict persistence of SRPE. 
One explanation might be that at baseline any lifetime PE were assessed. Some of those 
might have existed for a long time and some might no longer have been present at 
baseline assessment, possibly lowering ratings of distress and impact. Less distress and 
impact was also reflected by the fact that only four participants (all with validated PE at 
follow-up) were seeking help specifically for PE. Furthermore, our results are in line with 
other general population studies of individuals with PE13, 17, 39, 40, as well as in individuals 
meeting criteria for the Ultra High Risk state for psychosis41, showing high comorbidity 
with mood and anxiety symptoms and disorders.
Characteristics of persistence of FP SRPE and transition to validated PE
This study is unique in the fact that it could directly investigate possible differences in 
psychopathological and psychosocial characteristics related to persistence of FP SRPE, 
as well as transition to validated PE. While the group with persistent FP SRPE was distin-
guishable from those with remitted FP SRPE by lower general mental functioning in the 
last month and high neuroticism, the transition group was, in addition to these factors, 
also characterized by the presence of a lifetime mood and/or anxiety disorder, instances 
of childhood adversities and lower health in general as well as more SRPE at baseline. 
Findings extend those of Van Nierop et al.20 who reported that individuals with validated 
baseline PE were more often characterised by mood and anxiety disorder and four times 
more likely to seek help for their PE. In conclusion, the present study was able to show, 
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in a longitudinal design, that those who will later develop validated PE were already 
characterized by high levels of lifetime psychopathology and exposure to psychosocial 
risk indicators at baseline
.
Theoretical implications
Van Os and Linscott2 proposed an “extended psychosis phenotype” reflecting a behav-
ioural expression of vulnerability for psychotic disorder in the general population. It im-
plies that PE are not exclusive to, and can occur independently of, psychotic disorder. 
At any point in time, most likely when PE persist over time, individuals may become 
help-seeking, with transition to psychotic disorder eventually occurring in some. This 
model has recently been reformulated into an “extended and transdiagnostic psychosis 
phenotype” to account for anxiety and affective symptoms often coexisting alongside 
PE42 and suggests that it is the co-expression of comorbid symptoms that may result in 
greater severity, socio-environmental risk and poorer functioning. Importantly, a recent 
study on PE in the general population showed that the relationship between PE and 
mental disorders is bi-directional in nature17. The probability of transition to a clinical 
psychotic disorder increases as the load of socio-environmental adverse factors such as 
instances of childhood trauma increases16. Our findings provide further evidence for the 
validity of this model.
Strengths and limitations
Results of this study should be interpreted in the context of its strengths and limitations. 
A strength is the size of the baseline sample. Furthermore, as the study set-up allowed us 
to distinguish between FP SRPE and clinically validated PE at baseline and follow-up, this 
is the first longitudinal study able to examine differential outcomes and characteristics 
of FP SRPE in the general population.
There are some methodological limitations. First, outcomes of persistence of FP SRPE 
and transition to validated PE were rare (0.7% and 0.6% of the total baseline sample and 
8.6% and 7.5% of those with SRPE at follow-up and available for re-interview, respective-
ly), which may have impacted on the statistical power in analyses examining associations 
with psychopathological and psychosocial characteristics, especially when groups were 
compared. Second, we relied on retrospective reports of lifetime PE at baseline assess-
ment and as a result could have occurred many years before which may have impacted 
on the recall of these experiences.   Third, as self-report of PE was gathered during an 
interview with a lay interviewer this may have led to less acknowledgment of PE than on 
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a traditional pen-and-paper self-report assessment. Fourth, as we could only select data 
of those participants with complete data at baseline and follow-up, not all tested individ-
uals could be included in some of the analyses. At baseline, non-participants of clinical 
re-interview were characterized by higher number of SRPE. At follow-up, non-partici-
pants reported higher numbers of SRPE and had more often a lifetime mood disorder. It 
is therefore possible that the effect sizes would have been different if all data had been 
available. Finally, it has been shown that PE are more common in children compared to 
adolescents and adults43, 44.The current sample comprises an adult sample with a wide 
age range and although the sample was nationally representative for The Netherlands, 
younger subjects were somewhat underrepresented23. This might have led to an un-
derestimation of the prevalence of both the persistence of SRPE and transition to vali-
date PE over time. Similarly, the impact of risk factors might be different in younger age 
groups and studies including child and adolescent samples are therefore needed.
In conclusion, this study showed SRPE not confirmed by clinical interview are often ac-
companied by symptoms of general psychiatric problems, reports of childhood adver-
sity and lower psychosocial functioning, especially in those for whom FP SRPE persist 
or progress into clinically relevant psychotic symptoms. FP SRPE furthermore increase 
the likelihood of future general psychopathology and lower functioning and therefore 
warrant follow-up over time.
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SUPPLEMENTARY MATERIALS
Table S1. Baseline assessment - prevalence rates for dichotomous variables; psychopathological and 
psychosocial characteristics
Total sample Controls Remitted FP SRPE Persistent FP SRPE Transition to validated PE Incident FP SRPE Incident validated PE
Dichotomous variables N (%) N (%) N (%) N (%) N (%) N (%) N (%)
Lifetime mood disorder 905/4683 (19.3) 743/4147 (17.9) 89/312 (28.5) 12/32 (37.5) 14/28 (50.0) 28/110 (25.4) 19/54 (35.2)
Lifetime anxiety disorder 854/4683 (18.2) 706/4147 (17.0) 76/312 (24.7) 11/32 (34.4) 13/28 (46.4) 33/110 (30.0) 15/54 (27.8)
Lifetime substance disorder 729/4683 (15.6) 607/4147 (14.6) 70/312 (22.4) 10/32 (31.3) 8/28 (28.6) 21/110 (19.1) 13/54 (24.1)
Neuroticism (high/low) 1548/4607 (33.6) 1285/4077 (31.5) 136/310 (43.9) 21/31 (67.7) 20/28 (71.4) 61/109 (56.0) 25/52 (48.1)
Sexual abuse <16 357/4607 (7.8) 295/4077 (7.2) 40/310 (12.9) 5/31 (16.1) 5/28 (17.9) 9/109 (8.3) 3/52 (5.8)
Physical abuse <16 348/4607 (7.6) 284/4077 (7.0) 35/310 (11.3) 3/31 (9.7) 7/28 (25.0) 10/109 (9.2) 9/52 (17.3)
Emotional abuse <16 652/4607 (14.2) 527/4077 (12.9) 75/310 (24.2) 8/31 (25.8) 13/28 (46.4) 14/109 (12.8) 15/52 (28.9)
Psychological abuse <16 728/4607 (14.6) 595/4077 (14.6) 81/310 (26.1) 13/31 (41.9) 11/28 (39.3) 18/109 (16.5) 10/52 (19.2)
Regular bullying <16 615/4603 (13.4) 515/4073 (12.6) 56/310 (18.1) 6/31 (19.4) 6/28 (21.4) 20/109 (18.3) 12/52 (23.1)
Negative life events past year 2248/4607 (48.8) 1913/4077 (46.9) 196/310 (63.2) 23/31 (74.2) 19/28 (67.9) 62/109 (56.9) 35/52 (67.3)
Regular cannabis use (≥1/wk, past year) 69/3780 (1.8) 52/3419 (1.5) 10/241 (4.2) 1/26 (3.9) 2/23 (8.7) 3/90 (3.2) 1/47 (2.1)
Help seeking, generala 506/4607 (11.0) 398/4077 (9.8) 62/310 (20.0) 9/31 (29.0) 10/28 (35.7) 18/109 (16.5) 9/52 (17.3)
Help seeking, specificb na na 19/292 (6.1) 0/32 (0) 4/28 (14.3) na na
FP, false positive; SRPE, self-reported psychotic experiences; PE, psychotic experiences; na: not available; 
a General: psychiatric problems, including drug- or alcohol-related help seeking; b Specific: psychotic experiences
Table S2. Baseline assessment - means, minimum, maximum and SDs for continuous variables; 
psychopathology, general health, social functioning, and severity of SRPE
Total sample Controls Remitted FP SRPE Persistent FP SRPE Transition to validated PE Incident FP SRPE Incident validated PE
Continuous variables Mean (min – max) 
(SD)
Mean (min – max) 
(SD)
Mean (min – max)  
(SD)
Mean (min – max) (SD) Mean (min – max) 
 (SD)
Mean (min – max) 
(SD)
Mean (min – max) (SD)
General mental functioning 84.5 (8-100) (12.4) 85.1 (8-100) (11.9) 81.6 (20-100) (14.6) 76.5 (16-100) (18.9) 76.1 (24-100) (19.9) 79.5 (16-100) (14.3) 79.5 (28-100) (16.6)
General social functioning 91.5 (0-100) (17.0) 92.1 (0-100) (16.4) 87.9 (0-100) (20.5) 82.0 (0-100) (24.0) 75.9 (0-100) (28.9) 89.5 (37.5-100) (16.5) 85.4 (25-100) (20.3)
General physical functioning 92.6 (0-100) (16.2) 93.0 (0-100) (15.8) 90.1 (10-100) (18.1) 89.1 (40-100) (16.5) 86.8 (10-100) (20.8) 90.0 (25-100) (17.4) 82.3 (10-100) (25.3)
General health functioning 73.3 (0-100) (17.5) 73.9 (0-100) (17.0) 69.3 (10-100) (19.5) 65.9 (30-100) (17.9) 57.1 (0-100) (26.8) 69.2 (25-100) (17.5) 65.6 (15-100) (21.0)
Onset of SRPE (age in years)  - - 27.9 (3-62) (12.9) 29.8 (5-52) (13.2) 27.0 (2-59) (15.5)
Number of SRPE - - 1.4 (1-6) (0.8) 1.4 (1-4) (0.8) 2.0 (1-7) (1.5) - -
Frequency of SRPE - - 1.7 (1-4) (0.8) 1.9 (1-4) (0.9) 2.0 (1-3) (0.7) - -
Distress of SRPE - - 1.8 (0-4) (1.0) 1.8 (1-4) (1.0) 2.0 (1-4) (1.1) - -
Impact of SRPE - - 1.4 (0.5-4) (0.7) 1.5 (1-4) (0.8) 1.5 (1-3) (0.6) - -
FP, false positive; SRPE, self-reported psychotic experiences; PE, psychotic experiences; SD, standard deviation
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SUPPLEMENTARY MATERIALS
Table S1. Baseline assessment - prevalence rates for dichotomous variables; psychopathological and 
psychosocial characteristics
Total sample Controls Remitted FP SRPE Persistent FP SRPE Transition to validated PE Incident FP SRPE Incident validated PE
Dichotomous variables N (%) N (%) N (%) N (%) N (%) N (%) N (%)
Lifetime mood disorder 905/4683 (19.3) 743/4147 (17.9) 89/312 (28.5) 12/32 (37.5) 14/28 (50.0) 28/110 (25.4) 19/54 (35.2)
Lifetime anxiety disorder 854/4683 (18.2) 706/4147 (17.0) 76/312 (24.7) 11/32 (34.4) 13/28 (46.4) 33/110 (30.0) 15/54 (27.8)
Lifetime substance disorder 729/4683 (15.6) 607/4147 (14.6) 70/312 (22.4) 10/32 (31.3) 8/28 (28.6) 21/110 (19.1) 13/54 (24.1)
Neuroticism (high/low) 1548/4607 (33.6) 1285/4077 (31.5) 136/310 (43.9) 21/31 (67.7) 20/28 (71.4) 61/109 (56.0) 25/52 (48.1)
Sexual abuse <16 357/4607 (7.8) 295/4077 (7.2) 40/310 (12.9) 5/31 (16.1) 5/28 (17.9) 9/109 (8.3) 3/52 (5.8)
Physical abuse <16 348/4607 (7.6) 284/4077 (7.0) 35/310 (11.3) 3/31 (9.7) 7/28 (25.0) 10/109 (9.2) 9/52 (17.3)
Emotional abuse <16 652/4607 (14.2) 527/4077 (12.9) 75/310 (24.2) 8/31 (25.8) 13/28 (46.4) 14/109 (12.8) 15/52 (28.9)
Psychological abuse <16 728/4607 (14.6) 595/4077 (14.6) 81/310 (26.1) 13/31 (41.9) 11/28 (39.3) 18/109 (16.5) 10/52 (19.2)
Regular bullying <16 615/4603 (13.4) 515/4073 (12.6) 56/310 (18.1) 6/31 (19.4) 6/28 (21.4) 20/109 (18.3) 12/52 (23.1)
Negative life events past year 2248/4607 (48.8) 1913/4077 (46.9) 196/310 (63.2) 23/31 (74.2) 19/28 (67.9) 62/109 (56.9) 35/52 (67.3)
Regular cannabis use (≥1/wk, past year) 69/3780 (1.8) 52/3419 (1.5) 10/241 (4.2) 1/26 (3.9) 2/23 (8.7) 3/90 (3.2) 1/47 (2.1)
Help seeking, generala 506/4607 (11.0) 398/4077 (9.8) 62/310 (20.0) 9/31 (29.0) 10/28 (35.7) 18/109 (16.5) 9/52 (17.3)
Help seeking, specificb na na 19/292 (6.1) 0/32 (0) 4/28 (14.3) na na
FP, false positive; SRPE, self-reported psychotic experiences; PE, psychotic experiences; na: not available; 
a General: psychiatric problems, including drug- or alcohol-related help seeking; b Specific: psychotic experiences
Table S2. Baseline assessment - means, minimum, maximum and SDs for continuous variables; 
psychopathology, general health, social functioning, and severity of SRPE
Total sample Controls Remitted FP SRPE Persistent FP SRPE Transition to validated PE Incident FP SRPE Incident validated PE
Continuous variables Mean (min – max) 
(SD)
Mean (min – max) 
(SD)
Mean (min – max)  
(SD)
Mean (min – max) (SD) Mean (min – max) 
 (SD)
Mean (min – max) 
(SD)
Mean (min – max) (SD)
General mental functioning 84.5 (8-100) (12.4) 85.1 (8-100) (11.9) 81.6 (20-100) (14.6) 76.5 (16-100) (18.9) 76.1 (24-100) (19.9) 79.5 (16-100) (14.3) 79.5 (28-100) (16.6)
General social functioning 91.5 (0-100) (17.0) 92.1 (0-100) (16.4) 87.9 (0-100) (20.5) 82.0 (0-100) (24.0) 75.9 (0-100) (28.9) 89.5 (37.5-100) (16.5) 85.4 (25-100) (20.3)
General physical functioning 92.6 (0-100) (16.2) 93.0 (0-100) (15.8) 90.1 (10-100) (18.1) 89.1 (40-100) (16.5) 86.8 (10-100) (20.8) 90.0 (25-100) (17.4) 82.3 (10-100) (25.3)
General health functioning 73.3 (0-100) (17.5) 73.9 (0-100) (17.0) 69.3 (10-100) (19.5) 65.9 (30-100) (17.9) 57.1 (0-100) (26.8) 69.2 (25-100) (17.5) 65.6 (15-100) (21.0)
Onset of SRPE (age in years)  - - 27.9 (3-62) (12.9) 29.8 (5-52) (13.2) 27.0 (2-59) (15.5)
Number of SRPE - - 1.4 (1-6) (0.8) 1.4 (1-4) (0.8) 2.0 (1-7) (1.5) - -
Frequency of SRPE - - 1.7 (1-4) (0.8) 1.9 (1-4) (0.9) 2.0 (1-3) (0.7) - -
Distress of SRPE - - 1.8 (0-4) (1.0) 1.8 (1-4) (1.0) 2.0 (1-4) (1.1) - -
Impact of SRPE - - 1.4 (0.5-4) (0.7) 1.5 (1-4) (0.8) 1.5 (1-3) (0.6) - -
FP, false positive; SRPE, self-reported psychotic experiences; PE, psychotic experiences; SD, standard deviation
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ABSTRACT
Background: The liability-threshold model of psychosis risk predicts stronger phenotypic 
manifestation of the polygenic risk score (PRS) in the healthy relatives of patients, as 
compared with healthy comparison subjects. 
Methods: First-degree relatives of patients with psychotic disorder (871 siblings and 812 
parents) and healthy comparison subjects (n=523) were interviewed three times in 6 
years. Repeated measures of two psychosis phenotypes, the Community Assessment of 
Psychic Experiences (CAPE; self-report – subscales of positive, negative and depressive 
symptoms) and the Structured Interview for Schizotypy – Revised (SIS-R; clinical inter-
view – subscales of positive and negative schizotypy), were examined for association 
with PRS. Interview-based lifetime rate of depressive and manic episodes were also ex-
amined, as was association with repeated measures of intelligence quotient (IQ).
Results: In the relatives, PRS was associated with CAPE/SIS-R total score (respective-
ly, B=0.12, 95% CI 0.02-0.22 and B=0.11, 95% CI 0.02-0.20), the SIS-R positive subscale 
(B=0.16, 95% CI 0.04–0.28), the CAPE depression subscale (B = 0.21, 95% CI 0.07–0.34), 
any lifetime affective episode (OR 3.1, 95% CI 1.04-9.3), but not with IQ (B=−1.8, 95% CI 
−8.0 to 4.4). In the controls, similar associations were apparent between PRS on the one 
hand and SIS-R total score, SIS-R positive, SIS-R negative, any lifetime affective episode 
and, in contrast, lower IQ (B=−8.5, 95% CI −15.5 to 1.6).
Conclusion: In non-ill people, polygenic risk for psychotic disorder is expressed pleio-
tropically in the domain of neurodevelopment, emotion regulation and attribution of sa-
lience. In subjects at elevated genetic risk, emerging expression of neurodevelopmental 
alterations may create floor effects, obscuring genetic associations.
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INTRODUCTION
There is strong evidence that measures of psychosis proneness in non-clinical popula-
tions are associated with a family history of psychotic disorder1, 2. However, early reports 
on associations between measures of psychosis proneness in the general population 
and genome-wide association study (GWAS)-based polygenic risk scores (PRS) for schiz-
ophrenia3, 4 are inconclusive5-8. Any association between psychosis proneness and PRS 
may be stronger in relatives of patients, compared with the general population, given 
that expression of psychosis-related phenotypes likely is attributable to genes shared 
with the patient relative9, 10, whereas expression of psychosis-related phenotypes in gen-
eral population samples may be associated more with environmental effects2, 11, 12. We 
therefore hypothesized that the link between PRS and expression of psychosis pheno-
types would be stronger in relatives of patients, who share liability genes with their 
ill relative, as compared with the general population, whose level of genetic liability is 
much lower.
Data pertained to patients with psychotic disorder (n=1119), their parents (n=920) and 
siblings (n=1059) and healthy comparison subjects (n=586) participating in the baseline, 
3-year and 6-year follow-up assessments of the Genetic Risk and Outcome of Psycho-
sis (GROUP) study. Repeated measures of two psychosis phenotypes, indexed with the 
Community Assessment of Psychic Experiences (CAPE; self-report) and the Structured 
Interview for Schizotypy – Revised (SIS-R; clinical interview), were examined for associ-
ation with PRS. Given strong associations between psychosis phenotypes and measures 
of affective dysregulation13-18, affective outcomes were also included in the analyses. Giv-
en the commonly hypothesized notion that genetic effects in schizophrenia are mediat-
ed through altered neurodevelopment19, neurocognition was also examined in relation 
to PRS.
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METHODS
GROUP study
Full details of the GROUP study have been presented elsewhere20, 21. In representative 
geographical areas in the Netherlands and Belgium, patients were identified through cli-
nicians working in regional psychotic disorder services, whose caseload was screened for 
inclusion criteria. Subsequently, a group of patients presenting at these services either 
as out-patients or in-patients were recruited for the study. Healthy comparison subjects 
were selected through random mailings to addresses in the catchment areas of the cas-
es. The GROUP study was not conducted in a geographically well-defined small area, as 
it in fact included the majority of mental health services in the Netherlands, and a sub-
stantial part of mental health services in Dutch-speaking Belgium. Healthy comparison 
subjects could not be representative in all aspects, as an exclusion criterion was absence 
of a family history of psychotic disorder. The goal was to collect a group of healthy com-
parison subjects that (i) was collected from the same geographical area as the case in 
the relevant mental health service, (ii) was sufficiently large to allow for chance variation 
and (iii) was frequency-matched in age- and sex distribution to the siblings and (iv) had 
absence of family history of psychotic disorder. Table 1 shows that healthy comparison 
subjects, siblings and parents had similar sex distributions whilst healthy comparison 
subjects and siblings did not have large differences in age.
Table 1. Baseline demographics of GROUP participants in current analysis
Age Educationa IQ Urbanicity at birthb
Mean S.D. % Female Mean S.D. Mean S.D. Mean S.D. n
Healthy comparison 
subjects
31.10 10.70 0.55 2.95 1.27 110.16 14.79 2.57 1.68 523
Siblingss 27.85 8.32 0.53 2.63 1.48 104.00 15.21 2.52 1.63 871
Parents 54.83 6.83 0.57 2.53 1.57 103.54 16.68 2.26 1.58 812
Total 38.55 15.08 0.55 2.69 1.46 105.31 15.90 2.51 1.64 2206
a Education (Verhage): range 0 (no education), 3–5 (school diploma) to 8 (university degree).
b Urbanicity: 1=<500/km2; 2 500–1000/km2; 3=1000–1500/km2; 4=1500–2500/km2; 5=2500+/km2.
Sample
The full GROUP sample at baseline consisted of 1119 patients with non-affective psy-
chotic disorder, 1059 siblings of these patients, 920 parents of the patients and 586 
unrelated healthy comparison subjects.
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Inclusion criteria were: (i) age range 16–50 years and (ii) good command of Dutch lan-
guage. For patients, an additional inclusion criterion was the presence of a clinical diag-
nosis of non-affective psychotic disorder. Healthy comparison subject status was con-
firmed by using the Family Interview for Genetic studies22 with the healthy comparison 
subject as informant, to establish absence of first degree relatives with a psychotic disor-
der. Diagnosis was based on the Diagnostic and Statistical Manual of Mental Disorder-IV 
(DSM-IV) criteria23, assessed with the Comprehensive Assessment of Symptoms and His-
tory (CASH) interview24 or Schedules for Clinical Assessment for Neuropsychiatry (SCAN 
2.1)25. The majority of patients had a DSM-IV diagnosis of schizophrenia (DSM-IV 295.x; 
n=940, 84%). In the sibling and healthy comparison subject groups, there were respec-
tively, 154 (14%) and 59 participants (10%) with a history of a common mental disorder 
at baseline, the majority of whom had a mood disorder (DSM-IV 296.x). The study was 
approved by the standing ethics committee, and all the subjects gave written informed 
consent in accordance with the committee’s guidelines.
Sample for analysis
For the purpose of the current analyses, siblings, parents and healthy comparison sub-
jects groups were included. Analyses were restricted to the European white ethnic group 
(n=2218, or 87% out of a total of
2565 siblings, parents and healthy comparison subjects groups at baseline) given the 
fact that prevalence of risk alleles varies widely across ethnic groups, as may the risk 
associated with individual alleles, and evidence exists of differential effects of PRS across 
ethnic groups26. Observations of siblings and healthy comparison subjects who made a 
possible (n=2, of whom 1 of European white ethnic group) or definite (n=16, of whom 
11 of European white ethnic group) transition to a psychotic disorder over the follow-up 
period, and thus were re-classified as patients, were excluded from analysis. Applying 
ethnicity and transition criteria thus resulted in a baseline sample of 523 healthy com-
parison subjects, 871 siblings and 812 parents of siblings (total sample: n=2206). Of the 
2206, the number of individuals with data permitting calculation of the PRS was 1578 
(72%) with approximately equal proportions across healthy comparison subjects (73%), 
siblings (67%) and parents (75%).
SIS-R
The SIS-R was administered to healthy comparison subjects, parents and siblings. The 
SIS-R is a semi-structured interview containing 20 schizotypal symptoms and 11 schizo-
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typal signs rated on a 4-point scale27, 28. Symptoms are defined as verbal responses to 
standardized questions concerning, for example, magical ideation, illusions and ref-
erential thinking. Signs refer to behaviours that are rated by the interviewer such as 
goal directedness of thinking and flatness of affect. Questions and rating procedures 
are standardized. Guided by previous research, 33 item scores were reduced a priori 
to two-dimensional scores, representing the means of seven positive schizotypy items 
(covering the areas of  referential thinking, psychotic phenomena, derealisation, mag-
ical ideation, illusions and suspiciousness) and eight negative-disorganized schizotypy 
items (covering the areas of social isolation, sensitivity, introversion, restricted affect, 
disturbances in associative and goal-directed thinking, poverty of speech and eccentric 
behaviour). 
CAPE
The CAPE (www.cape42.homestead.com) was developed in order to rate self-reports 
of lifetime psychotic experiences29. Items are modelled on patient experiences as con-
tained in the Present State Examination, 9th version30, schedules assessing negative 
symptoms such as the Scale for the Assessment of Negative Symptoms (SANS)31 and the 
Subjective Experience of Negative Symptoms (SENS)32 and scales assessing depressive 
symptoms such as the Calgary Depression Scale33. Items are scored on a 4-point scale. In 
the current analyses, CAPE dimensions of frequency of positive experiences (20 items), 
negative experiences (14 items) and depressive experiences  (eight items) were included 
(measured at baseline and 3- and 6-year follow-up), representing the person’s  perceived 
psychosis load over the lifetime (at baseline) or in the past 3 years (follow-up). A total 
score representing the mean of all items was calculated for each dimension.
Manic and depressive episodes
Lifetime rate of depressive and manic episodes were derived from the CASH interview 
(data available for 3 of the 4 centres).
Intelligence quotient (IQ)
At baseline and 3-year follow-up, IQ was estimated based on the four-subtest version 
(Information, Block Design, Digit Symbol Coding and Arithmetic)34 of the Wechsler Adult 
Intelligence Scale (WAIS-III)35. At 6-year follow-up, IQ was estimated based on a short 
version of the WAIS-III short form: the Digit Symbol Coding subtest, uneven items of the 
Arithmetic subtest, uneven items of the Block Design subtest, every third item of the 
Information subtest36.
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Follow-up
Healthy comparison subjects and siblings were eligible for follow-up; parents were only 
assessed at baseline. Of the 523 healthy comparison subjects and 871 siblings at base-
line, 80% (n=1115) were assessed at 3-year follow-up (healthy comparison subjects: 79%, 
n= 415; siblings: 80%, n=700) and 69% (n=973) at 6-year follow-up (healthy comparison 
subjects: 68%, n=357; siblings: 71%, n=616). Ratings of CASH, SCAN, SIS-R and CAPE at 
follow-up reflected the period between baseline and first follow-up, and between first 
and second follow-up, respectively. Mean time to first follow-up was 3.3 years (S.D.=0.5) 
and mean between first and second follow-up was 3.1 years (S.D.=0.4).
Genotyping, imputation and PRS
Genotyping was performed using two platforms. A total of 1434 participants (758 
patients, 676 healthy comparison subjects) were genotyped on the Illumina plat-
form for 547 383 SNPs on the Illumina HumanHap 550k v3.0 beadchip. A second 
group of 1968 participants (393 patients, 154 controls and 1421 healthy relatives) 
were genotyped for 929 556 SNPs using the Affymetrix genome-wide Human SNP 
Array version 6.0.
A binary data set of the Illumina platform was generated including 547 383 genotyped 
variants in 1434 subjects. We excluded 36 samples showing a sex mismatch between 
recorded and the genetically determined gender type, leaving 1,398 people for further 
analysis. We excluded SNPs that were haploid or had missing rates per SNP of >0.10, or a 
MAF of <0.01 or a HWE p value<0. 00001 (in healthy comparison subjects) and excluded 
individuals, with a missing rate >10%, altogether yielding 515 286 variants and 1393 indi-
viduals (737 patients and 656 healthy comparison subjects) for further analysis. Next, a 
binary data set of Affymetrix platform was generated including 929 556 SNPs genotyped 
in 1968 subjects (393 patients and 1575 relatives), of which 729 597 SNPs and 1968 
individuals passed the standard quality processing checks. We successfully converted 
genetic coordination of all variants (except for 57 from Illumina and 86 from Affymetrix) 
from Human NCBI36/hg18 to GRCh37/hg19 using Liftover (online tools) for all samples. 
Next, we imputed both platform samples on the backbone of 1000 G Phase-3 reference 
haploblocks, as implemented in the Haplotype Reference Consortium (HRC)37, using the 
Michigan Imputation Server and the SHAPEIT option for phasing. This yielded 46 178 
415 imputed variants, which was reduced to 16 353 433 SNPs after selecting SNPs with 
a quality score (info score) threshold of >0.30, of which 9 067 392 variants and 1393 
subjects passed the post-imputation QC. As for Affymetrix genotypes, 1kG-based impu-
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tation yielded 46 178 419 imputed SNPs, which were reduced to 9 122 501 SNPs after 
implementing post-imputation quality controls in 1968 subjects. These were included in 
the next step.
In order to calculate PRS, we obtained summary statistics of the genome-wide associ-
ation study from the Psychiatric Genomic Consortium-2 (PGC2)38, which included the 
GROUP subjects. We performed meta-analysis again while excluding GROUP samples 
as well as other Dutch samples, including a total of 17 104 566 SNPs, of which 8 242 
976 SNPs were common with imputed GROUP genotypes from Illumina-based variants 
and 8 290 712 variant from Affymetrix-based variants. Following the approach taken by 
the international psychiatric GWAS consortium, we calculated a PRS at the metagwas 
p-threshold of <0.1 for association with Schizophrenia by PGC2. This included 2 302 038 
SNPs of which 1 481 064 SNPs were common with the Illumina genotype dataset, and 1 
483 770 SNPs were common with the Affymetrix genotype data set (1 455 047 SNPs are 
common across both platforms). Furthermore, we repeated our association analysis at 
p-threshold of <0.01, which constituted 449 794 SNPs (364 121 common with the Illumi-
na platform, 363305common with the Affymetrix platform and 360 150 SNPs common 
across both platforms). We used PRSice39 software to calculate PRS; by LD clumping of 
r2 value < 0.2, at distance threshold of 250 kb, while adjusting for 10 eigenvectors cal-
culated by Eigenstrat40. This led to inclusion of 119 653 SNPs from the Illumina platform 
and 119 271 SNPs from Affymetrix for estimating PRS at p-metagwas<0.1; and 25 250 
SNPs from the Illumina and 25 152 SNPs from the Affymetrix platform to estimate PRS at 
p-metagwas<0.01. We calculated different PRS using different p value thresholds, from 0 
to 0.50, and checked the explained variances at the different threshold of PRS on schizo-
phrenia using Nagelkerke’s R-square. The analyses are based on the p-threshold of 0.01 
with sensitivity analyses for the p-threshold of 0.1. For ease of interpretation, a constant 
was added to the two PRS scores, so that the minimum value was 0.
Analyses
GROUP database version 5.0 was used for all analyses. Random intercept multilevel 
regression models (given clustering of individuals within families as well as clustering of 
repeated measures within subjects) with SIS-R and CAPE measures as dependent varia-
bles were fitted using the MIXED routine in the Stata program, version 1441. Independent 
variables were PRS, a priori corrected for age and sex. In addition, binary outcomes of 
CASH lifetime depressive and manic episode were modelled using the Stata MEQRLOGIT 
multilevel random intercept logistic regression routine, similarly adjusted for age and sex.
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In order to examine robustness of findings with regard to assumptions of normality, 
log-transformed outcomes were additionally examined, using the Stata LNSKEW0 rou-
tine. LNSKEW0 creates newvar=ln(+/−exp− k), choosing k and the sign of exp so that the 
skewness of newvar is zero. In order to assess to what degree   associations between 
PRS and measures of psychosis proneness were independent, regression analyses were 
conducted for one measure of psychosis proneness, corrected for all the others. In order 
to examine to what degree any association between PRS and measures of psychosis 
proneness were mediated by IQ, IQ was added to the analyses as a covariate.
64  |  Chapter 3
RESULTS
Descriptive results and interaction by group
Sample characteristics are displayed in Table 1. Values of the CAPE and SIS-R total score, 
lifetime depressive and manic episodes and PRS are shown in Table 2, by group and sex. 
CAPE and SIS-R subscale scores, by group and sex, are shown in Table 3.
Table 2. Depression and mania outcomes, and polygenic risk scores by group and by sex
% Depressive episodea % Manic episodea PRS
Rate n Rate n Mean S.D. n
Group
  Healthy comparison subjects 0.27 445 0.02 445 0.60 0.21 382
  Siblings 0.33 656 0.04 656 0.83 0.15 586
  Parents 0.30 583 0.02 583 0.83 0.15 610
Sex
  Men 0.22 739 0.03 739 0.77 0.20 720
  Women 0.37 945 0.03 945 0.77 0.19 858
Total 0.30 1684 0.03 1684 0.77 0.19 1578
PRS, polygenic risk score.
aLifetime rate, calculated with baseline sample as denominator and including episodes occurring over the 
6-year post-baseline follow-up period in the numerator.
The PRS of the healthy comparison subjects (0.60, S.D.=0.21) was significantly lower 
than the PRS in the combined group of parents and siblings (0.83, S.D.=0.15; p<0.001). 
The PRS in the group of parents and siblings was significantly correlated with the PRS in 
the patient group (r=0.30, p<0.0001).
Graphical examination of the scatterplots of PRS on the one hand and CAPE/SIS-R total 
scores (Fig. 1a–d), CAPE subscale scores (Fig. 2a–f), SIS-R subscales scores (Fig. 3a–d) 
and IQ (Fig. 4a, b) on the other suggests association between PRS and various aspects of 
psychopathology and cognition in both groups.
Associations in relatives and healthy comparison subjects
Given the graphical suggestion of differences in the pattern of associations, analyses 
were conducted separately for relatives and the healthy comparison group. The pattern 
of correlation between the CAPE and  SIS-R total and subscale scores were similar for 
relative and healthy comparison subjects, in that within-instrument scale correlations 
were high, whereas between-scale correlations were only moderate (Table 4).
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Fig. 1. (a–d) Scatterplots with linear regression line of polygenic risk score (PRS) on the one hand, and, on 
the other, Community Assessment of Psychic Experiences (CAPE) total score in healthy comparison subjects 
(Fig. 1a); Structured Interview for Schizotypy – Revised (SIS-R) total score in healthy comparison subjects 
(Fig. 1b); CAPE total score in relatives (Fig. 1c); and SIS-R total score in relatives (Fig. 1d).
Results of the multilevel random regression analyses are shown in Tables 5–7. In the 
relatives (Table 6), PRS was associated with CAPE total score (B=0.12, 95% CI 0.02–0.22, 
p=0.015), SIS-R total score (B= 0.11, 95% CI 0.02–0.20, p=0.013) as well as with CAPE 
depression (B=0.21, 95% CI 0.07–0.34, p=0.004) and the SIS-R positive subscale (B=0.16, 
95% CI 0.04–0.28, p=0.008). Analyses with log-transformed scales showed similar re-
sults (Table 5). Analyses of the CAPE the SIS-R subscales, in which subscales were con-
trolled for each other, showed that associations were reducible to the association with 
CAPE depression, which continued to be associated with PRS (B=0.10, 95% CI 0.02–0.19, 
p=0.021) whereas the association with the SIS-R positive subscale was rendered non-sig-
nificant (Table 5).
The association between CAPE depression and PRS was not affected by IQ, as the associ-
ation with CAPE depression remained similar when IQ was added in addition to age and 
sex (B=0.20, 95% CI 0.06–0.34, p=0.005).
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In the healthy comparison subjects (Table 6), PRS was associated with the SIS-R total score 
(B=0.16, 95% CI 0.07–0.25, p=0.000) and both the SIS-R positive subscale (B=0.22, 95% CI 
0.10–0.35, p=0.000) and the SIS-R negative subscale (B=0.11, 95% CI 0.03–0.19, p=0.10) 
(Table 6). Analyses with log-transformed scales were similar (Table 6). In the analysis in 
which all subscales were controlled for each other, only the association with the SIS-R pos-
itive subscale remained significant (B=0.14, 95% CI 0.05–0.24, p=0.004; Table 6).
Analyses of association between PRS and CASH based lifetime depressive and manic 
episodes revealed evidence for association in both the relatives (OR any affective epi-
sode=3.1, 95% CI 1.04–9.3, p=0.043) and the healthy comparison subjects (OR any affec-
tive episode=3.4, 95% CI 0.9–12.7, p=0.075) (Table 7).
In the relatives, no large or significant association was apparent between PRS and IQ in 
a separate model of IQ, corrected for age and sex (B=−1.8, 95% CI −8.0 to 4.4; p=0.566). 
In the healthy comparison subjects, there was evidence for an association between IQ 
Table 3. Cape and SIS-R subscale scores by group and by sex
CAPE total CAPE POS CAPE-NEG CAPE-DEP SIS-R total
SIS-R
positive
SIS-R
negative
Time Mean S.D. n Mean S.D. n Mean S.D. n Mean S.D. n Mean S.D. n Mean S.D. n Mean S.D. n
Group
1 HCS 0.42 0.23 502 0.19 0.17 500 0.48 0.32 500 0.59  0.34 502 0.27 0.25 515 0.30 0.35 515 0.24 0.23 514
Siblings 0.45 0.27 767 0.19 0.18 765 0.54  0.38 765 0.61 0.38 767 0.31  0.28 858 0.36 0.41 858 0.26 0.24 858
Parentsa 0.41  0.23 692 0.13 0.13 692 0.50 0.33 692 0.60  0.35 692 0.29 0.24 806 0.25 0.30 806 0.32 0.28 806
2 HCS 0.30  0.23 401 0.08 0.12 401 0.39 0.31 400 0.43 0.35 401 0.26  0.20 402 0.27 0.29 402 0.24 0.21 400
Siblings 0.35 0.28 675 0.10 0.14 673 0.46 0.40 674 0.49  0.40 675 0.29 0.25 683 0.31 0.34 683 0.28 0.25 683
Parentsa - - - - - - - - - - - - - - - - - - - - -
3 HCS 0.32   0.26 343 0.08 0.15 343 0.41 0.34 343 0.48 0.41 343 0.27  0.21 336 0.28 0.29 336 0.25 0.22 336
Siblings 0.35   0.28 594 0.08 0.12 593 0.47 0.40 593 0.50  0.41 594 0.30 0.24 598 0.31 0.31 598 0.29 0.25 598
Parentsa - - - - - - - - - - - - - - - - - - - - -
Sex
1 Men 0.40  0.23 890 0.17 0.16  889 0.50 0.33 889 0.52 0.32 890 0.28 0.25 984 0.28 0.33 984 0.29 0.27 983
Women 0.45 0.26 1071 0.17 0.17 1068 0.52 0.35 1068 0.67 0.38 1071 0.30 0.27 1195 0.33 0.38 1195 0.27 0.25 1195
2 Men 0.30 0.24 478 0.10 0.13 478 0.42 0.35 478 0.40 0.34 478 0.27 0.23 486 0.26 0.30 486 0.27 0.25 485
Women 0.36 0.28 598 0.09 0.13 596 0.45 0.39 596 0.53 0.40 598 0.29 0.24 599 0.32 0.34 599 0.26 0.23 598
3 Men 0.31 0.25 419 0.09 0.13 418 0.43 0.36 418 0.42 0.36 419 0.29 0.24 420 0.28 0.30 420 0.29 0.27 420
Women 0.36 0.29 518 0.08 0.13 518 0.46 0.39 518 0.55 0.44 518 0.29 0.22 514 0.31 0.31 514 0.27 0.22 514
CAPE, Community Assessment of Psychic Experiences (subscales of positive, negative and depressive symp-
toms); SIS-R, Structured Interview for Schizotypy – Revised (subscales of positive and negative schizotypy).
a Parents baseline measures only.
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and PRS, adjusted for age and sex (B=−8.5, 95% CI −15.5 to −1.6; p=0.017). The associa-
tion between PRS and IQ in the healthy comparison subjects remained after controlling 
for SIS-R total score (B=−7.5, 95% CI −14.5 to −0.4; p=0.038). Similarly, the association 
between PRS and SIS-R total score in the healthy comparison subjects remained after 
controlling for IQ (B=0.16, 95% CI 0.07–0.25; p=0.001).
Sensitivity analyses at PRS p-threshold of 0.1
Results for the sensitivity analyses were at the PRS p-threshold of 0.1 were very similar 
to the analyses at the P-threshold of 0.01. The association between PRS and IQ was 
slightly weaker in the healthy comparison group (B=−7.1, 95% CI −15.1 to 0.9, p=0.081). 
In the relatives group, associations between PRS and the CAPE positive and negative 
subscale were also significant and associations were not reducible to CAPE depression 
but to the SIS-R positive subscale.
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1 Men 0.40  0.23 890 0.17 0.16  889 0.50 0.33 889 0.52 0.32 890 0.28 0.25 984 0.28 0.33 984 0.29 0.27 983
Women 0.45 0.26 1071 0.17 0.17 1068 0.52 0.35 1068 0.67 0.38 1071 0.30 0.27 1195 0.33 0.38 1195 0.27 0.25 1195
2 Men 0.30 0.24 478 0.10 0.13 478 0.42 0.35 478 0.40 0.34 478 0.27 0.23 486 0.26 0.30 486 0.27 0.25 485
Women 0.36 0.28 598 0.09 0.13 596 0.45 0.39 596 0.53 0.40 598 0.29 0.24 599 0.32 0.34 599 0.26 0.23 598
3 Men 0.31 0.25 419 0.09 0.13 418 0.43 0.36 418 0.42 0.36 419 0.29 0.24 420 0.28 0.30 420 0.29 0.27 420
Women 0.36 0.29 518 0.08 0.13 518 0.46 0.39 518 0.55 0.44 518 0.29 0.22 514 0.31 0.31 514 0.27 0.22 514
CAPE, Community Assessment of Psychic Experiences (subscales of positive, negative and depressive symp-
toms); SIS-R, Structured Interview for Schizotypy – Revised (subscales of positive and negative schizotypy).
a Parents baseline measures only.
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Table 4. Pattern of Pearson’s correlation coefficients between psychopathology measures in relatives (top) 
and controls (bottom)
SIS-R  
total
CAPE  
total
SIS-R
negative
CAPE
negative
SIS-R 
positive
CAPE 
positive
CAPE
depressive
Relatives
  SIS-R total 1
  CAPE total 0.50 1
  SIS-R negative 0.82 0.42 1
  CAPE negative 0.45 0.92 0.43 1
  SIS-R positive 0.88 0.42 0.44 0.35 1
  CAPE positive  0.38 0.65 0.19 0.48 0.42 1
  CAPE depressive 0.45 0.93 0.39 0.75 0.38 0.49 1
HCS
  SIS-R total 1
  CAPE total 0.46 1
  SIS-R negative 0.82 0.36 1
  CAPE negative 0.40 0.90 0.36 1
  SIS-R positive 0.89 0.42 0.46 0.33 1
  CAPE positive 0.33 0.68 0.16 0.49 0.39 1
  CAPE depressive 0.43 0.92 0.35 0.72 0.38 0.50 1
CAPE, Community Assessment of Psychic Experiences (subscales of positive, negative and depressive symp-
toms); SIS-R, Structured Interview for Schizotypy – Revised (subscales of positive and negative schizotypy); 
HSC, healthy control subjects.
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Fig. 2. (a–f) Scatterplots with linear regression line of polygenic risk score (PRS) on the one hand, and, on the 
other, Community Assessment of Psychic Experiences (CAPE) positive score in healthy comparison subjects 
(Fig. 2a), CAPE negative score in healthy comparison subjects (Fig. 2b), CAPE depression score in healthy 
comparison subjects (Fig. 2c), CAPE positive score in relatives (Fig. 2d), CAPE negative score in relatives (Fig. 
2e), CAPE depression score in relatives (Fig. 2f).
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Table 5. Results of regression analyses in relatives of patients
Association of psychopathology measure with PRS
Association of log-transformed psychopathology 
measure with PRS
Association of psychopathology subscales with 
PRS, corrected for the other subscales
B (0.95% CI) p n B (0.95% CI) p N B (0.95% CI) p N
Measure
  CAPE total 0.12 (0.02-0.22) 0.015 1916 0.16 (0.01-0.31) 0.032 1916 NAa
  CAPE positive 0.04 (-0.02 to 0.10) 0.150 1913 0.32 (-0.01 to 0.65) 0.059 1913 -0.01 (-0.05 to 0.04) 0.083 1884
  CAPE negative 0.13 (-0.01 to 0.27) 0.075 1914 0.12 (-0.05 to 0.28) 0.170 1914 -0.04 (-0.13 to 0.05) 0.385 1884
  CAPE depressive 0.21 (0.07-0.34) 0.004 1916 0.21 (0.07-0.36) 0.005 1916 0.10 (0.02-0.19) 0.021 1884
  SIS-R total 0.11 (0.02-0.20) 0.013 2071 0.24 (0.04-0.43) 0.016 2071 NAa
  SIS-R positive 0.16 (0.04-0.28) 0.008 2071 0.51 (0.19-0.83) 0.002 2071 0.08 (-0.02 to 0.18) 0.136 1884
  SIS-R negative 0.08 (-0.02 to 0.17) 0.103 2071 0.14 (-0.06 to 0.33) 0.166 2071 0.02 (-0.06 to 0.10) 0.616 1884
a NA: analyses were conducted with the five subscales: CAPE positive, CAPE negative, CAPE depressive, 
SIS-R positive, SIS-R negative.
B, regression coefficient; 95% CI, 95% confidence interval; p, p-value; n, number of observations, PRS, poly-
genic risk score; CAPE, Community Assessment of Psychic Experiences (subscales of positive, negative and 
depressive symptoms); SIS-R, Structured Interview for Schizotypy – Revised (subscales of positive and neg-
ative schizotypy).
Table 6. Results of regression analyses in healthy control subjects 
Association of psychopathology measure with PRS
Association of log-transformed psychopathology 
measure with PRS
Association of psychopathology subscales with 
PRS, corrected for the other subscales
B (0.95% CI) p n B (0.95% CI) p N B (0.95% CI) p N
Measure
  CAPE total 0.04 (-0.07 to 0.14) 0.465 911 0.01 (-0.17 to 0.19) 0.917 911 NAa
  CAPE positive 0.03 (-0.04 to 0.10) 0.451 910 0.20 (-0.27 to 0.66) 0.400 910 -0.00 (-0.06 to 0.05) 0.872 889
  CAPE negative -0.13 (-0.15 to 0.12) 0.848 909 -0.07 (-0.24 to 0.10) 0.431 909 -0.10 (-0.19 to 0.01) 0.030 889
  CAPE depressive 0.11 (-0.04 to 0.26) 0.147 911 0.07 (-0.11 to 0.24) 0.441 911 0.08 (-0.02 to 0.18) 0.093 889
  SIS-R total 0.16 (0.07-0.25) 0.000 921 0.40 (0.18-0.63) 0.000 921 NAa
  SIS-R positive 0.22 (0.10-0.35) 0.000 921 0.60 (0.28-0.93) 0.000 921 0.14 (0.05- 0.24) 0.004 889
  SIS-R negative 0118 (0.03 to 0.19) 0.000 919 0.31 (0.09-0.33) 0.005 919 0.04 (-0.03 to 0.11) 0.244 889
a NA: analyses were conducted with the five subscales: CAPE positive, CAPE negative, CAPE depressive, SIS-R 
positive, SIS-R negative.
B, regression coefficient, 95% CI, 95% confidence interval; p, p-value; n, number of observations, PRS, poly-
genic risk score; CAPE, Community Assessment of Psychic Experiences (subscales of positive, negative and 
depressive symptoms); SIS-R, Structured Interview for Schizotypy – Revised (subscales of positive and neg-
ative schizotypy).
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Fig. 3. (a–d) Scatterplots with linear regression line of polygenic risk score (PRS) on the one hand, and, on the 
other, Structured Interview for Schizotypy – Revised (SIS-R) positive score in healthy comparison subjects 
(Fig. 3a), SIS-R negative score in healthy comparison subjects (Fig. 3b), SIS-R positive score in relatives (Fig. 
3c), SIS-R negative score in relatives (Fig. 3d).
Fig. 4. (a, b) Scatterplots with linear regression line of polygenic risk score (PRS) on the one hand and, on 
the other, intelligence quotient (IQ) score in the healthy comparison subjects (Fig. 4a) and IQ score in the 
relatives (Fig. 4b).
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Table 7. Results of regression analyses in baseline sample for lifetime manic and depressive episodes (in-
cluding episodes over 6-year follow-up) in relatives and healthy comparison subjects. Odds ratio reflects 
association between polygenic risk score on the one hand, and depressive/manic episode on the other 
Relatives Healthy control subjects
OR (0.95% CI) p n OR (0.95% CI) p N
Measure
  Depressive episode 2.6 (0.9-7.9) 0.089 911 3.4 (0.9-13.0) 0.069 323
  Manic episode 6.4 (0.3-132.6) 0.228 910 0.7 (0.01-38.2) 0.867 323
  Affective episodea 3.1 (1.04-9.3) 0.043 909 3.4 (0.0-12.7) 0.075 323
a Any depressive or manic episode.
OR, odds ratio; 95% CI, 95% confidence interval; p, p-value; n, number of observations
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DISCUSSION
The main findings were that (i) PRS was pleiotropically associated with measures of 
affective dysregulation, aberrant salience and neurocognition; (ii) The association be-
tween neurocognition and PRS was present in the healthy comparison subjects but not 
in the relatives, and was independent of CAPE/SIS-R measures; (iii) Interview-based 
SIS-R measures appeared to be more sensitive than CAPE-based self-reports in detecting 
genetic association in the healthy comparison group.
According to the liability-threshold model, a person with a number of risk variants low-
er than or equal to the critical threshold would not develop schizophrenia, whereas a 
person with more risk variants would42. As individuals at higher than average genetic 
risk, such as the first-degree relatives of patients, have higher levels of psychometric and 
neurocognitive endophenotypes associated with psychotic disorder10, 43, associations be-
tween PRS and such endophenotypes may be more  apparent in this group. However, in 
the current analysis, there was no evidence that associations between PRS and meas-
ures of psychopathology and cognition were stronger in the relatives of patients as com-
pared with a group of healthy comparison subjects. Indeed, given stronger evidence for 
association between PRS and cognition in the healthy control group, the results suggest 
it may be more, not less difficult to demonstrate associations in the relatives.
A previous investigation in this sample, focussing on the association between childhood 
trauma and IQ, reported a similar finding in that the association between IQ and child-
hood trauma was large in the healthy comparison group, intermediate in the relatives 
and not apparent in the patient group44. Thus, in subjects at higher than average (envi-
ronmental or genetic) risk, emerging expression of phenotypic alterations may create 
floor effects, obscuring associations. The results of this study again suggest that particu-
larly measures in the neurodevelopmental domain may be sensitive to such a floor ef-
fect, as associations between PRS and subthreshold measures of psychopathology were 
apparent in both the relative and the healthy comparison groups.
Affective dysregulation, aberrant salience and genetic liability to psychosis
There is a well-established link between affective dysregulation and psychosis, both at 
the level of clinical illness45, 46, subthreshold psychotic experiences13-18, so-called clinical 
high-risk states47 and in the early prodromal stages48. In addition, many studies have sug-
gested an important role of affective dysregulation in the formation of psychotic symp-
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toms49-53, and molecular genetic studies suggest an overlap between schizophrenia and 
affective illness54, 55.
There is evidence that psychosis represents a severity dimension of an initial state of 
affective dysregulation17, 56 and that clinical high risk samples with high risk of conversion 
to psychotic disorder mainly consist of individuals with affective dysregulation57.  There-
fore, early states of affective dysregulation may give rise to more severe states in which 
psychotic symptoms arise58. Additional exposure may be required for psychotic symptom 
formation, research showing higher risks of psychotic symptom formation with progres-
sively greater level of exposure to environmental risk factors59-61.
The findings agree with the literature, suggesting that the association between genetic 
risk and psychosis proneness is not only mediated by psychoticism and neurodevelop-
mental alterations, but also by measures of affective dysregulation. The effects of poly-
genic risk thus may be examined further in network models, focussing particularly on 
the strength of the connection between affective dysregulation, cognition and psychotic 
symptoms. Similarly, gene–environment interactions may converge at the level of the 
connection between affective dysregulation, cognition and psychotic symptoms.
Cognitive alterations and neurodevelopmental hypothesis
The premorbid cognitive alterations in schizophrenia are one of the core findings sup-
porting the neurodevelopmental hypothesis62. There was evidence for an association be-
tween IQ and PRS, however it may be hypothesized that environmental exposures such 
as childhood trauma, that have been shown to also impact cognitive development63-66 
may also play a causal role in the development of cognitive alterations in psychosis44, 
67-69. In addition, genetic variation and epistasis not included in the PRS may contribute 
to cognitive alterations as well. It has been reported that less than a fifth of the effect of 
family history on the occurrence of psychotic disorder is mediated by PRS70, leaving room 
for the impact of other genetic factors, assuming not all of the remainder of the effect of 
family history is ‘environmental’.
Given evidence that most of the overall effect of a schizophrenia diagnosis on cognitive 
performance is mediated through a single common factor, indicating that a generalized 
cognitive deficit is a core underlying feature71, a general measure like IQ arguably is the 
most useful to examine in the context of associations with PRS. There have been conflict-
ing reports on associations between measures of cognition and schizophrenia polygenic 
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scores in patient and control samples using a variety of different cognitive measures19, 72, 
73, however no previous report has examined the association in a large sample of non-ill 
individuals at higher than average genetic risk with repeated measures of IQ over time. 
Given evidence for an association between PRS and IQ in healthy control group, it may 
be hypothesized that PRS for schizophrenia is expressed, at least in part, as a cognitive 
measure that correlates with IQ.
Methodological issues
The results should be interpreted in the light of several methodological considerations. 
First, although the sample size was substantial, it was still relatively small for a molecular 
genetic study. Nevertheless, effect sizes were detectable. A previous general population 
study with a larger sample suggested a weak association with CAPE negative scores how-
ever in that study5, CAPE positive and CAPE depression scores were not included. Given 
that CAPE negative scores are strongly associated with CAPE depression scores (0.7 in the 
current study), the reported association with CAPE negative scores may be considered 
compatible with the  current findings7, given that CAPE depression in the healthy com-
parison group directionally showed the same type of association as in the relatives, albe-
it weaker. In any case, the results of this study show that self-reports of psychosis-prone-
ness in the general population may not be sensitive in detecting genetic associations. 
Second, it could be argued that lack of association between IQ and PRS in the relatives 
cannot be interpreted fully without examination of the association between IQ and PRS 
in their patient relatives; if the association is present in the patient group but not in their 
relatives, this may indicate that PRS can contribute to IQ in interaction with other genetic 
or non-genetic factors that patients may have been differentially exposed to. However, 
analysis of the association between repeated measure of IQ and PRS in the patient group 
(1304 observations in 596 patients) similarly yielded no evidence of association (B=1.7, 
95% CI -4.5 to 7.9; p=0.597). Third, it could be argued that the association between PRS 
and measures of affective dysregulation in the relatives is confounded by PRS-associated 
poor illness outcome in the patients, negatively impacting mental health of the relatives. 
However, the absence of an association between PRS and cognitive alterations, which 
are associated with poor outcome, makes it unlikely that PRS is associated with poor 
outcome. Although PRS was associated with positive symptoms of psychosis, positive 
symptoms are not associated with poor outcome. In order to verify this issue analytical-
ly, we re-examined the association between PRS and CAPE depression, additionally ad-
justing the analysis for the following outcome measures in the patient relative: number 
of unmet needs, measures with the Camberwell Assessment of Needs74, GAF-symptoms 
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and GAF-disability75. This adjustment did not reduce the association (B=0.22, 95% CI 
0.08–0.36, p=0.003). Finally, although two different genotyping platforms were used, 
one for controls and another for relatives, the use of imputation across platforms can 
be considered an effective way to control for this. In addition, analyses in the relatives 
were entirely within-platform, and analyses in the healthy comparison subjects was also 
largely within platform.
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ABSTRACT
Objective: The aim of this study was to assess associations between momentary stress 
and both affective and psychotic symptoms in everyday life of individuals at clinical high 
risk (CHR), compared to chronic psychotic patients and healthy controls, in search for 
evidence of early stress sensitization. It also assessed whether psychotic experiences 
were experienced as stressful.
Method: The experience sampling method was used to measure affective and psychotic 
reactivity to everyday stressful activities, events and social situations in 22 CHR patients, 
24 patients with a psychotic disorder and 26 healthy controls. 
Results: Multilevel models showed significantly larger associations between nega-
tive affect (NA) and activity-related stress for CHR patients than for psychotic patients 
(p=0.008) and for CHR compared to controls (p<0.001). Similarly, the association be-
tween activity-related stress and psychotic symptoms was larger in CHR than in patients 
(p=0.02). Finally, the association between NA and symptoms (p<0.001) was larger in CHR 
than in patients.
Conclusion: Stress sensitization seems to play a role particularly in the early phase of 
psychosis development as results suggest that CHR patients are more sensitive to daily 
life stressors than psychotic patients. In this early phase, psychotic experiences also con-
tributed to the experience of stress. 
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INTRODUCTION
It has long been suggested that stress plays an important role in the emergence and 
course of psychotic disorder1-5. Stressful life events6, childhood adversity7, as well as 
small everyday hassles8, 9 have been associated with the development and course of 
psychotic disorder. In order to further elucidate the role of stress in the aetiology of 
psychotic disorder, attention has shifted to studies of the putative prodromal phase of 
a psychotic disorder. Participants in such studies are those who experience subclinical 
psychotic symptoms and meet well established prodromal criteria that describe them to 
be at ultra-high risk (UHR)10 or clinical high risk (CHR)11 for a transition to disorder. In the 
present study, the term clinical high risk is utilized. 
CHR patients may be more exposed to stressful experiences. Findings regarding the 
number of life events in CHR patients compared to controls are mixed, with some stud-
ies reporting an association between the occurrence of traumatic experiences as well 
as other negative life events and the expression of subclinical psychotic symptomatolo-
gy12-19, while other studies reported no difference in the number of major life events20, 21 
or even significantly fewer life events22. Alternatively, CHR patients may specifically differ 
in their tolerance of stress. Indeed, life events19, 22, as well as daily life hassles19 were ap-
praised as significantly more upsetting by CHR patients than controls. Additionally, CHR 
patients reported impaired tolerance and increased functional impairment in response 
to normal stress compared to healthy controls20 and higher self-reported psychosocial 
stress levels compared to first-episode psychosis patients23. 
Previous studies with the Experience Sampling Method (ESM, a structured diary tech-
nique in which subjects are asked in normal daily life to report their thoughts, feelings 
and symptoms, and also the context (e.g. location, company, activity) and the appraisal 
of the context, several times per day) have shown a higher emotional and psychotic re-
activity to small daily life stressors, in psychotic patients, their unaffected relatives, and 
in those at psychometric risk for psychotic disorder when compared to healthy controls2, 
24-27. It has been suggested that the (repeated) exposure to early severe stressors in-
creases sensitivity to small stresses in daily life2, 4, 28, and that this process of ‘behavioural 
sensitization’ is a vulnerability marker for psychosis. 
However, until now, only one ESM study29 has investigated both emotional and sympto-
matic reactivity to daily life stress in a sample of CHR participants. Compared to psychot-
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ic patients and controls, the CHR group experienced greater negative affect (NA) when 
confronted with stressful activities and social situations, but not after unpleasant events 
(i.e., emotional stress reactivity). Both the CHR and psychotic patient group showed an 
increase in psychotic symptoms in response to daily life stressors (i.e., psychotic stress 
reactivity), in comparison to controls. However, psychotic stress reactivity was compa-
rable across patient groups. The results suggest that stress reactivity for small daily life 
stressors and therefore early stress sensitization occurs before the onset of psychotic 
disorders and is not just the consequence of a chronic illness.
What is often neglected in stress research is that psychotic experiences in themselves 
may be an important source of distress. A recent study30 has shown that intensity of 
distress related to subclinical symptoms was related to transition risk. Furthermore, ESM 
studies with psychotic patients have reported that psychotic symptoms are associated 
with distress and an increase of NA31-33. This may be particularly true for CHR patients, 
for whom these experiences are new. 
Aims of the study
Our aim was to examine 1) whether emotional reactivity to stress differs in Clinical High 
Risk patients, chronic psychotic patients and healthy controls, 2) whether psychotic reac-
tivity to stress differs in CHR patients versus chronic psychotic patients, and 3) whether 
psychotic symptoms in itself are increasing negative affect in both patient groups. 
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METHODS
Sample
The sample consisted of 27 patients who were diagnosed with a non-affective psychotic 
disorder, 27 participants at CHR for psychosis, and 27 healthy controls. Participants in 
the CHR group were between 18 and 45 years of age, and had at least one of the follow-
ing: (i) attenuated positive symptoms; (ii) brief limited intermittent psychotic symptoms 
(BLIPS), both assessed with the Structured Interview for Prodromal Symptoms (SIPS) 34; 
(iii) presence of at least 2 basic symptoms (e.g., subtle thought and speech disturbanc-
es) assessed with the Schizophrenia Prediction Instrument, Adult version (SPI-A)35; (iv) 
a significant drop in functioning (30% or more on the Global Assessment of Functioning 
(GAF) Scale for at least 1 month within the last year) in combination with genetic risk; or 
(v) a significant drop in functioning plus a diagnosis of schizotypal personality disorder. 
Momentary assessment data for the CHR group were collected in an add-on study of 
the ‘PREVENT’ project (for more details see36), a large German multisite early recogni-
tion and intervention in psychosis project. CHR participants who took part in PREVENT 
were randomly assigned to cognitive behavioural therapy, treatment with Aripiprazole 
(Abilify©) and medical management or placebo plus medical management. As the study 
is not finished yet, disclosure of the assignments of our participants is not yet possible. 
ESM data collection was started directly after inclusion in the PREVENT.
Controls between the ages of 18 and 45 years were recruited by advertisements at the 
University of Bonn and other public buildings in Bonn. The Structured Clinical Interview 
for DSM-IV axis I disorders (SCID-I)37 was used to assess axis I disorders in the CHR group 
and to exclude any participants with a psychiatric disorder from the control group. Con-
trol participants were also excluded in case of a family history of psychotic disorder.
The ESM data of the psychotic patients were gathered as part of an add-on study to the 
Genetic Risk and Outcome of Psychosis (GROUP) study38, which investigated risk and pro-
tective factors for psychosis. Patients were recruited through in-and out-patient mental 
health facilities in the Southern part of the Netherlands and (the Dutch speaking part of) 
Belgium. Inclusion criteria for the patient group were age 16-60 years and a diagnosis of 
schizophrenia or schizoaffective disorder as assessed with the Comprehensive Assess-
ment of Symptoms and History (CASH)39. Patients with substance-related psychosis and 
psychosis with a known organic cause were excluded. For the current analyses, only 
those patients with minimum illness duration of 5 years since their first psychotic epi-
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sode were selected. Exclusion criteria for all three groups were a history of brain disease 
or head injury with loss of consciousness. All participants gave written informed consent, 
conforming to local ethics committee guidelines.
The Experience Sampling Method
The Experience Sampling Method (ESM) is a within-day, momentary self-assessment 
technique40, 41. Participants received a digital wristwatch and self-assessment forms col-
lected in a booklet for each day. Ten times a day on six consecutive days, the watch 
emitted a signal (beep) at unpredictable moments between 7:30 a.m. and 10:30 p.m. 
After each beep, participants were asked to immediately report their thoughts, mood, 
symptoms, current context (e.g., their location, social company, activities), and subjec-
tive appraisals of the current situation. All self-assessments were rated on 7-point Likert 
scales. To ensure reliability of the completed reports, participants also recorded the time 
of completion of the report, which was compared with the time at which the watch had 
emitted a signal. All reports completed more than 15 minutes after the signal were ex-
cluded from the analyses, since previous work42 has shown that reports completed after 
this interval are less reliable and consequently less valid. Participants with less than 20 
valid reports (out of 60) were excluded from the analysis.
Assessment of mood
Negative affect was assessed at each beep with six mood related adjectives (down, 
guilty, insecure, lonely, anxious, irritated) rated on seven-point Likert scales (1=not at all, 
7=very). However, detailed factor analyses based on the ESM data collected in several 
studies conducted in our department, have shown that the ‘down’ and ‘irritated’ varia-
bles have high negative cross-loadings on the positive affect measure (personal commu-
nication43). Therefore, mean scores on the items ‘guilty’, ‘insecure’, ‘lonely’ and ‘anxious’ 
were used as a measure of NA in the analyses.
Assessment of momentary psychotic symptoms
Psychotic symptomatology was assessed at each beep with seven symptom related 
items. Hallucinations were asked directly (‘I hear voices’ and ‘I see things that are not re-
ally there’), while the presence of delusions was assessed indirectly by items that include 
aspects of mental states that are directly associated with delusions in schizophrenia44, 45. 
These were: ‘I cannot get these thoughts out of my head’; ‘I feel suspicious’; ‘I feel unre-
al’ and ‘My thoughts are influenced by others’. The item ‘I am afraid I will lose control’ is 
related to psychosis in general.
Clinical High Risk for psychosis: the association between momentary stress, affective and psychotic symptoms  |  89
4
Assessment of momentary stress
Stress was conceptualized as the subjectively appraised stressfulness of distinctive (so-
cial) events and minor disturbances that continually happen in the natural flow of dai-
ly life. Three different stress measures were computed. For Activity-related stress, the 
question ‘What are you doing?’ served as a starting point. Subsequently, three questions 
(i.e., ‘I would rather do something else’; ‘This is difficult for me’ and ‘I can do this well’, 
reverse coded) were scored on a 7-point Likert scale (1 to 7), and were combined into 
a mean activity-related stress variable. Event-related stress was based on the question 
‘What was the most important event since the last beep?’ Participants subsequently 
scored how pleasant/unpleasant the event was on a bipolar scale (-3 very unpleasant, 0 
neutral, +3 very pleasant). Positive events (scores 1, 2 and 3) were recoded to zero, and 
negative scores multiplied by -1 (i.e., higher scores now reflect higher stress/unpleas-
antness levels) for the event-related stress variable. For Social stress participants were 
asked to indicate whether they were in the company of others or alone. If they were in 
company of one or more persons, they were asked to rate the item ‘I would prefer to be 
alone’ (1 to 7). This score was used as the social stress variable.
Analyses
Groups were compared with respect to continuously measured baseline characteristics 
by means of ANOVAs. Chi-square tests were used to compare groups with respect to cat-
egorical variables. Group comparisons (ANOVAs) were also performed to test whether 
the average levels of NA, momentary psychotic symptoms as well as stress related to un-
pleasant activities, events and social situations differed between the psychotic patients, 
CHR patients and controls.
For the further analyses, we used multivariate multilevel models46, 47, an extension of 
standard hierarchical linear models when analysing multiple (correlated) outcomes. In 
particular, a certain pair of variables (e.g., activity stress and NA) was repeatedly meas-
ured within participants using ESM, as described earlier. For each participant, we there-
fore had up to 60 (measurement occasions) × 2 (outcomes) = 120 observations available. 
The data therefore conformed to a three-level structure, with the two outcomes nested 
within measurement occasions (“beeps”), which in turn were nested within participants. 
To model the association between the two outcomes at the participant and at the beep 
level, we used a linear mixed-effects model with two correlated random effects at the 
participant level (corresponding to two dummy variables indicating whether a particular 
row of data corresponded to outcome 1 or outcome 2) and with correlated residuals at 
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the beep level. The variance-covariance matrices of the random effects at the partici-
pant level and the residuals at the beep level were allowed to be fully unstructured. Age 
and gender and their interactions with the dummy variables were included as covari-
ates in the model, since previous ESM research has shown a heightened affective stress 
response in female compared to male psychotic patients48 and participants in the psy-
chotic patient group were older than those in the CHR and control groups. As it can be 
hypothesized that the association between stress and psychotic symptoms is influenced 
by low mood (i.e., high NA), we ran the models testing the association between stressors 
and momentary psychotic symptoms both with and without NA and it’s interactions with 
the dummy variables as covariates.
Models were fitted separately in each of the three groups. To test whether the degree of 
association (i.e., correlation) between two outcomes differed between the groups at the 
beep level, we extracted the estimated correlations with their corresponding standard 
errors and then conducted Wald-type tests (i.e., 𝑧𝑧 = (𝜌𝜌%& − 𝜌𝜌%()/+𝑆𝑆𝑆𝑆[𝜌𝜌%&]( + 𝑆𝑆𝑆𝑆[𝜌𝜌%(]( 
 𝜌𝜌%&	 
 𝜌𝜌%(	 
 𝑆𝑆𝑆𝑆[𝜌𝜌%&]  
 𝑆𝑆𝑆𝑆[𝜌𝜌%(]  
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are the beep-level correlations for the first and second group, respectively, and 
𝑧𝑧 = (𝜌𝜌%& − 𝜌𝜌%()/+𝑆𝑆𝑆𝑆[𝜌𝜌%&]( + 𝑆𝑆𝑆𝑆[𝜌𝜌%(]( 
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 denote the corresponding standard errors). The models were fitted with re-
stricted maximum likelihood (REML) estimation using the mixed routine in Stata 13.149.
We used this method to investigate whether: (i) the association strength between stress 
(activity-related, event-related and social) and NA differed between the CHR and psy-
chotic patient groups as well as the CHR and healthy control groups; (ii) the association 
strength between stress and momentary psychotic symptoms differed between the CHR 
and psychotic patients groups, once in the standard model and once in the model with 
NA added as a covariate; and (iii) the association strength between momentary psychot-
ic symptoms and negative emotions (symptoms as stressor) differed between CHR and 
psychotic patients. 
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RESULTS
Participants and descriptive statistics
The total sample consisted of 27 healthy controls, 27 CHR patients, and 27 psychotic pa-
tients. Inclusion criteria were incomplete for three CHR participants and were therefore 
excluded. After dropping the invalid beeps (i.e., filled out more than 15 minutes after the 
actual beep) and selecting those participants who had filled out a minimum of 20 valid 
beeps, 26 healthy controls, 22 CHR, and 24 patients remained, with a total number of 
2950 observations and a mean number of 41.0 (S.D=9.8) beeps.
Demographic and clinical characteristics are shown in Table 1. The patients were sig-
nificantly older than both the CHR patients and controls (F(2,69)=17.01, p <0.001, Tuk-
ey-Kramer: patients>CHR, controls, p<0.001). Gender (χ2=1.61, p=0.45) and education 
level (χ2=6.13, p=0.41) were similarly distributed over the three groups.
Table 1. Sociodemographic and clinical characteristics of the research sample.
Psychotic patients 
(n=24)
Clinical High Risk patients 
(n=22)
Control subjects 
(n=26)
Demographic variables
Agea, b, mean (SD), range 33.9 (8.8), 20-50 25.2 (5.0), 19-38 24.5 (3.6), 19-33
Gender (m/f) 15/9 17/5 16/10
Civil status, n (%)
   Not married 15 (63) 19 (86) 21 (81)
   Married/living together 6 (25) 1 (5) 4 (15)
   Divorced 3 (12)
   Widowhood 1 (4)
   Missing 2 (9)
Work situation, n (%)
   Household 1 (4)
   School/Education 1 (4) 14 (64) 17 (65)
   Regular work 12 (50) 3 (14) 8 (31)
   Structured work 3 (13)
   Non-structured activities 5 (21) 4 (18)
   Other 1 (4)
   Missing 2 (8) 1 (4)
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Table 1. Continued.
Psychotic patients 
(n=24)
Clinical High Risk patients 
(n=22)
Control subjects 
(n=26)
Education level, n (%)
   No education 1 (5)
   Secondary school 17(71) 15 (68) 22 (85)
   Higher education 7(29) 5 (23) 4 (15)
   Missing 1 (5)
Clinical variables
DSM IV axis I diagnosis (n)
   Schizophrenia 15
   Schizoaffective Disorder 7
   Brief Psychotic Disorder 1
   Delusional Disorder 1
   Major Depression 7
   Dysthymia 1
   Social Phobia 2
   OCD 2
   PTSD 1
   Panic Disorder 1
   Alcohol misuse 1
   No diagnosis 10 26
Psychotic episodes (PE) , mean 
(SD), range
2.7 (1.7), 1 - 8
Illness duration, mean (SD), range 9.6 (5.2), 5.0 - 21.5
Age of first PE, mean (SD), range 24.3 (6.7), 12 - 41
Anti-psychotic medication use 
y/n/?
18/4/2
PANSS Positive symptoms 1.83 (0.77)
a Patients are significantly older than controls (p<0.001).
b Patients are significantly older than Clinical High Risk patients (p<0.001).
The groups did not differ on the mean number of valid beeps (see Table 2). The CHR 
and psychotic patient groups reported significantly more NA and momentary psychotic 
symptoms when compared with the controls (see Table 2 for all results). The CHR group, 
but not the patient group reported significantly more activity-related and social stress 
in comparison to controls. Furthermore, social stress was significantly higher in CHR pa-
tients compared to psychotic patients, while the psychotic patients did not differ from 
controls. No other significant differences were observed.
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Table 2. Means (standard deviations) and F test statistics of the number of valid beeps and ESM variables 
for psychotic patients, CHR patients and controls.
Mean (SD) a
Psychotic 
patients 
(n=24)
Clinical high 
risk patients
(n=22)
Control 
subjects  
(n=26)
F   
(df=2, 69)
 
p
 
Tukey-Kramerb
Valid beeps
41.5 (10.5), 
range 20 - 60
38.5 (9.7), 
range 21 - 58
42.7 (9.3), 
range 23 - 56
1.14 0.33
Activity-related stress 2.53 (0.87) 2.80 (0.69) 2.28 (0.53) 3.22 0.046 3 < 2*
Event-related stress 0.21 (0.43) 0.27 (0.25) 0.15 (0.11) 1.00 0.37
Social stress 1.66 (0.75) 2.59 (1.27) 1.54 (0.60) 9.42 0.0002
1 < 2** 
& 3 < 2***
NA 1.95 (0.98) 2.02 (0.84) 1.17 (0.21) 10.11 0.0001 3 < 1**,  2**
MPS 1.67 (0.71) 1.68 (0.61) 1.07 (0.17) 10.38 0.0001 3 < 1**, 2**
NA, negative affect; MPS, momentary psychotic symptoms.
a For each subject, a mean was calculated over all reports, and the mean per subject was additionally aggre-
gated over the group to obtain the group mean (SD).
b 1. Psychotic patients; 2. CHR; 3. Controls.
*p≤0.05, ** p≤0.01, ***p≤0.001. 
(i) Is the association between stress and negative affect different in the three groups?
The results of the multivariate multilevel models showed the correlation coefficients 
between NA and activity-related, event-related and social stress all to be positive, for 
the psychotic patient group, CHR group and control group (range 0.11 - 0.28, see Table 
3). For NA and activity-related stress the association was significantly stronger in the CHR 
group compared to both the psychotic patient group (Z=-2.67, p=0.008) as well as the 
healthy controls (Z=3.68, p=0.0002), as displayed in Figure 1. The associations between 
NA and event-related stress and NA and social stress were not significantly different in 
the three groups.
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(ii) Is the association between stress and momentary symptoms different for Clinical 
High Risk vs. psychotic patients?
The correlation coefficients between momentary psychotic symptoms and activity-relat-
ed, event-related and social stress were positive for both the CHR patients and psychotic 
patients (range 0.08 - 0.24, see Table 3). For momentary psychotic symptoms and activ-
ity-related stress the association was significantly stronger in the CHR group compared 
to the psychotic patient group (Z=-2.29, p=0.02). While the association between symp-
toms and event-related stress was stronger in the CHR group as compared to psychotic 
patients, it did not reach statistical significance (Z=-1.66, p=0.10). No group differences 
were detected for symptoms and social stress. In the additional analyses where NA was 
added as a covariate in the models, the association between activity-related stress and 
symptoms was no longer significantly different between groups (Z=-0.53, p=0.60), as 
were none of the other comparisons. 
(iii) Are momentary psychotic symptoms more emotionally distressing for Clinical High 
Risk vs. psychotic patients?
Positive associations between momentary psychotic experiences and NA were found for 
the CHR and psychotic patient groups (see Table 3). Group comparison showed the as-
sociation to be significantly larger in the CHR group than in the psychotic patients group 
(Z=-5.42, p<0.001), as displayed in Figure 1.
Table 3. Multivariate multilevel model correlations at beep level between the stress variables, Negative 
Affect and Momentary Psychotic Experiences, controlled for age and gender.
Psychotic patients Clinical High Risk patients Control subjects Group comparisons Wald testb
1  vs. 2 (ref) 2 vs.3 (ref)
Association CC SE 95% CI CC SE 95% CI CC SE 95% CI Z P Z P
AS & NA 0.16 0.03 0.09 - 0.22 0.28 0.03 0.21 - 0.34 0.11 0.03 0.05 - 0.17 -2,67 0.008 3.68 <0.001
ES & NA 0.15 0.03 0.09 - 0.21 0.16 0.03 0.09 - 0.23 0.12 0.03 0.06 - 0.18 -0.25 0.80 1.00 0.32
SS & NA 0.20 0.04 0.13 - 0.27 0.16 0.05 0.07 - 0.25 0.15 0.04 0.08 - 0.23 0.74 0.46 0.08 0.93
AS & MPS 0.14 0.03 0.07 - 0.20 0.24 0.03 0.17 - 0.30 -2.29 0.02
AS & MPSa 0.09 0.03 0.03 - 0.15 0.11 0.03 0.05 - 0.18 -0.53 0.60
ES & MPS 0.08 0.03 0.01 - 0.14 0.16 0.04 0.09 - 0.23 -1.66 0.10
ES & MPSa 0.03 0.03 -0.03 - 0.10 0.08 0.04 0.01 - 0.15 -1.04 0.30
SS & MPS 0.15 0.04 0.07 - 0.23 0.19 0.04 0.10 - 0.27 -0.60 0.55
SS & MPSa 0.09 0.04 0.01 - 0.17 0.12 0.05 0.03 - 0.21 -0.47 0.64
NA & MPS 0.33 0.03 0.27 - 0.38 0.53 0.03 0.48 - 0.58 -5.42 <0.001
CC, correlation coefficient; SE, standard error; 95% CI,  95% confidence interval; NA, negative affect; MPS, 
momentary psychotic symptoms; AS, activity-related stress; ES, event-related stress;  SS, social stress. 
a. Results of models with NA included as a covariate. 
b. 1. Psychotic patients; 2. CHR; 3. Controls.
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Fig. 1. Left: Correlation coefficients between negative affect (NA) and activity-related stress (AS) per group. 
Right: Correlation coefficients between momentary psychotic symptoms (MPS) and activity-related stress 
per group.
*p≤0.01, ** p≤0.001.
Table 3. Multivariate multilevel model correlations at beep level between the stress variables, Negative 
Affect and Momentary Psychotic Experiences, controlled for age and gender.
Psychotic patients Clinical High Risk patients Control subjects Group comparisons Wald testb
1  vs. 2 (ref) 2 vs.3 (ref)
Association CC SE 95% CI CC SE 95% CI CC SE 95% CI Z P Z P
AS & NA 0.16 0.03 0.09 - 0.22 0.28 0.03 0.21 - 0.34 0.11 0.03 0.05 - 0.17 -2,67 0.008 3.68 <0.001
ES & NA 0.15 0.03 0.09 - 0.21 0.16 0.03 0.09 - 0.23 0.12 0.03 0.06 - 0.18 -0.25 0.80 1.00 0.32
SS & NA 0.20 0.04 0.13 - 0.27 0.16 0.05 0.07 - 0.25 0.15 0.04 0.08 - 0.23 0.74 0.46 0.08 0.93
AS & MPS 0.14 0.03 0.07 - 0.20 0.24 0.03 0.17 - 0.30 -2.29 0.02
AS & MPSa 0.09 0.03 0.03 - 0.15 0.11 0.03 0.05 - 0.18 -0.53 0.60
ES & MPS 0.08 0.03 0.01 - 0.14 0.16 0.04 0.09 - 0.23 -1.66 0.10
ES & MPSa 0.03 0.03 -0.03 - 0.10 0.08 0.04 0.01 - 0.15 -1.04 0.30
SS & MPS 0.15 0.04 0.07 - 0.23 0.19 0.04 0.10 - 0.27 -0.60 0.55
SS & MPSa 0.09 0.04 0.01 - 0.17 0.12 0.05 0.03 - 0.21 -0.47 0.64
NA & MPS 0.33 0.03 0.27 - 0.38 0.53 0.03 0.48 - 0.58 -5.42 <0.001
CC, correlation coefficient; SE, standard error; 95% CI,  95% confidence interval; NA, negative affect; MPS, 
momentary psychotic symptoms; AS, activity-related stress; ES, event-related stress;  SS, social stress. 
a. Results of models with NA included as a covariate. 
b. 1. Psychotic patients; 2. CHR; 3. Controls.
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DISCUSSION
This study investigated emotional and psychotic reactivity to daily life stress in those at 
risk for a psychotic disorder compared to chronic psychotic patients and healthy con-
trols. As hypothesized, our results showed increased emotional stress reactivity, par-
ticularly related to activities, to be associated with psychosis, mainly at the early stag-
es of illness. Contrary to our hypothesis, psychotic-reactivity in response to unpleasant 
activities was increased in CHR compared to chronic psychotic patients. This suggests 
that emotional and psychotic stress sensitization occurs prior to the development of a 
full-blown psychotic state. Furthermore, as hypothesized, CHR patients experienced the 
psychotic symptoms as more distressing compared to chronic patients.
Emotional and psychotic stress reactivity
Our results of increased emotional stress reactivity in CHR compared to chronic patients 
are replicating the findings of Palmier-Claus and colleagues29. Furthermore, results are 
in line with studies in CHR samples using questionnaires showing higher psychosocial 
stress sensitivity in CHR participants compared to controls23, reduced tolerance to nor-
mal stress20, higher self-reported distress in response to life events19, 22 as well as to daily 
life stressors15, 50, especially for those reporting life events to be more distressing, sug-
gestive of stress sensitization19. Psychotic stress reactivity, however, was stronger in the 
CHR patients compared to psychotic patients, contrary to our hypothesis based on the 
findings of Palmier-Claus and colleagues29. One possible explanation for this difference 
may be related to selection of the psychotic patients. We specifically selected psychotic 
patients with an illness duration of at least 5 years, to compare our CHR group with 
chronic patients. The patient sample of Palmier-Claus and colleagues29 is likely more 
mixed with both recent onset and more chronic patients, as they did not provide specific 
inclusion criteria in that regard. This is reflected in the difference in mean illness dura-
tion, with our sample having a mean illness duration of 9.6 (SD=5.2) years compared to 
6.5 (SD=8.2) years reported in their paper. Psychotic stress reactivity may thus be more 
characteristic of the early psychotic phase and becoming less prominent when illness 
duration progresses.
There are several other possible explanations for our findings of heightened emotional 
and psychotic stress reactivity in CHR patients compared to the chronic psychotic pa-
tients. First, the CHR may experience more severe stressors or these may occur more 
often than those experienced by the patient group, as was indeed confirmed by our 
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findings of increased activity and social stress in this group. As high levels of social anx-
iety have been reported to characterize help-seeking CHR patients51, 52, more exposure 
to social activities in our CHR group helps to explain the difference with the psychotic 
patients, who have possibly adjusted their lives in order to avoid stressful (social) situ-
ations. Alternatively, less exposure to activities, events and social situations might be 
a consequence of more negative symptoms53, which has been related to lower social 
functioning, work performance, and social skills. In accordance with this, a recent study 
comparing negative symptoms in psychotic and CHR patients54 reported that psychotic 
patients differed from CHR patients by reporting less motivation for engagement with 
family and recreational activities. However, as negative symptoms are profound not only 
in psychotic patients but also in help-seeking CHR patients55 and the recent study of 
Cressman and colleagues51 showed the level of anhedonia to be comparable to that of 
psychotic patients, the influence on the reported group difference in exposure to (social) 
activities is probably limited. 
Second, a recent study has reported that CHR patients do not seem to possess the skills 
to effectively cope with stress in general. Compared to healthy controls, CHR patients 
used more maladaptive coping strategies (e.g., blaming one’s self for the occurrence 
of the event) and fewer adaptive (e.g., choosing to reinterpret the event in a positive 
fashion) coping strategies, and the use of these strategies might limit their functioning 
even further or exacerbate symptoms56. Furthermore, use of adequate coping strategies 
like stress reduction has been found to predict an improvement with regard to psychotic 
symptoms over time57.
Third, most of our psychotic patients used anti-psychotic medication. It could therefore 
be that anti-psychotic medication partly dampens emotional and psychotic stress reac-
tivity, resulting in the difference observed between our patient groups. Some evidence 
comes from a recent study58 in which psychotic patients who use antipsychotic medica-
tion subjectively reported dampened emotional experience. However, as not all our psy-
chotic patients were using antipsychotic medication and some of the CHR patients have 
been using medication, use of antipsychotics is unlikely to fully explain the difference in 
stress reactivity between the groups.
Finally, the results of our sensitivity analyses investigating the influence of low mood on 
psychotic reactivity underscore the close relationship between stress, symptoms and 
low mood. When NA was added to the psychotic stress reactivity models, it was no 
98  |  Chapter 4
longer significantly higher in the CHR group compared to more chronic patients, suggest-
ing that psychotic stress reactivity is mediated by low mood at the early phases of illness.
Psychotic symptoms and distress
The current study provided evidence that psychotic symptoms in themselves may be a 
source of distress, particularly in CHR patients. These symptoms are relatively new for 
CHR patients and belief conviction may not have been fully developed. The unknown 
nature of these symptoms may intensify the levels of distress. Results of a recent study 
on stigma related to labels and symptoms of CHR also identified subclinical psychotic 
symptoms in themselves to be a source of distress59. CHR patients experienced more 
stigma from symptoms than from the psychosis risk-label, and specifically the “shame” 
related to symptoms was associated with depression. 
Another possible explanation might be that CHR patients may have received no or limit-
ed treatment, either psycho-education or psychological treatment, for these symptoms 
as ESM assessment started just after identification of CHR status, which may result in less 
effective coping strategies. A previous ESM study of psychotic patients33 indeed showed 
that a greater endorsement of a psychological explanation of delusions and hallucina-
tions was related to less disruption of functioning, less distress and less NA. On the other 
hand, chronic patients may differ from CHR patients in coping strategies they use to deal 
with the symptoms. Lardinois and colleagues31 showed that psychotic patients who used 
more non-psychotic coping strategies (i.e., active problem-solving or avoiding, passive 
illness behaviour and problem-avoiding) had more conscious appraisal of distress as-
sociated with symptoms than those who adopted a more symptomatic coping strategy, 
for example following or obeying orders induced by the symptoms or locking oneself in.
Theoretical and clinical implications
Overall, our findings further support the hypothesis that increased stress reactivity can 
be viewed as an affective pathway to psychosis2. They also highlight the important role 
of distress, represented in this study as an increase in NA, with the emergence of psy-
chotic symptoms. The results suggest that CHR patients may get caught in a downward 
spiral of feeling distressed by their psychotic symptoms, which may in turn increase the 
intensity of psychotic symptoms.
Our findings underscore the need for early intervention in CHR patients in order to in-
terrupt this vicious cycle. Decreasing stress reactivity as well as decreasing the distress 
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associated with the psychotic symptoms is relevant in this respect. The newest genera-
tion of Cognitive Behavioural Therapies (CBTs) puts high emphasis on the context (hence 
the name “contextual CBT”). Stress reduction techniques, which incorporate elements 
of Mindfulness or Acceptance and Commitment Therapy may be an effective treatment 
strategy (for a review see60). Given the observation that CHR patients coping strategies 
are often ineffective and can enhance symptoms56 and use of adequate strategies have 
been found to be predictive of improvement in psychotic symptoms57, interventions that 
help CHR patients to develop and apply adequate coping strategies are also likely to be 
effective.
Limitations
The results should be viewed in the light of several methodological issues. First, as with 
all ESM studies, measurements are based on subjective reports. Therefore, it can be 
argued that the results are not psychometrically precise. However, although subjective 
reports are considered less reliable (e.g., do all participants interpret or answer the 
questions identically?), previous research indicates that subjective reports can be valid 
and are important in order to understand the changes in symptoms61.
Second, the items used to assess momentary psychosis are relatively broad, as items 
were used that participants could self-report about. However, one could question 
whether they truly reflect a psychotic state. For example, ‘I cannot get these thoughts 
out of my head’ may equally reflect anxiety or depression. A principal component analy-
sis on the psychosis items resulted in two factors, one factor representing hallucinations 
(the two hallucination items) and all the other items loading equally on a second factor, 
which would then reflect delusions. However, does this second factor truly reflect delu-
sions? All items scored equally strong on the factor delusions including ‘I feel suspicious’, 
or ‘My thoughts are influenced by others’, suggesting that the composite score most 
likely represents delusions. Furthermore, previous studies from our group showed that 
the psychosis score as used in the current paper had concurrent validity (as the ESM 
psychosis scores were significantly correlated with the score on the positive items but 
not the negative items of the PANSS) and convergent validity using the known-groups 
technique )as it distinguished patients from relatives and controls26). This supports that 
the composite score of all items does reflect psychosis. However, the psychosis items 
could be strengthened in future research for example by using focus groups with people 
who have experienced psychosis.
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Third, the study was cross-sectional and therefore no direct causality can be inferred 
from these results. Furthermore, the possibility of reverse causality cannot be excluded. 
There is a possibility that increased NA or increased levels of psychotic symptoms influ-
ence the subjective appraisal of the environment or that increased NA causes psychotic 
symptoms to be experienced as more intense. However, as was suggested previously, 
the overall effect would still be for the individual to experience psychosis associated with 
an environmental event26.
Fourth, the possible influence of medication use to the examined associations could not 
be tested in the current study, since CHR medication use was not yet available. While 
at present disclosure of treatment is not yet available, CHR participants did receive ei-
ther cognitive behavioural therapy, treatment with Aripiprazole (Abilify©) plus medical 
management or a placebo plus medical management. The majority of psychotic patients 
used anti-psychotic medication at the time of testing. Future studies are needed to ex-
amine the effect of medication use properly by comparing patients groups with and 
without anti-psychotic medication use.
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ABSTRACT
Background: Hallucinations and persecutory delusions are core features of (subclinical) 
psychosis, often causing considerable distress. The phenomenology of hallucinations 
and persecutory delusions has previously been investigated in the realm of daily life 
in psychosis spectrum patients and we aimed to extend this investigation to patients 
with a first psychotic episode (FEPs) and individuals at clinical high risk for psychosis 
(CHR-Ps). The prevalence, course and the co-occurrence of hallucinations and feelings 
of suspiciousness in daily life, as well as their temporal relation to emotions, anxiety and 
self-esteem were investigated over a 6-day period.
Methods: The Experience Sampling Method, a structured diary technique, was used to 
investigate hallucinatory experiences and suspiciousness in daily life in a pooled data-set 
of 33 CHR-Ps and 34 FEPs. Hallucinations were defined using participants’ scores on the 
items “I see things that are not really there” and “I hear voices”, and suspiciousness with 
the item “I feel suspicious”.
Results: Overall, 24% of CHR-Ps and 39% FEPs reported hallucinations and 91% and 58% 
reported suspiciousness, respectively. Hallucinations and suspiciousness co-occurred 
regularly within the same person in both CHR-Ps and FEPs. Anxiety, negative emotions, 
decreased self-esteem and delusional ideation accompanied hallucinatory and paranoid 
episodes. Decreased self-esteem preceded suspiciousness in FEPs and CHR-Ps, as did 
increased delusional intensity and visual hallucination intensity for CHR-Ps.
Discussion: Hallucinations and suspiciousness are common in CHR-P and FEP and reg-
ularly co-occur. Low self-esteem and delusional ideation may precede suspiciousness, 
while anxiety is elevated during hallucinatory and paranoid episodes.
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INTRODUCTION
Hallucinations and delusions including feelings of suspiciousness and persecution are 
considered core positive symptoms of psychosis spectrum disorders. These symptoms 
are reported by chronic patients, by patients experiencing a first psychotic episode 
(FEPs) and at an attenuated level in those individuals meeting criteria for clinical high risk 
for psychosis (CHR-Ps). However, the actual phenomenology of these experiences, espe-
cially in these early phases of psychosis, has hardly been investigated. The few reporting 
prevalence rates found hallucinations in 73% and delusions in 74% of FEPs1. In contrast, 
34-60% of CHR-Ps reported hallucinations while 82% had delusions2, 3. Furthermore, 
co-occurrence of hallucinations and delusions was found to be relatively high (~40%) in 
the CHR-P state2, and with 80% even higher in FEPs, while 18% reported only delusions 
and 2% had only hallucinations4. 
Results of studies examining the content of these (attenuated) psychotic symptoms in 
more detail have shown that persecutory ideation including being ‘monitored’ was re-
ported by 54% of FEPs1 and 54% of CHR-Ps5. Auditory hallucinations have been reported 
by 70% of FEPs and 29-57% had visual hallucinations with the majority of those being 
relatively mild in nature and often described as ‘vague shadows’1, 6. Furthermore, visual 
and auditory hallucinations seem to co-occur in 84-88% of individuals6, 7.
Previous studies have used the Experience Sampling Method to investigate persecutory 
delusions and auditory and visual hallucinations in daily life of psychosis spectrum pa-
tients. ESM is a structured self-assessment technique in which participants are prompted 
at random intervals throughout the day to report their current experiences8. With this 
method, it is possible to investigate subjective experiences that are related to delusions 
such as feeling suspicious, unreal, experiencing loss of control, having intruding thoughts 
or the idea that your thoughts are influenced by others as well as hallucinations. Preva-
lence rates in daily life were between 49-67% for persecutory delusions and 40-73% for 
hallucinations9-13. Furthermore, it was also clear that delusions and hallucinations are 
often reported together in daily life. 
Two studies have used ESM to explore the temporal dynamics of delusions and halluci-
nations. For example, when the intensity of suspiciousness is increasing, how long does 
that last over time? And what is predictive of such an increase? For episodes of perse-
cutory delusions, it was found that anxiety and low self-esteem preceded onset of these 
108  |  Chapter 5
episodes whereas all negative emotions (feeling down, irritated, lonely, anxious) and 
reductions in self-esteem where present during an episode14. With regard to hallucina-
tions, it was found that auditory and visual hallucinations are discrete phenomena with 
distinct points of onset and termination, which were associated with higher negative 
affect and may be preceded by delusional ideation10. Combined these findings indicate 
that the intensity of these experiences fluctuates over periods of hours and days10, 13, 15 
and suggest that despite psychotic experiences in daily life being a persistent problem, 
patients are not constantly engulfed by their symptoms. 
However, the phenomenology and temporal dynamics of delusions and hallucinations 
have not been examined in patients with a first psychotic episode or those at clinical 
high risk for the development of psychosis. Therefore, using ESM in a sample of CHR-P 
and FEP we examined (i) the prevalence and course of hallucinations and delusions with 
a specific focus on suspiciousness, over a 6-day period, (ii) the difference in prevalence 
and course of these experiences between the two patient groups, and (iii) the temporal 
association between the onset of a hallucinatory/suspicious episode and the intensity of 
emotional experiences and self-esteem.
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METHODS
Sample
The current sample comprised of 33 CHR-P individuals and 34 FEP patients. Momentary 
assessment data were pooled from two ESM studies investigating early psychosis. Data 
of 23 CHR-Ps were collected in an add-on study16 of the ‘PREVENT’ project, a large Ger-
man multisite early recognition and intervention in psychosis project (for more details 
see 17). The data of 10 CHR-Ps and 34 FEPs were collected the IThink study, as part of a 
study of early psychosis and participants were recruited in the south of the Netherlands 
and Belgium.
All participants were between 15 and 45 years of age. Participants in the CHR-P group 
had at least one of the following: (i) attenuated positive symptoms; (ii) brief limited in-
termittent psychotic symptoms (BLIPS), both assessed with the Structured Interview for 
Prodromal Symptoms (SIPS, for PREVENT)18 or the Comprehensive Assessment of At Risk 
Mental State (CAARMS)19; (iii) presence of at least 2 basic symptoms (e.g., subtle thought 
and speech disturbances) assessed with the Schizophrenia Prediction Instrument, Adult 
version (SPIA, for PREVENT20; (iv) genetic risk (i.e. a first degree relative with psychotic 
disorder) or a diagnosis of schizotypal personality disorder; all in combination with a 
significant drop in functioning of 30% or more on the Global Assessment of Functioning 
(GAF) Scale for at least 1 month within the last year. For the FEP group, participants 
were included if onset of their first and only psychotic episode had occurred within two 
years prior to participation and were assessed with the Comprehensive Assessment of 
Symptoms and History (CASH) 21. Participants with psychosis due to a known organic 
cause were excluded. All participants gave written informed consent, conforming to local 
ethics committee guidelines.
The Experience Sampling Method
The Experience Sampling Method (ESM) is a within-day, momentary self-assessment 
technique8, 22. Participants received either a digital wristwatch and self-assessment 
forms collected in a booklet for each day (PREVENT) or a PDA, the ‘PsyMate’. Ten times 
a day on six consecutive days, the watch or PDA emitted a signal (beep) at unpredictable 
moments between 7:30 a.m. and 10:30 p.m. After each beep, participants were asked 
to immediately report their thoughts, mood, symptoms, current context (e.g., their lo-
cation, social company, activities), and subjective appraisals of the current situation. All 
self-assessments were rated on 7-point Likert scales. To ensure reliability of the com-
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pleted reports, participants using the watch and booklets participants recorded the time 
of completion of the report which was compared with the time at which the watch had 
emitted a signal. All reports completed more than 15 minutes after the signal were ex-
cluded from the analyses, since previous work23 has shown that reports completed after 
this interval are less reliable and consequently less valid. Participants with less than 20 
valid reports (out of 60) were excluded from the analysis.
ESM measures
Suspiciousness and delusional intensity 
Intensity of suspicious feelings was measured using the item “I feel suspicious”. Delu-
sional intensity was measured using five items (“I feel suspicious”, “I cannot get these 
thoughts out of my head”, “I’m afraid I will lose control”, “I feel unreal” and “My thoughts 
are influenced by others”) rated on 7-point Likert scales.
Hallucinatory intensity
Auditory hallucinatory (AH) intensity was assessed with the item “I hear voices” and 
visual hallucinatory (VH) intensity was assessed with the item “I see things that are not 
really there” (rated on 7-point Likert scales, ranging from 1 not at all to 7 very).
Suspicious and hallucinatory episodes
A suspicious episode was defined as one or more consecutive moments with a score of 
≥3 on the item “I feel suspicious”. A hallucinatory episode was defined as one or more 
consecutive moments with a score of ≥3 on either or both of the items “I hear voices” 
and “I see things that are not really there”. As was done previously10, 14, we took a liberal 
approach to missing data allowing a maximum of one missing data point per episode 
since this was a naturalistic study (although nights were considered as interruptions). In 
order to analyse temporal dynamics and relation to emotions, anxiety, self-esteem and 
delusions and if applicable suspiciousness and AH and VH hallucinations, moments were 
categorized as either the last moment before an suspicious or hallucinatory episode, the 
first moment in an episode, a moment during an episode (not first or last moment), the 
last moment during an episode, the first moment after an episode and unrelated to an 
episode (i.e., all the other moments; see Figures 1 and 2). Length of episodes was calcu-
lated by adding the number of beeps inside an episode.
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Emotional experience, anxiety and self-esteem
Participants’ momentary mood states were assessed with 7 mood adjectives rated on 
7-point Likert scales (1 not at all to 7 very). The mean score on items “I feel cheerful/
relaxed/ satisfied” represented positive affect (PA). The items “I feel insecure/lonely/
anxious/guilty” constituted negative affect (NA). All analyses were conducted with both 
this general measure of NA and with the single item “I feel anxious”. The mean score on 
the items “I like myself”, “I am ashamed of myself” and “I doubt myself” (both reverse 
coded) represented self-esteem. 
Statistical analyses
The CHR-P and FEP groups were compared on sociodemographic and ESM characteris-
tics by means of t-tests and chi-square tests for continuous and dichotomous variables, 
respectively. Two-sided independent samples T-test were used to examine group differ-
ences in momentary NA, PA, anxiety, self-esteem, suspiciousness, delusional as well as 
auditory and visual hallucinatory intensity between individuals reporting hallucinations 
and/or delusions during the ESM assessment period and those who did not in the CHR-P 
and FEP groups separately. T-tests were also used to directly compare the CHR-P and 
FEP groups on these variables. For the further analyses, multilevel linear modelling tech-
niques were used to study the dynamics of suspiciousness and hallucinations. Models 
were fitted with maximum likelihood estimation (MLE) using the XTREG module in Stata 
13.124. Age and sex were a priori added to the models as covariates. Effect sizes from 
predictors in the multilevel model were expressed as B, representing the fixed regression 
coefficient. Analyses on episodes were carried out on participants reporting at least one 
suspicious or AH/VH episode, and separately per experience and per group. In the anal-
yses on the dynamics of suspiciousness and hallucinations, moments within an episode 
were compared with observations unrelated to these experiences. In these models, 
current suspicious and delusional intensity, AH and VH intensity, affect and self-esteem 
were dependent variables and phase of the suspicious or hallucinatory episode (unre-
lated to episode, last moment before episode, first moment in episode, moment during 
episode, last moment during episode and first moment after episode, see Figures 1 and 
3) the independent variable. The estimated B’s with their corresponding standard errors 
were extracted from the models and entered in Wald-type tests in order to examine 
differences in effect sizes between the CHR-P and FEP groups for each of the phases of 
suspicious and hallucinatory episodes. 
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RESULTS
Sample and descriptive statistics
Sixteen (2 CHR-P and 14 FEP) of 83 recruited participants were excluded from the analy-
ses because of an insufficient number of valid ESM observations (<20). The final sample 
therefore comprised 67 participants, divided in 33 CHR-Ps and 34 FEPs. The groups did 
not differ on the number of valid reported moments. FEPs reported significantly higher 
levels of PA (M=3.55 (.80) vs. M=4.27 (1.00), t=3.23, p<0.01) compared to CHR-Ps. CHR-
Ps reported significantly higher delusional intensity (M=2.31 (1.13) vs. M=1.69 (.87), t=-
2.52, p<0.05) and suspiciousness (M=2.15 (1.04) vs. M=1.61 (.83), t=-2.37, p<0.05) than 
FEPs. In contrast, FEPs reported higher AH intensity than CHR-Ps, although this failed to 
reach statistical significance (M=1.62 (1.46) vs. M=1.16 (.49), t=1.73, p=0.09), and groups 
did not differ on VH intensity. Additional information regarding sociodemographic char-
acteristics and ESM reports is summarized in Table 1.
Prevalence and course of suspiciousness and hallucinations
Thirty of 33 CHR-Ps (91%) reported ESM increased suspiciousness, at 400 out of 1140 
moments (35%), comprising a total of 173 suspicious episodes (mean 5.8, range 1-12). 
Mean episode duration was 2.3 moments and in 53% of these episodes the length was 
restricted to 1 moment. Twenty of 34 FEPs (59%) reported ESM increased suspicious-
ness, at 160 out of 672 moments (24%), resulting in 92 suspicious episodes (mean 4.6, 
range 1-16). Mean episode duration was 1.7 moments and in 68% of episodes the dura-
tion of the episode was 1 moment. Of all individuals reporting suspicious episodes, 22 
CHR-Ps (73%) and 9 FEPs (45%) did not report additional hallucinations. In contrast, all 
eight CHR-Ps  and 11 of 13 FEPs (85%) with hallucinations reported also suspiciousness 
and both experiences occurred within the same moment for 6 of these CHR-Ps (75%) 
and 7 (64%) of these FEPs, respectively, representing ~20% of all recorded moments. 
One CHR-P participant reported paranoia during all assessed moments. 
Eight of 33 CHR-Ps (24%) reported ESM-hallucinations. Of these, 1 reported only AHs, 3 
reported only VHs, 1 reported both AHs and VHs although in separate moments and 3 
reported AHs and VHs to co-occur in the same moment. Among those CHR-Ps reporting 
hallucinations (either AHs, VHs or both) hallucinations were present at 68 out of 298 
moment (23%), composing a total of 34 hallucinatory episodes (mean 4.3, range 1-9). 
Mean episode duration was 2.0 moments and the length was restricted to one moment 
in 68% of the hallucinatory episodes. 
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Table 1. Demographic, clinical and ESM characteristics
Clinical High Risk 
(n=33)
FEP 
(n=34)
FEP vs. CHR
Demographic variables
Age, mean (SD), range 23.3 (5.3), 15-38 22.8 (5.1), 16-31 t= -.41, ns
Gender (m/f) 23/10 19/15 ns*
Civil status, n (%) ns*
   Not married 29 (88) 31 (91)
   Married/living together 2 (6) 3 (8)
  Unknown 2 (6) -
Work situation, n (%)a ns*
   School/Education 23 (70) 18 (53)
   Regular work 4 (12) 6 (18)
   Structured work - 2 (6)
   Non-structured activities 4 (12) 5 (15)
   Other/unknown 2 (6) 3 (9)
Education level, n (%) p<0.01
   No education 1 (3) -
   Primary school - 2 (6)
   Secondary school 21 (64) 11 (33)
   Higher education 10 (30) 20 (61)
   Unknown 1 (3) -
ESM episode data
Number of valid reports, mean (SD), range 38.2 (8.8), 20-58 35.8 (9.4), 21-58 t= -1.07, ns
Number of hallucinatory episodes, mean 
(SD), range
34, 4.3 (3.5), 1-9 60, 4.6 (3.3), 1-9 t=.24, ns
Length of hallucinatory episodes (mo-
ments), mean (SD), range
2.0 (1.8), 1-7 3.7 (3.1), 1-10 t=2.92, p<0.01
Number of paranoid episodes, mean (SD), 
range
174, 5.6 (3.3), 1-12 91, 4.8 (4.4), 1-16 t= -.76, ns
Length of paranoid episodes (moments), 
mean (SD), range
2.3 (2.0), 1-10 1.7 (1.5), 1-8 t=-2.45, p<0.05
NOS, not otherwise specified; ESM, Experience Sampling Method; SD, standard deviation; ns, not signifi-
cant.*Fisher’s Exact test a due to rounding, percentages may not add exactly to 100%.
Thirteen of 34 FEPs (39%) reported ESM-hallucinations. Of these, 6 reported only AHs, 
1 reported VHs and AHs on separate moments and 6 reported AHs and VHs to co-occur 
within the same moment. Together FEPs reported hallucinations (either AHs, VHs or 
both) at 221 out of 477 moments (46%), comprising 60 hallucinatory episodes (mean 
4.6, range 1-9). Mean episode duration was 3.7 moments and in 37% of the episodes 
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the length was 1 moment. One CHR-P participant and 4 FEPs reported hallucinations 
during at least 90% of all moments, with 1 FEP reporting hallucinations present during 
all assessed moments (56 out of 60). 
Difference in prevalence and course of suspiciousness and hallucinations in CHR-P ver-
sus FEP
More CHR-Ps than FEPs reported paranoia (X2=9.10, p=0.003). In contrast, the groups 
did not differ on the number of participants reporting hallucinations or the number of 
suspicious and hallucinatory episodes. However, the duration of suspicious episodes was 
significantly shorter in FEPs than in CHR-Ps, while the duration of hallucinatory episodes 
was significantly longer in FEPs than in CHR-Ps (see Table 1).
Emotional state, anxiety, self-esteem and delusional and hallucinatory intensity
Suspicious episode
CHR-Ps with suspicious episodes reported higher intensity of momentary psychotic ex-
periences, anxiety and NA and lower PA and self-esteem than those without suspicious 
episodes, although none reached statistical significance (Table 2). In contrast, suspicious 
FEPs reported significantly lower levels of PA and self-esteem, higher levels of NA and 
anxiety as well as higher overall delusional intensity than non-suspicious FEPs. Direct 
comparison of FEPs and CHR-Ps with increased suspiciousness showed that FEPs report-
ed significantly higher AH intensity, while the reverse effect was observed for PA.
Focussing on those participants who experienced episodes of suspiciousness, Figure 1a 
and 1b illustrate that both CHR-Ps and FEPs reported the presence of some delusion-
al ideation even in moments unrelated to suspicious episodes. Both CHR-Ps and FEPs 
reported significantly lower levels of self-esteem and PA as well as higher levels of NA, 
anxiety, AH intensity and delusional intensity during an episode compared to moments 
unrelated with the episodes (Table 3, Figure 1a & 1b). In the CHR-P group there were 
small but significant increases in delusional and AH intensity even before episode on-
set and a small but significant peak in AH intensity occurred the first moment after the 
end of the suspicious episode (Table 3 & figure 1a). Furthermore, small but significant 
levels of suspiciousness lingered even after the end of an episode, as did the decrease 
in self-esteem.  In addition, FEPs showed a significant decrease in self-esteem and PA 
before the onset of an episode (Table 3 & figure 1b). Finally, direct comparison of FEPs 
and CHR-Ps showed that the decrease in PA before onset of the episode in FEPs was 
also significant compared to CHR-Ps, for whom PA levels were comparable to moments 
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unrelated to an episode. During an episode FEPs reported significantly higher AH and 
VH intensity, paranoia, delusional intensity, more NA and anxiety and lower self-esteem 
compared to CHR-Ps (Table 3).
Fig. 1. Dynamics of suspicious episodes in CHR-P (1a) & FEP (1b)
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Table 2. Comparison on group level 
Mean (SD) Mean (SD) FEP vs. CHR-P
Hal (1) No Hal (2) t-test 1 vs. 2 Suspic (3) No Suspic (4) t-test 3 vs. 4 t-test 1 t-test 3
Negative affect CHR-P 2.95 (1.33) 2.09 (.86) t=2.14, p=0.04 2.40 (1.04) 1.25 (.10) t=1.89, p=0.07
t=.98, ns t= -.35, ns
FEP 2.34 (1.41) 1.61 (.57) t=2.14, p=0.04 2.29 (1.16) 1.31 (.32) t=3.09 p<0.01
Positive affect CHR-P 3.40 (.75) 3.60 (.82) t= -.64, ns 3.51 (.82) 3.95 (.34) t= -.89, ns
t=1.44, ns t=1.53, ns
FEP 4.05 (1.14) 4.40 (.91) t= -.99, ns 3.92 (1.07) 4.76 (.65) t= -2.59, p=0.01
Self-esteem CHR-P 4.14 (1.50) 5.10 (1.23) t= -1.82, p=0.08 4.77 (1.36) 5.88 (.40) t= -1.39, ns
t=.98, ns t=.50, ns
FEP 4.82 (.1.57) 5.72 (.81) t= -2.22, p=0.03 4.96 (1.36) 5.97 (.65) t= -2.55, p=0.02
Anxiety CHR-P 2.48 (1.46) 1.88 (.97) t=1.33, ns 2.12 (1.13) 1.15 (.10) t=1.46, ns
t= -.43, ns t= -.17, ns
FEP 2.19 (1.47) 1.42 (.47) t=2.25, p=0.03 2.06 (1.21) 1.22 (.33) t=2.51, p=0.02
Delusional intensity CHR-P 2.89 (1.36) 1.91 (.81) t=2.51, p=0.02 2.24 (1.04) 1.26 (.42) t=1.59, ns
t= -1.38, ns t= -1.20, ns
FEP 2.14 (1.12) 1.28 (.29) t=3.37, p<0.01 1.89 (.97) 1.21 (.27) t=2.55, p=0.02
Suspiciousness CHR-P 2.63 (.98) 2.17 (1.19) t=.99, ns 2.40 (1.13) 1.06 (.06) t=2.02, p=0.05
t= -1.61, ns t= -1.82, p=0.07
FEP 1.86 (1.10) 1.29 (.43) t=2.16, p=0.04 1.85 (.90) 1.01 (.03) t=3.50, p=0.001
AH intensity CHR-P 1.65 (.86) 1.00 (.01) t=3.90, p<0.001 1.17 (.51) 1.00 (.00) t=.58, ns
t=1.26, ns t=2.00, p=0.05
FEP 2.61 (2.04) 1.01 (.02) t=3.63, p=0.001 1.80 (1.54) 1.40 (1.36) t=.75, ns
VH intensity CHR-P 1.70 (1.25) 1.00 (.005) t=2.89, p=0.01 1.19 (.69) 1.00 (.00) t=.46, ns
t=.34, ns t=1.40, ns
FEP 1.93 (1.67) 1.00 (.01) t=2.58, p=0.01 1.61 (1.40) 1.01 (.01) t=1.59, ns
Hal: Hallucination(s) reported; Suspic: suspiciousness reported. *p<0.05, ** p<0.01, *** p<0.001. 
Temporal dynamics of hallucinations and suspiciousness in clinical high risk and first episode psychosis  |  117
5
Table 2. Comparison on group level 
Mean (SD) Mean (SD) FEP vs. CHR-P
Hal (1) No Hal (2) t-test 1 vs. 2 Suspic (3) No Suspic (4) t-test 3 vs. 4 t-test 1 t-test 3
Negative affect CHR-P 2.95 (1.33) 2.09 (.86) t=2.14, p=0.04 2.40 (1.04) 1.25 (.10) t=1.89, p=0.07
t=.98, ns t= -.35, ns
FEP 2.34 (1.41) 1.61 (.57) t=2.14, p=0.04 2.29 (1.16) 1.31 (.32) t=3.09 p<0.01
Positive affect CHR-P 3.40 (.75) 3.60 (.82) t= -.64, ns 3.51 (.82) 3.95 (.34) t= -.89, ns
t=1.44, ns t=1.53, ns
FEP 4.05 (1.14) 4.40 (.91) t= -.99, ns 3.92 (1.07) 4.76 (.65) t= -2.59, p=0.01
Self-esteem CHR-P 4.14 (1.50) 5.10 (1.23) t= -1.82, p=0.08 4.77 (1.36) 5.88 (.40) t= -1.39, ns
t=.98, ns t=.50, ns
FEP 4.82 (.1.57) 5.72 (.81) t= -2.22, p=0.03 4.96 (1.36) 5.97 (.65) t= -2.55, p=0.02
Anxiety CHR-P 2.48 (1.46) 1.88 (.97) t=1.33, ns 2.12 (1.13) 1.15 (.10) t=1.46, ns
t= -.43, ns t= -.17, ns
FEP 2.19 (1.47) 1.42 (.47) t=2.25, p=0.03 2.06 (1.21) 1.22 (.33) t=2.51, p=0.02
Delusional intensity CHR-P 2.89 (1.36) 1.91 (.81) t=2.51, p=0.02 2.24 (1.04) 1.26 (.42) t=1.59, ns
t= -1.38, ns t= -1.20, ns
FEP 2.14 (1.12) 1.28 (.29) t=3.37, p<0.01 1.89 (.97) 1.21 (.27) t=2.55, p=0.02
Suspiciousness CHR-P 2.63 (.98) 2.17 (1.19) t=.99, ns 2.40 (1.13) 1.06 (.06) t=2.02, p=0.05
t= -1.61, ns t= -1.82, p=0.07
FEP 1.86 (1.10) 1.29 (.43) t=2.16, p=0.04 1.85 (.90) 1.01 (.03) t=3.50, p=0.001
AH intensity CHR-P 1.65 (.86) 1.00 (.01) t=3.90, p<0.001 1.17 (.51) 1.00 (.00) t=.58, ns
t=1.26, ns t=2.00, p=0.05
FEP 2.61 (2.04) 1.01 (.02) t=3.63, p=0.001 1.80 (1.54) 1.40 (1.36) t=.75, ns
VH intensity CHR-P 1.70 (1.25) 1.00 (.005) t=2.89, p=0.01 1.19 (.69) 1.00 (.00) t=.46, ns
t=.34, ns t=1.40, ns
FEP 1.93 (1.67) 1.00 (.01) t=2.58, p=0.01 1.61 (1.40) 1.01 (.01) t=1.59, ns
Hal: Hallucination(s) reported; Suspic: suspiciousness reported. *p<0.05, ** p<0.01, *** p<0.001. 
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Table 3. Dynamics of suspiciousness
Phase 1 (B) Phase 2 (B) Phase 3 (B) Phase 4 (B) Phase 5 (B)
Negative affecta CHR-P .01 (.10) .61 (.08)*** .76 (.09)*** .72 (.10)*** .13 (.10)
FEP .26 (.15) 1.15 (.11)*** 1.53 (.19)*** 1.16 (.19)*** .21 (.17)
FEP vs. CHR-P Z=1.31, ns Z=3.96, p<0.001 Z=3.70, p<0.001 Z=2.04, p<0.05 Z=.43, ns
Positive affecta CHR-P .05 (.14) -.35 (.10)** -.41 (.12)** -.43 (.14)** .09 (.14)
FEP -.43 (.17)* -.44 (.12)*** -.79 (.21)*** -.22 (.21) -.08 (.18)
FEP vs. CHR-P Z= -2.19, p<0.05 Z= -.59, ns Z= -1.59, ns Z=.86, ns Z= -.73, ns
Self-esteema CHR-P -.20 (.10)* -.47 (.07)*** -.46 (.09)*** -.41 (.10)*** -.23 (.10)*
FEP -.43 (.14)** -.75 (.11)*** -.71 (.18)*** -.86 (.18)*** -.17 (.16)
FEP vs. CHR-P Z= -1.29, ns Z= -2.15, p p<0.05 Z= -1.24, ns Z= -2.21, p<0.05 Z= .36, ns
Anxietya CHR-P .12 (.14) .71 (.11)*** .93 (.13)*** .82 (.14)*** .24 (.14)
FEP .05 (.20) 1.18 (.15)*** 1.71 (.24)*** .94 (.24)*** .17 (.22)
FEP vs. CHR-P Z= -.29, ns Z=2.55, p<0.05 Z=2.87, p<0.01 Z=.42, ns Z= -.27, ns
Delusional intensitya CHR-P .28 (.07)*** 1.07 (.06)*** 1.04 (.07)*** 1.08 (.08)*** .19 (.08)
FEP .11 (.10) .910 (.07)*** 1.31 (.12)*** 1.36 (.12)*** .17 (.11)
FEP vs. CHR-P Z= -1.35, ns Z= -1.80, ns Z=2.00, p<0.05 Z=1.94, p=0.05 Z= -.16, ns
Suspiciousness a CHR-P .14 (.09) 2.72 (.07)*** 2.78 (.08)*** 2.56 (.09)*** .24 (.09)*
FEP .10 (.12) 2.78 (.09)*** 3.46 (.14)*** 3.18 (.14)*** .21 (.13)
FEP vs. CHR-P Z= -.25, ns Z=.53, ns Z=4.16, p<0.001 Z=3.67, p<0.001 Z= -.16, ns
AH intensitya CHR-P .17 (.06)** .14 (.05)** .05 (.06) .03 (.06) .17 (.07)*
FEP .12 (.15) .31 (.11)** .58 (.18)** .39 (.18)* .06 (.16)
FEP vs. CHR-P Z= -.30, ns Z=1.50, ns Z=2.80, p<0.01 Z=1.87, ns Z= -.61, ns
VH intensitya CHR-P .02 (.06) .04 (.04) .02 (.05) -.04 (.06) .02 (.06)
FEP .05 (.13) .07 (.10) .31 (.16) .69 (.16)*** .05 (.14)
FEP vs. CHR-P Z=.22, ns Z=.29, ns Z=1.77, ns Z=4.35,  p<0.001 Z=.19, ns
*p<0.05, **p<0.01, ***p<0.001. Phase 1: last moment before onset of episode; Phase 2: first moment of 
episode; Phase 3: during episode; Phase 4: last moment of episode; Phase 5: first moment after end of ep-
isode. AH=auditory hallucinations, VH=visual hallucinations a Regression coefficient indicates the difference 
in intensity of the variables as compared to moments unrelated to a paranoid episode
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Table 3. Dynamics of suspiciousness
Phase 1 (B) Phase 2 (B) Phase 3 (B) Phase 4 (B) Phase 5 (B)
Negative affecta CHR-P .01 (.10) .61 (.08)*** .76 (.09)*** .72 (.10)*** .13 (.10)
FEP .26 (.15) 1.15 (.11)*** 1.53 (.19)*** 1.16 (.19)*** .21 (.17)
FEP vs. CHR-P Z=1.31, ns Z=3.96, p<0.001 Z=3.70, p<0.001 Z=2.04, p<0.05 Z=.43, ns
Positive affecta CHR-P .05 (.14) -.35 (.10)** -.41 (.12)** -.43 (.14)** .09 (.14)
FEP -.43 (.17)* -.44 (.12)*** -.79 (.21)*** -.22 (.21) -.08 (.18)
FEP vs. CHR-P Z= -2.19, p<0.05 Z= -.59, ns Z= -1.59, ns Z=.86, ns Z= -.73, ns
Self-esteema CHR-P -.20 (.10)* -.47 (.07)*** -.46 (.09)*** -.41 (.10)*** -.23 (.10)*
FEP -.43 (.14)** -.75 (.11)*** -.71 (.18)*** -.86 (.18)*** -.17 (.16)
FEP vs. CHR-P Z= -1.29, ns Z= -2.15, p p<0.05 Z= -1.24, ns Z= -2.21, p<0.05 Z= .36, ns
Anxietya CHR-P .12 (.14) .71 (.11)*** .93 (.13)*** .82 (.14)*** .24 (.14)
FEP .05 (.20) 1.18 (.15)*** 1.71 (.24)*** .94 (.24)*** .17 (.22)
FEP vs. CHR-P Z= -.29, ns Z=2.55, p<0.05 Z=2.87, p<0.01 Z=.42, ns Z= -.27, ns
Delusional intensitya CHR-P .28 (.07)*** 1.07 (.06)*** 1.04 (.07)*** 1.08 (.08)*** .19 (.08)
FEP .11 (.10) .910 (.07)*** 1.31 (.12)*** 1.36 (.12)*** .17 (.11)
FEP vs. CHR-P Z= -1.35, ns Z= -1.80, ns Z=2.00, p<0.05 Z=1.94, p=0.05 Z= -.16, ns
Suspiciousness a CHR-P .14 (.09) 2.72 (.07)*** 2.78 (.08)*** 2.56 (.09)*** .24 (.09)*
FEP .10 (.12) 2.78 (.09)*** 3.46 (.14)*** 3.18 (.14)*** .21 (.13)
FEP vs. CHR-P Z= -.25, ns Z=.53, ns Z=4.16, p<0.001 Z=3.67, p<0.001 Z= -.16, ns
AH intensitya CHR-P .17 (.06)** .14 (.05)** .05 (.06) .03 (.06) .17 (.07)*
FEP .12 (.15) .31 (.11)** .58 (.18)** .39 (.18)* .06 (.16)
FEP vs. CHR-P Z= -.30, ns Z=1.50, ns Z=2.80, p<0.01 Z=1.87, ns Z= -.61, ns
VH intensitya CHR-P .02 (.06) .04 (.04) .02 (.05) -.04 (.06) .02 (.06)
FEP .05 (.13) .07 (.10) .31 (.16) .69 (.16)*** .05 (.14)
FEP vs. CHR-P Z=.22, ns Z=.29, ns Z=1.77, ns Z=4.35,  p<0.001 Z=.19, ns
*p<0.05, **p<0.01, ***p<0.001. Phase 1: last moment before onset of episode; Phase 2: first moment of 
episode; Phase 3: during episode; Phase 4: last moment of episode; Phase 5: first moment after end of ep-
isode. AH=auditory hallucinations, VH=visual hallucinations a Regression coefficient indicates the difference 
in intensity of the variables as compared to moments unrelated to a paranoid episode
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Table 4. Dynamics of hallucinations
Phase 1 (B) Phase 2 (B) Phase 3 (B) Phase 4 (B) Phase 5 (B)
Negative affecta CHR-P .10(.28) .43 (.21)* .85 (.34)* .27 (.36) .10 (.26)
FEP .54 (.27)* .91 (.18)*** 1.02 (.20)*** .83 (.22)*** .81 (.44)
FEP vs. CHR-P Z=1.14, ns Z=1.76, ns Z=.44, ns Z=1.33, ns Z=1.39, ns
Positive affecta CHR-P .51 (.36) -.60 (.26)* -.46 (.41) .26 (.45) .55 (.33)
FEP .17 (.30) -.38 (.20) -.53 (.22)* -.12 (.25) -.39 (.48)
FEP vs. CHR-P Z= -.73, ns Z=.66, ns Z= -.15, ns Z= -.75, ns Z= -1.62, ns
Self-esteema CHR-P .29 (.26) .09 (.19) -.38 (.31) -.04 (.33) .36 (.24)
FEP -.36 (.24) -.65 (.16)*** -.78 (.18)*** -.64 (.20)** -.51 (.39)
FEP vs. CHR-P Z= -1.83, ns Z= -2.96, p<.01 Z= -1.11, ns Z= -1.53, ns Z= -1.89, ns
Anxietya CHR-P .60 (.40) .85 (.29)** 1.56 (.48)** 1.32 (.40)* .39 (.38)
FEP .63 (.35) 1.06 (.23)*** 1.30 (.26)*** 1.14 (.29)*** 1.19 (.57)*
FEP vs. CHR-P Z=.06, ns Z=.56, ns Z= -.47, ns Z= -.31, ns Z=1.19, ns
Delusional intensitya CHR-P -.03 (.23) .53 (.17)* .72 (.33)* .34 (.35) .26 (.26)
FEP .29 (.19) .91 (.13)*** 1.02 (.14)*** 1.06 (.16)*** .21 (.30)
FEP vs. CHR-P Z=1.04, ns Z=1.81, ns Z=.90, ns Z=1.69, ns Z= -.09, ns
Suspiciousnessa CHR-P -.27 (.43) .17 (.32) .52 (.51) -.27 (.55) .61 (.40)
FEP .55 (.34) .58 (.22)** .81 (.25)** .75 (.28)** .68 (.55)
FEP vs. CHR-P Z=1.50, ns Z=1.07, ns Z=.52, ns Z=1.64, ns Z=.10, ns
AH intensitya CHR-P .02 (.20) 1.81 (.14)*** 3.17 (.22)*** 2.80 (.25)*** -.26 (.18)
FEP -.08 (.19) 3.32 (.13)*** 3.65 (.14)*** 3.36 (.16)*** -.26 (.35)
FEP vs. CHR-P Z= -.33, ns Z=7.93, p<.001 Z=1.79, ns Z=1.93, ns Z= -.05, ns
VH intensitya CHR-P -.21 (.20) 1.30 (.15)*** 1.95 (.25)*** 2.12 (.26)*** -.23 (.19)
FEP .02 (.25) .81 (.17)*** 1.02 (.17)*** 1.10 (.21)*** .28 (.40)
FEP vs. CHR-P Z=.71, ns Z= -2.16,  p<0.05 Z= -2.97,  p<0.01 Z= -3.05,  p<0.01 Z=1.13, ns
*p<0.05, **p<0.01, ***p<0.001. Phase 1: last moment before onset of episode; Phase 2: first moment of 
episode; Phase 3: during episode; Phase 4: last moment of episode; Phase 5: first moment after end of ep-
isode. AH=auditory hallucinations, VH=visual hallucinations a Regression coefficient indicates the difference 
in intensity of the variables as compared to moments unrelated to a paranoid episode
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Table 4. Dynamics of hallucinations
Phase 1 (B) Phase 2 (B) Phase 3 (B) Phase 4 (B) Phase 5 (B)
Negative affecta CHR-P .10(.28) .43 (.21)* .85 (.34)* .27 (.36) .10 (.26)
FEP .54 (.27)* .91 (.18)*** 1.02 (.20)*** .83 (.22)*** .81 (.44)
FEP vs. CHR-P Z=1.14, ns Z=1.76, ns Z=.44, ns Z=1.33, ns Z=1.39, ns
Positive affecta CHR-P .51 (.36) -.60 (.26)* -.46 (.41) .26 (.45) .55 (.33)
FEP .17 (.30) -.38 (.20) -.53 (.22)* -.12 (.25) -.39 (.48)
FEP vs. CHR-P Z= -.73, ns Z=.66, ns Z= -.15, ns Z= -.75, ns Z= -1.62, ns
Self-esteema CHR-P .29 (.26) .09 (.19) -.38 (.31) -.04 (.33) .36 (.24)
FEP -.36 (.24) -.65 (.16)*** -.78 (.18)*** -.64 (.20)** -.51 (.39)
FEP vs. CHR-P Z= -1.83, ns Z= -2.96, p<.01 Z= -1.11, ns Z= -1.53, ns Z= -1.89, ns
Anxietya CHR-P .60 (.40) .85 (.29)** 1.56 (.48)** 1.32 (.40)* .39 (.38)
FEP .63 (.35) 1.06 (.23)*** 1.30 (.26)*** 1.14 (.29)*** 1.19 (.57)*
FEP vs. CHR-P Z=.06, ns Z=.56, ns Z= -.47, ns Z= -.31, ns Z=1.19, ns
Delusional intensitya CHR-P -.03 (.23) .53 (.17)* .72 (.33)* .34 (.35) .26 (.26)
FEP .29 (.19) .91 (.13)*** 1.02 (.14)*** 1.06 (.16)*** .21 (.30)
FEP vs. CHR-P Z=1.04, ns Z=1.81, ns Z=.90, ns Z=1.69, ns Z= -.09, ns
Suspiciousnessa CHR-P -.27 (.43) .17 (.32) .52 (.51) -.27 (.55) .61 (.40)
FEP .55 (.34) .58 (.22)** .81 (.25)** .75 (.28)** .68 (.55)
FEP vs. CHR-P Z=1.50, ns Z=1.07, ns Z=.52, ns Z=1.64, ns Z=.10, ns
AH intensitya CHR-P .02 (.20) 1.81 (.14)*** 3.17 (.22)*** 2.80 (.25)*** -.26 (.18)
FEP -.08 (.19) 3.32 (.13)*** 3.65 (.14)*** 3.36 (.16)*** -.26 (.35)
FEP vs. CHR-P Z= -.33, ns Z=7.93, p<.001 Z=1.79, ns Z=1.93, ns Z= -.05, ns
VH intensitya CHR-P -.21 (.20) 1.30 (.15)*** 1.95 (.25)*** 2.12 (.26)*** -.23 (.19)
FEP .02 (.25) .81 (.17)*** 1.02 (.17)*** 1.10 (.21)*** .28 (.40)
FEP vs. CHR-P Z=.71, ns Z= -2.16,  p<0.05 Z= -2.97,  p<0.01 Z= -3.05,  p<0.01 Z=1.13, ns
*p<0.05, **p<0.01, ***p<0.001. Phase 1: last moment before onset of episode; Phase 2: first moment of 
episode; Phase 3: during episode; Phase 4: last moment of episode; Phase 5: first moment after end of ep-
isode. AH=auditory hallucinations, VH=visual hallucinations a Regression coefficient indicates the difference 
in intensity of the variables as compared to moments unrelated to a paranoid episode
122  |  Chapter 5
Hallucinatory episode
CHR-Ps with hallucinations reported significantly higher levels of NA, delusional intensity 
as well as AH and VH intensity compared to CHR-Ps without hallucinations, while self-es-
teem was lower at trend level (Table 2). FEPs reporting hallucinations had significantly 
higher levels of NA, anxiety, suspiciousness, delusional, AH and VH intensity as well as 
lower self-esteem compared to FEPs without hallucinations.
When we focus on those participants who did report hallucinations, Figures 2a and 2b 
illustrate that suspiciousness and delusional ideation are elevated in moments unrelated 
and just before onset of hallucinatory episodes, although especially in the CHR-P group. 
CHR-Ps reported a significantly lower level of PA and higher levels of NA, anxiety and 
delusional intensity during an episode compared to moments unrelated to an episode 
(Table 4 & Figure 2a). FEPs reported significantly lower levels of self-esteem and PA as 
well as higher levels of NA, anxiety, delusional intensity and suspiciousness during a hal-
lucinatory episode. For the CHR-Ps, no significant differences were found on moments 
prior or following an episode as compared to moments unrelated to an episode, where-
as for FEPs a significant increase in NA occurred prior to the onset of a hallucinatory epi-
sode (Figure 2b). Furthermore, anxiety, NA and suspiciousness levels remained elevated 
after the episode ended, although the latter two this increase did not reach statistical 
significance. Direct comparison of CHR-P and FEP groups showed that FEPs were charac-
terised by a significantly lower level of self-esteem and a higher level of AH intensity than 
CHR-Ps at the onset of an episode, while differences did not remain significant during an 
episode. In contrast, VH intensity was significantly increased in CHR-Ps compared to FEPs 
during all phases of a hallucinatory episode (Table 4).
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Fig. 2. Dynamics of hallucinations in CHR-P (2a) & FEP (2b) 
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DISCUSSION
Main findings
This is the first study to examine hallucinations and suspiciousness in the context of daily 
life over a six-day period in participants in the early stages of psychosis. More CHR-Ps 
than FEPs reported suspiciousness (91% vs. 58%, respectively), the duration of suspi-
cious episodes was longer and comprised more than a third of all recorded moments 
in CHR-Ps. FEPs reporting suspiciousness in daily life had more distress as reflected by 
more NA, anxiety and delusional intensity and lower self-esteem than those FEPs not 
reporting suspiciousness. In the CHR-P group these differences were less distinct. In con-
trast, hallucinations (AH, VH or both) were more often reported by FEPs than CHR-Ps 
(39% vs. 24%, respectively) and hallucinatory episodes lasted longer in FEPs. Whereas 
in the CHR-P group suspiciousness was reported as an isolated experience, report of 
hallucinations was accompanied by suspiciousness in almost all individuals regardless 
of clinical status. In both groups, individuals with hallucinations also reported signifi-
cant higher NA, anxiety and delusional intensity and lower self-esteem than those with-
out and intensity of AH was higher in FEPs than in CHR-Ps, suggesting that presence of 
hallucinations reflects a more severe illness state. This study furthermore showed that 
hallucinatory and suspicious episodes are discrete phenomena with distinct points of in-
itiation and termination and are accompanied by increases in NA, anxiety and delusional 
ideation. Decreases in self-esteem were apparent in FEPs during both types of episodes, 
while it was only characteristic for suspicious episodes in CHR-Ps. Our findings showed 
that both groups, but especially CHR-Ps, showed elevated levels of suspiciousness and 
delusional ideation that increased further during episodes. Finally, only FEPs showed 
changes in affect prior to onset of both types of episodes.
Phenomenology and temporal dynamics of suspicious and hallucinatory episodes
Current results are in line with previous studies using ESM showing that despite psy-
chotic experiences in daily life being a persistent problem, individuals are not constantly 
engulfed by their symptoms in their daily lives10-12, 14, as symptoms were present in 23-
46% of moments in those reporting symptoms. Fifty-nine percent of individuals suffering 
from a first psychotic episode reported suspicious feelings to occur in daily life, which 
is comparable to the 54% of FEPs who reported specific persecutory ideas including the 
feeling of being ‘monitored’ in a cross-sectional study1 and the 49-67% of psychotic dis-
order patients in previous studies using ESM11, 12. In contrast, 91% of individuals at clinical 
high risk for psychosis reported suspiciousness in daily life, even more than in a previ-
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ous study which found subclinical delusions in 82% of their sample2 and 54% reporting 
paranoid feelings5. Less than half of FEPs with daily life suspiciousness reported this as 
their only symptom compared to almost three-quarter of CHR-Ps. Currently suspicious 
FEPs were clearly distressed by these symptoms as they reported more NA, anxiety, de-
lusional intensity and lower self-esteem than current symptom-free FEPs. In contrast, 
these effects were less apparent for currently suspicious CHR-Ps. Interestingly, episode 
duration was longer in CHR-P compared to FEPs and CHR-Ps reported significantly more 
suspiciousness and more general delusional ideation (i.e. feeling unreal, fear of losing 
control, getting stuck in ones thinking and the idea that other might influence ones 
thoughts) than FEPs. Therefore, the CHR-P state can be argued to reflect a primarily 
‘suspicious-delusional state’.
Hallucinations were reported by 39% of FEPs in daily life, a rate very similar to the 40% 
reported by Oorschot and colleagues10 in their study of psychosis spectrum patients, 
although lower than in other studies using ESM11, 13. However, those studies used a more 
liberal approach in defining hallucinations (minimal score of 2 rather than 3) possibly 
explaining the difference with this study. Our reported rate is lower than that of ~70% 
for auditory hallucinations1, 6, although more similar to 29-57% for visual hallucinations 
in FEPs in cross-sectional studies1, 6.  A possible explanation is that FEPs were allowed 
to be in remission if their psychotic episode had occurred within the previous 2 years. 
Furthermore, 31 of the 34 FEPs used or had previously used anti-psychotic medication 
likely resulting in less prevalent current symptoms in daily life.
Furthermore, reflecting results of previous cross-sectional studies and studies using 
ESM4, 11, 13, hallucinations and suspiciousness almost always clustered within the same 
individuals with a first psychotic episode. Similarly, even though only about a quarter of 
CHR-Ps reported hallucinations in daily life, which were less prevalent than in cross-sec-
tional studies2, 3, all these individuals also experienced feelings of suspiciousness. Both 
CHR-Ps and FEPs were thus characterised by a ‘hallucinatory-delusional state’, which was 
associated with more as reflected by higher NA, anxiety, delusional intensity and lower 
self-esteem compared to individuals without current hallucinations. Combined these re-
sults suggest that presence of hallucinations is related to a more severe stage of psychot-
ic illness. However, FEPs spend more time in this mixed state as duration of hallucinatory 
episodes was significantly longer than in CHR-Ps.
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Our results confirm previous results showing that hallucinations have a fairly sudden 
onset and termination10, 13 and show that this also applies to suspiciousness, overall 
suggesting that both are on/off phenomena as illustrated by Figures 1 and 2. However, 
these figures also show that both FEPs and CHR-Ps are reporting low intensity delu-
sional ideation even in moments not related to suspicious and hallucinatory episodes 
and this is especially apparent for CHR-Ps with hallucinations. This might explain why 
we did not find a significant increase in delusional ideation before onset of a hallucina-
tory episode as reported by Oorschot and colleagues10 in psychosis spectrum patients. 
However, whereas suspiciousness and delusional ideation accompanied hallucinations 
at the onset and over the course of episodes in FEPs, delusional ideation increased only 
during longer episodes in CHR-Ps (i.e. episodes lasting ≥2 moments). In contrast, a small 
increase in delusional intensity was apparent in CHR-Ps in the last moment before onset 
of suspicious episodes, as were small increases in AH which intensified over the course 
of the episodes in both groups. Similarly, Ben-Zeev and colleagues12 found that increased 
perceptual abnormalities in psychosis spectrum patients preceded persecutory ideation. 
Current results show that the interplay between hallucinations and delusions varies 
slightly over the different phases of illness.
Psychotic patients are characterised by highly variable levels of self-esteem and this in-
stability was especially related to paranoid feelings15. In our study, reduced self-esteem 
was more apparent for suspicious episodes than for hallucinatory episodes, for which it 
was present in FEPs. In contrast, even before onset of suspicious episodes self-esteem 
was decreased and decreased further over the duration of episodes, as was reported 
for a sample of participants with experiences ranging across the paranoia continuum14. 
This reduction remained even after the end of an episode in CHR-Ps. Our findings fur-
ther emphasise the important role of negative self-evaluation in the development of 
suspiciousness and consistent with the suggestion suspicious individuals assume others 
to share their own negative evaluations of themselves, which in elicits the perceived 
malevolence of others14.
As reported by previous ESM studies with participants across the psychosis continuum 
and psychotic patients with acute paranoia and hallucinations10, 11, 14, we found both ex-
periences to be accompanied be a decrease in positive emotions and increases in nega-
tive emotions and anxiety in FEPs, although individual differences in these relationships 
have been reported25. Current results are furthermore in line with cross-sectional stud-
ies showing increased anxiety levels in patients with (auditory) hallucinations and per-
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secutory delusions26-29. Importantly, our results expand these findings by showing that 
these effects also apply in the clinical high risk for psychosis state.
Anxiety has been found to be a strong predictor of onset and intensity of paranoid and 
hallucinatory episodes in daily life13, 14, although current results are less conclusive. Anx-
iousness was somewhat although not significantly elevated prior to onset of halluci-
nations or paranoia in both CHR-P and FEP patients. A previous study of Oorschot and 
colleagues25 found that an anxious state was only apparent in the moment before a 
paranoid episode in a small number of their psychotic patients. This might also be the 
case for current participants. In contrast, hallucinations and suspiciousness were accom-
panied by increases in anxiety. Worrying and rumination have been found to predict 
delusional and hallucinatory experiences and distress9. Feeling worried and having ru-
minating thoughts, accompanied by a drop in self-esteem are likely triggers of psychotic 
experiences, which in turn elicit anxiety. This suggestion is supported by our finding that 
anxiety remained increased after the end of a hallucinatory episode for FEP patients, for 
whom the content of hallucination might be more disturbing and a source for ruminating 
thoughts, whereas anxiety dropped after the end of a hallucination in CHR-Ps. 
Theoretical implications
Both cognitive and biological theories of psychosis argue that transition to psychosis is 
the results of the co-occurrence of hallucinations and delusions30-32. Subtle perceptual 
alterations or anomalous experiences occurring in an early phase can be very disturbing 
and warrant an explanation resulting in the gradual formation of delusional ideas under 
the influence of emotional processes. In line with these theories, epidemiological stud-
ies have shown that these perceptual alterations or hallucinations along with the dis-
tress they cause and accompanied by depressive symptoms have been associated with 
development of more severe types or secondary delusions. These secondary delusions 
concern loss of control (e.g. thought withdrawal and insertion, thought broadcasting) 
and belief that emotions, impulses and/or actions are controlled by an outside force, 
which in turn are associated with poorer outcome in psychotic patients33-37.
Taken together current findings on prevalence and phenomenology of psychotic experi-
ences in daily life in the early phase of psychosis are in line with epidemiological studies 
showing that clustering of hallucinations and delusions as compared to either symptoms 
in isolation, results in a deepened psychotic state34, 35. In this ‘hallucinatory-delusional 
state’ experiences become more persistent, associated with negative symptoms and an 
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increased risk of clinical outcome38, 39 and this state occurs more often in individuals with 
higher levels of exposure to genetic and environmental risk factors34, 35, suggesting it 
forms a crucial stage in the development of psychotic disorder. It is therefore attractive 
to hypothesize that the relatively small current subsample of CHR-Ps (24%) reporting 
both types of experiences in daily life are more likely to make the transition to psychotic 
disorder than those reporting suspiciousness only, although follow-up studies are need-
ed to confirm this hypothesis.
Clinical implications
The current findings have implications for clinical practice. Thorough investigation of 
the exact nature of (attenuated) psychotic symptoms is needed as severity and risk for 
transition is likely to be higher for individuals reporting both suspiciousness and hallu-
cinations. Clinicians need to be aware of the central role of emotion-related processes, 
anxiety and self-esteem for the occurrence of hallucinations and suspiciousness in daily 
life not only in patients with a first episode of psychosis for whom these processes are 
relevant with respect to prevention of illness progression, but also for those at high clin-
ical risk for transition to psychosis. Use of momentary assessment can help to unravel 
symptom patterns as they supply both the individual patient and clinician with large 
amount of detailed information about symptoms and their relationships with mood, 
anxiety, self-esteem all in the social context of daily life.
In psychotic spectrum patients investigation of different ‘types’ of paranoia (i.e. “poor 
me” and “bad me”) has shown that a complicated relationship exists with self-esteem, 
experiential avoidance and social stress in which paranoia sometimes has a beneficial 
effect on self-esteem and possibly serve a protective mechanism40-42. Future studies in 
CHR-P and FEP groups are needed to determine the exact role of all these processes in 
these populations. Taken together, these findings warrant for a systematic evaluation 
of the type of paranoia and self-esteem (variability) to determine the best treatment 
strategy which can help improve self-esteem regulation and in turn symptomatology 
and anxiety.
Limitations
The results of this study should be interpreted in the context of several methodological 
limitations. First, as with all ESM studies, measurements are based on subjective reports. 
Therefore, it can be argued that the results are not psychometrically precise. Howev-
er, although subjective reports are considered less reliable (e.g., do all participants in-
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terpret or answer the questions identically?), previous research indicates that subjective 
reports can be valid and are important especially in order to understand the changes in 
symptoms43. In addition, as we combined two samples, data was gathered with help of an 
electronic device and by the use of a paper-and-pencil diary method. The paper-and pencil 
method has been questioned as it may lead to poor participant compliance. However, pre-
vious studies have demonstrated that the traditional paper-and-pencil diary methods are 
not inferior to electronic diary methods with regard to compliance rates44, 45.
Second, our measure of paranoia ‘I feel suspicious’ was defined more narrowly than in 
previous ESM studies of paranoid or persecutory ideation9, 14. However, prevalence rates 
were similar to earlier studies. Further investigation of the content of paranoid beliefs 
and their relationship to emotional processes may help therapies to focus on the mecha-
nism of change in suspicious thinking instead of focussing solely on symptom reduction.
Third, given the small number of CHR-P and FEP participants who only reported either 
visual or auditory hallucinations, we were not able to investigate the temporal dynam-
ics of auditory and visual hallucinations separately as was done by Oorschot and col-
leagues10 in a large sample of psychotic spectrum patients. Furthermore, as we were 
unable to assess the precise nature of content of auditory and visual hallucinations, we 
could not discern whether these were more crystallized in FEPs compared to CHR-Ps. 
However, results of this study showed that regardless of participant status, psychotic 
experiences in daily life were related with low mood and anxiety. Future studies with 
larger samples should examine these factors in more detail.
Fourth, as with all ESM studies of symptomatology, the random-sampling design might 
have caused an underestimation of hallucination and paranoia frequency, since we can-
not rule out the possibility that patients are less prone to respond to a beep when hal-
lucinating or feeling suspicious. Alternatively, we might have missed hallucinations or 
paranoia occurring between beeps. Furthermore, episode duration may have been over-
estimated as it is possible that we may have missed symptom-free periods in between 
consecutive beeps. In contrast, an episode duration may have been underestimated in 
participants who reported hallucinations or paranoia (almost) continuously as per defi-
nition we defined the end of an episode as the last moment of the day. However, our 
results also indicated that the majority of episodes were present only during one mo-
ment, suggesting that the on and offset of hallucinatory and paranoid episodes is highly 
variable.
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General discussion
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Psychotic disorders are associated with a high burden for patients themselves as well 
as for their family members and friends. Early identification and intervention for sub-
clinical psychotic symptoms may influence illness trajectory, possibly averting the tran-
sition to fully-fledged psychotic disorder and improving functioning and quality of life. 
To accomplish this goal psychosis research and clinical care have started to focus on 
investigation of subclinical psychotic symptoms in help-seeking individuals meeting 
criteria for clinical high risk for psychosis (CHR-P) as well as in non-help seeking indi-
viduals from the general population and unaffected first-degree relatives of psychotic 
disorder patients.  
The current thesis aimed to gain more insight in mechanisms and risk factors involved 
in the development from subclinical psychotic symptoms to clinically relevant psychotic 
symptoms and psychotic disorder. The occurrence of (subclinical) psychotic symptoms 
was studied across the psychosis continuum in individuals from the general population, 
unaffected first-degree relatives of psychotic disorder patients, patients at clinical high 
risk for psychosis (CHR-P), patients with a first psychotic episode (FEP) and long-term 
psychotic disorder patients. 
The first part of this thesis focussed on the epidemiology of development of subclinical 
psychotic symptoms in individuals from the general population and unaffected relatives 
of psychotic disorder patients as assessed through both self-report and clinical interview 
measures. Using a longitudinal design, in chapter 2 we examined the progression and 
outcome of baseline ‘false-positive’ self-reported psychotic experiences (FP SRPE) over 
a 3-year follow-up period in individuals from the general population, which have been 
suggested to represent the lowest expression of psychosis risk along the continuum. We 
showed that ‘False positive SRPE’, are not truly ‘false’ as they index risk for development 
of clinically relevant psychotic symptoms, presence of mood and anxiety disorders and 
reduced functioning. Self-reported PE, even unconfirmed, therefore warrant ‘watchful 
waiting’ and follow-up over time especially when they are reported by individuals with 
reduced psychosocial functioning and general psychiatric problems. In chapter 3 we ex-
amined in a sample of unaffected first-degree relatives of psychotic disorder patients 
and healthy controls if genetic risk, as reflected by the Polygenic Risk Score for schizo-
phrenia (PRS), was associated with the expression of psychosis conceptualized as sub-
clinical psychotic symptoms assessed through both self-report and clinical interview. We 
found that while PRS was not associated with subclinical psychotic symptoms obtained 
through self-report, it was associated with subclinical symptoms obtained in a clinical 
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interview in both unaffected first-degree relatives and healthy controls. PRS was further-
more positively associated with the lifetime number of affective episodes.
The second part of this thesis aimed at exploring the phenomenology of psychotic expe-
riences in daily life in CHR-P patients, patients with a first episode of psychosis (FEP) and 
long-term psychotic disorder patients, to examine differences and similarities between 
the at-risk for psychosis stage, an ‘intermediate’ stage and an ‘endpoint’ stage along the 
extended psychosis continuum. The Experience Sampling method (ESM) was applied to 
zoom in into the microenvironment to study the dynamics of momentary psychotic ex-
periences over time in the context of daily living. In chapter 4 we examined emotional 
and symptomatic stress-reactivity to daily life stressors as potential risk factors for psy-
chosis development. We found that stress sensitization seems to play a role particularly 
in the early phase of psychosis development as results suggest that CHR-P patients are 
more sensitive to daily life stressors than long-term psychotic disorder patients, as they 
showed higher levels of emotional and symptomatic stress reactivity. In this early phase, 
momentary psychotic symptoms also contributed to the experience of stress as they 
were associated with an increase in negative affect. 
Finally, in chapter 5 we specifically investigated the phenomenology of hallucinations 
and suspiciousness and their relationship with mood, anxiety and self-esteem in CHR-P 
and FEP patients. Episodes of suspiciousness were more prevalent than hallucinatory 
episodes and this was especially prominent for the CHR-P patients for whom episodes 
of suspiciousness lasted longer than for FEP patients, while only a minority reported 
hallucinations. Although hallucinations were more prevalent in FEP patients, episode 
duration was longer in CHR-P patients. Both symptoms were often reported by the same 
individual and co-occurred regularly at the same moment. Suspiciousness and halluci-
nations had a fairly sudden onset and ending, implying they are discrete on/off phe-
nomena. Intensity of delusional ideation, negative affect and anxiety increased where-
as self-esteem decreased during suspicious and hallucinatory episodes, indicating that 
these (subclinical) symptoms were distressing.  
The benefit of combining subjective self-report and objective interview measures in 
psychosis research
Psychopathology relates per definition to the expression of subjectively distressing ‘ab-
normal’ experiences. In psychosis research and clinical practice, both self-report and in-
terview measures are used to assess presence of anomalous experiences and the degree 
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in which they are distressing and pathological. Self-report measures have the advantage 
of being less time consuming than interviews, however, these are subjective in nature 
making it uncertain whether all individuals interpret and answer questions identically. 
Especially when (subclinical) psychotic symptoms are retrospectively assessed through 
self-report, is it possible that interpretation and answer style are under the influence 
of factors such as personal relevance, recency effects, novelty, significance or mood. 
Furthermore, self-report measures are unable to filter contextual information needed to 
determine the clinical validity and relevance of reported ‘psychotic symptoms’1. In con-
trast, contextual information can be elicited through semi-structured clinical interviews 
by trained and experienced clinicians. This distinction in results based on assessment 
method2, 3 is illustrated by findings that in general population studies prevalence rates 
of subclinical psychotic symptoms obtained by self-report measures are several times 
higher than those obtained through clinical interview4-8. Some of these self-reported 
psychotic symptoms are true (subclinical) psychotic symptoms, although around 40% are 
not truly psychotic in nature and are referred to as ‘false-positive’ self-reported psychot-
ic experiences (FP SRPE). 
Examples of FP SRPE are hearing or seeing a departed loved one during a bereave-
ment period, or solely having hallucinations after use of a specific hallucinogenic 
drug9. Furthermore, factor analyses of self-reported PLEs assessed with the CAPE10, 
the self-report instrument which was used in chapter 3, in help-seeking non-psychot-
ic individuals and in individuals from the general population have identified several 
subtypes being persecution/paranoia, bizarre experiences, hallucinations, and para-
normal beliefs/magical thinking11, 12. Whereas persecution, bizarre experiences and 
hallucinations were more likely to be associated with distress and poor functioning 
and may represent expressions of underlying vulnerability for psychotic disorder, this 
was not found for paranormal beliefs and magical thinking, suggesting these may be 
a normal personality variant. Furthermore, in the general population sample very few 
endorsed experiencing bizarre experiences, perceptual abnormalities or persecuto-
ry ideas subtypes for a large proportion of time, and magical thinking was the most 
common subtype of self-reported psychotic symptoms that was endorsed as  ‘always 
or almost always’ present12. We can therefore argue that the majority of self-reported 
psychotic symptoms in both healthy controls and unaffected relatives were those of 
the paranormal beliefs and magical thinking subtype, which are unlikely to present 
true risk for psychotic disorder. 
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Some researchers have therefore argued that subclinical psychotic symptoms detected 
through self-report measures only have minimal direct clinical significance for the predic-
tion of psychosis onset1, 8, 9. However, an earlier study with a different general population 
sample found FP SPRE to predict transition to psychotic disorder, although the effect size 
was smaller than in individuals with validated psychotic symptoms13. In chapter 2 we con-
firmed that even FP SRPE are clinically relevant for psychosis development as well as for 
the development of general psychopathology. Individuals reporting these were 6 times 
more likely to develop clinically significant (subclinical) psychotic symptoms and had a 
higher likelihood of reduced functioning and more general psychopathology than healthy 
controls. Interestingly, individuals who developed valid psychotic symptoms after first re-
porting FP SRPE were already different at baseline from individuals for whom FP SRPE were 
transitory in nature. This supports the suggestion that (subclinical) psychotic symptoms are 
the outcome of more severe baseline severity of multidimensional psychopathology14-16. 
The group of individuals that transitioned to valid psychotic symptoms showed more 
mood and anxiety problems, high neuroticism, reported more childhood adversities and 
were more often help-seeking and reported more and more frequent FP SRPE. 
Use of self-report measures of psychotic experiences in both the general and clinical 
population will result in an overestimation of their prevalence. In turn, this might delude 
the effects of true subclinical symptoms on transition risk and functioning. However, 
when combined, self-report and clinical interview measures can provide valuable infor-
mation about psychosis development and directions for future research into risk factors 
and targets for treatment, especially when used in longitudinal studies.
In clinical care, self-report measures of psychotic experiences should always be followed 
by a clinical interview.  Importantly, chapter 2 illustrated that even non-confirmed or FP 
SRPE should not be dismissed as irrelevant, as they predicted higher levels of general 
psychopathology and help-seeking. Regular reassessment of even FP SRPE for individu-
als remaining in care for other psychological problems is therefore recommended. 
Overall, the scientific and clinical significance of subclinical psychotic symptoms will thus 
depend strongly on the manner and context in which these are assessed. The findings 
of chapter 3 illustrate this point. We found that Polygenic Risk Score (PRS) for schizo-
phrenia was positively and significantly associated with subclinical psychotic symptoms 
assessed with an objective interview measure in both unaffected first-degree relatives 
of psychotic patients and healthy controls. In contrast, PRS was not associated with PLEs 
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assessed with a self-report measure. These results thus suggest that studies of gene-en-
vironment relationships in psychosis are more likely to be informative when objective 
interview measures of subclinical psychotic symptoms are used. As suggested previous-
ly9, it can be recommended that future studies of subclinical psychotic symptoms should 
only use self-report measures as a screening tool. PLEs should then be examined in detail 
by clinical interview. The use of a semi-structured psychosis risk assessment interview 
like the CAARMS or the SIPS is advised as it allows validation of an experience as a true 
subclinical symptom while also obtaining detailed information about the frequency of a 
symptoms and determination of CHR-P or psychosis status.  
Even though retrospective self-report has important issues that have to be considered, 
self-report measures can be very informative when experiences are not assessed retro-
spectively but in real time by use of simple and straightforward questions as is done with 
the Experiences Sampling Method (ESM)17, 18. When assessment of experiences is ‘in the 
moment’, answers are less prone to the occurrence of biases and forgetting that hamper 
traditional retrospective assessment approaches19. The ESM method has several other ad-
vantages. It allows the assessment of various constructs including quality of life and psy-
chopathology as well as psychological mechanisms like stress-sensitivity and coping that 
are difficult to assess using cross-sectional questionnaires. ESM studies are ecologically 
valid as they allow studying individuals within their own real-life environment.  ESM is 
situated in the complex context of daily life and therefore able to measure the variation in 
symptoms and mood in response to environmental factors present in daily life, whereas 
questionnaires and most interviews do not focus on how contextual factors impact these 
outcome variables. In addition, questionnaires and interviews require patients to be aware 
of the dynamics of symptoms and their interactions with other factors. However, as differ-
ent constructs like symptoms, mood, stress and social company are measured separately 
from each other and only associated to each other in the analyses conducted by the re-
searcher, ESM provides information that the participant is not aware of and therefore not 
influenced by an individual’s own expectations. Finally, ESM allows for the cross-sectional 
as well as longitudinal study of variation and dynamic relationships given that data collec-
tion encompasses multiple assessments over time which creates a detailed picture of the 
occurrence and the dynamics of symptoms, mood and other constructs in daily life. 
Studies using ESM in psychotic disorder patients have provided valuable information 
on the phenomenology of positive symptoms20-26, negative symptoms27-29 and their rela-
tionship to emotions and contextual factors, but also social functioning29, 30 in daily life. 
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Importantly, ESM has significantly improved our understanding of the association be-
tween a number of putative psychological mechanisms and psychotic symptoms31. It has 
shown that psychotic patients are characterised by increased emotional and symptomat-
ic reactivity when confronted with everyday small stressors32, 33. Other ESM studies have 
investigated putative psychological mechanisms and their relationship with (subclinical) 
psychotic symptoms including cognitive self-consciousness34, meta-cognitive beliefs34, 
35, self-esteem26, 35, 36, coping37, cognitive appraisal25, affective disturbance20, 38, enhanced 
threat anticipation and experiences of aberrant novelty and salience39.
The studies in chapter 4 and chapter 5 have further extended ESM research to the ear-
ly phase of psychosis in FEP patients and before onset of psychosis in CHR-P patients. 
Providing evidence for the hypothesis that enhanced stress sensitivity is an underlying 
mechanism for psychosis development, we found in chapter 4 that CHR-P patients show 
increased emotional stress reactivity for small daily life hassles not only compared to 
healthy controls, but to long-term psychotic disorder patients as well. Our results are 
very similar to findings of two other recent ESM studies in CHR-P and (first episode) 
psychotic disorder patients39, 40, suggesting that stress sensitization seems to play a role 
particularly in the early phase of psychosis development. Furthermore, psychotic disor-
der patients show symptomatic reactivity to small daily life stressors. This process of ‘be-
havioural sensitization’ has been argued to reflect an affective pathway to psychosis that 
underlies a more reactive, episodic type of psychosis that characterizes a subgroup of 
patients with predominantly positive psychotic symptoms41. Results in chapter 4 showed 
that symptomatic stress reactivity for stressful activities was stronger in CHR patients 
than in long-term psychotic disorder patients, although the other two recent studies 
did not find differences between CHR-Ps and (first episode) psychotic patients39, 40. Be-
havioural sensitization thus occurs before onset of psychotic disorder and is not just the 
result of chronic psychotic illness.
The ESM study in chapter 5 is the first to examine the phenomenology of positive (sub-
clinical) psychotic symptoms in daily life, thereby expanding our knowledge about the 
characteristics of these symptoms. Our results highlight the existence of similarities and 
differences between CHR-P and FEP patients regarding the prevalence and dynamics 
of suspiciousness and hallucinations in daily life and their dynamic relationships with 
mood, anxiety and self-esteem as such providing targets for early interventions.
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Expanding the experience sampling method to clinical practice
In scientific studies, important information regarding inter-individual and intra-individ-
ual differences is lost due to averaging data over groups. This is illustrated by a previous 
study where rather than performing group comparisons, particular symptoms patterns 
and internal and contextual triggers for paranoia were examined per individual24. Where-
as previous studies22, 25 and our study in chapter 5 showed that paranoia is related to 
increased anxiety levels at group level, the study of Oorschot and colleagues24 focussed 
on emotions preceding and following paranoia in each individual and found that both 
the emotional state preceding paranoid thoughts and the emotional impact of these 
thoughts showed large and meaningful variation between individuals with psychotic dis-
order patients. In some, emotional changes preceded paranoia whereas anxiety resulted 
from having paranoid thoughts in others. For others, paranoia was followed by a state of 
relaxation. In addition, results of this particular study also pointed out the importance 
of intra-individual differences in symptoms in the flow of daily life. It was shown that 
whereas one patient had a clear ‘peak’ in paranoia-level and low paranoia intensity dur-
ing the rest of the day, another reported a steady medium paranoia-level throughout the 
day. However, by averaging these scores as is done in group comparisons this resulted 
in an overall medium daily paranoia level for both patients, obscuring clinically relevant 
information.
These results clearly highlight the value of ESM as an additional diagnostic tool in regu-
lar clinical practice. It allows tailoring of diagnosis and treatment planning to the needs 
of a specific patient and treatment monitoring. Rapid feedback is now available due to 
data collection via smart phone applications, which have also simplified the user ex-
perience and reduced the logistic burden of data collection and analysis. This allows 
ESM to be applied as an ecological momentary intervention (EMI)42, 43. In a review of the 
EMIs in psychiatry it was found that few studies have investigated the possibilities and 
the efficacy. However, these studies underscored feasibility and acceptability of mobile 
health (mHealth) approaches in patients with severe mental illness. Importantly, EMIs 
provide the opportunity for intervening in dynamics of daily life between the individual 
and his/her environment that may be at the core of psychiatric symptom. Furthermore, 
an integration of EMI and real-life assessment using ESM seems to promote greater ef-
ficacy, especially when the intervention can be provided in moments when intervention 
is needed 44. Finally, it has been argued that costs may be reduced and outcomes may 
be improved by implication of blended care in which face-to-face treatment is combined 
with ESM-based intervention in daily life to enhance application of psychological inter-
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ventions under real-world conditions42. ESM offers the opportunity to enhance self-mon-
itoring, self-insight and personalized health care, and the results of studies in this thesis 
suggest that EMIs should aim application of at stress reduction techniques in daily life in 
CHR-P and FEP patients. If stress reactivity is subsequently reduced this might reduce the 
occurrence of suspicious feelings and hallucinations, which in turn will have a positive 
effect on mood and prevent strong decreases of self-esteem which often occurs during 
these symptoms and reduce anxiety.
Beyond the high-risk for psychosis state: importance of a broad clinical staging ap-
proach of mental disorders
In order to promote early detection of individuals at high risk for the development and 
active intervention with the goals to delay or even prevent onset of first episode psy-
chotic disorder the Clinical High-Risk state for psychosis (CHR-P) paradigm was intro-
duced about 2 decades ago. It has accumulated a lot of knowledge on subclinical psy-
chotic symptoms and risk factors for psychosis development. The transition rate of up to 
29% of CHR-P patients at 2-year follow-up and of 36% after 3 years 45, 46 and the finding 
that ~70% of CHR-P patients develop schizophrenic psychoses47, makes this CHR-P state 
a specific marker for research on predictors and mechanisms of developing psychosis48.
This average transition rate of 36% after three years suggest that current CHR-P criteria, 
emphasizing onset or worsening of subclinical psychotic symptoms, are still insufficient 
in predicting imminent onset of psychosis and thus in need of refinement49. Recently, the 
CHR-P paradigm has also been critiqued on other points14, among them that the focus 
lies solely on ‘risk’ and ‘transition’ and that by doing so any subclinical positive symp-
toms are implicitly treated as a pathway to schizophrenia and imminent bad outcome. 
It has also been argued that determining psychosis risk solely on the presence of sub-
clinical psychotic symptoms is too restrictive, transition rates are only high because of 
sample enrichment strategies rather than the criteria themselves, and differential out-
comes other than transition (i.e. remission and persistence of subclinical symptoms) as 
well as the presence of other psychopathological symptoms as markers of relative poor 
outcome of multidimensional psychopathology in terms of functioning have been largely 
ignored. Furthermore, the fact that CHR-P patients are help-seeking limits their epidemi-
ologically representativeness for the broad range of psychotic experiences and subclin-
ical symptoms in the general population of which not all are associated with distress or 
other forms of psychopathology. Finally, referring to CHR-P patients as if they are a class 
is not warranted as samples differ widely due to different sampling strategies and exclu-
sion criteria across studies regarding previous use of anti-psychotic medication, mood 
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stabilizers, presence of manic symptoms and previous drug-induced psychotic states, 
which strongly limits generalisability of findings.
However, while these methodological concerns certainly demand attention and im-
provement, the other concerns raised have certainly been noted before50 and CHR-P 
researchers have acknowledged that the specific focus on psychosis is too narrow and 
epidemiologically incomplete. The need to refine criteria has prompted investigation of 
other factors than subclinical positive psychotic symptoms that might be predictive for 
transition including social and role functioning and negative symptoms, both found to 
predict transition and low functioning over time51-54. In addition, recent studies55-57 have 
shown that the 3 subgroups making up the CHR-P state differ in their risk for transition, 
with the BLIPS group having the highest risk followed by the subclinical symptoms group 
while the genetic vulnerability group was not associated with an increased transition 
rate compared to the group not meeting CHR-P criteria. However, by focussing on out-
comes broader than transition, a very recent study showed that all 3 subgroups did not 
differ on severity of baseline negative symptoms or long-term non-transition outcomes 
including positive and negative symptom severity, psychosocial functioning and prev-
alence of non-psychotic disorders at follow-up58. This led the authors to suggest that 
when the CHR-P construct is viewed not simply as a marker of psychosis, but rather as a 
transdiagnostic risk state signifying need for clinical care, their findings do not support 
segregation of CHR-P groups into separate clinical entities as proposed based on the 
findings of differential transition risk55, 59. Finally, the combined results of a number of 
studies indicate that the positive symptom category of thought disorder/conceptual dis-
organization may constitute a robust clinical predictor of transition in CHR-P sample60-66. 
In line with these findings a recent study found that prediction of onset of psychosis 
was improved by using a state-dependent prognostic model which included the neg-
ative psychotic symptoms of observed flattened affect and subjective impaired motor 
functioning, impaired social functioning and distress associated with suspiciousness49.
In recent years an increasing number of studies have investigated outcomes other than 
transition and focus has shifted to factors associated with low functioning. It has be-
come apparent over the last decade that clinical implications of CHR-P status extend 
beyond risk of transition to psychosis. Most individuals who meet CHR-P criteria will not 
develop a psychotic disorder46, 57, 67 but will experience persistent subclinical psychotic 
symptoms67, 68, large impairments in psychosocial functioning and quality of life, similar 
to those in other psychiatric disorders69, 70 and high rates of non-psychotic, especially 
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mood and anxiety  symptoms and disorders 68, 70, 71 which all warrant treatment in their 
own right, while only in 35% of individuals subclinical symptoms will fully remit72. Such 
findings have already driven a reframing of CHR-P as a clinical state signifying pluripo-
tent, transdiagnostic risk and the need for clinical care, rather than simply a marker of 
psychosis risk and are in line with the clinical staging model of psychiatry50, 73-79.
This model positions an individual along a continuum of illness which is defined accord-
ing to stages: Stage 0: no current symptoms, Stage 1a: help-seeking with distress, Stage 
1b: subclinical syndrome and Stages 2 to 4: full threshold disorder with varying degrees 
of recurrence and severity76, 77. In this broad model of staging in psychiatry the focus is 
shifted from the narrow focus in the CHR-P paradigm to a general syndrome of early 
mental distress requiring non-specific psychological self-management interventions to 
prevent more severe stages of psychopathology which includes the CHR-P state (stage 
1b), which may develop in more specific, and relatively treatment-resistant, syndromes 
later on. This allows for the introduction of stage-specific treatments, varying from 
non-specific non-pharmacological self-management approaches in the early stages to 
more active treatments in the advanced stages50, 75. It offers a conceptual framework 
than can guide the search for risk and protective factors for disease progression from 
incidental non-distressing PLEs in the general population to psychotic symptoms in long-
term psychotic disorder patients.
Importantly, the general staging model allows for overlap in symptoms of different di-
agnostic outcomes in a particular individual, which is common especially in the earlier 
phases of disease progression but is not recognized by the current diagnostic criteria. 
This is also apparent for psychosis as studies have shown the existence of an important 
link between mood and anxiety symptoms and psychosis, which is found at the level of 
clinical illness80-82, subclinical psychotic symptoms83-85 and PLEs16, 86-91, and many studies 
have suggested an important role for affective dysregulation in the formation of psy-
chotic symptoms41, 92-94. The results of chapter 3 add evidence to the transdiagnostic 
nature of psychosis as we found that genetic risk for psychosis reflected by PRS is not 
only expressed as subclinical psychotic symptoms, but also as affective dysregulation 
in the form of positive associations between PRS and the lifetime number of affective 
episodes in both unaffected first-degree relatives and healthy controls. This finding is 
in line with molecular genetic studies that suggest overlap between schizophrenia and 
affective disorders95, 96.
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Early identification of subclinical psychotic symptoms: when and where?
Psychotic disorder has an enormous impact on the lives of patients and their loved ones, 
and even subclinical psychotic symptoms are often distressing. In addition, many indi-
viduals meeting CHR-P criteria have clinically debilitating symptoms of comorbid diag-
noses, including anxiety, depression and substance abuse. Similar to psychotic disorder 
patients, CHR-P individuals are often characterised by high neuroticism and high levels 
of negative symptoms and significant impairments in academic performance and oc-
cupational functioning, difficulties with interpersonal relationships and a substantially 
compromised subjective quality of life97-102. Therefore, identification and intervention 
should happen as early as possible. Importantly, whereas extension of screening with 
self-report measures to help-seeking individuals in primary mental health care will help 
to detect individuals for whom subclinical psychotic symptoms are distressing and are 
at increased risk for psychotic disorder, extending early detection to non-help seeking 
populations by for example screening adolescents in schools or via the internet will not 
be efficient103. Given that psychotic experiences are reasonably common and mostly 
non-distressing in the general population104, 105 and adolescents in particular12, 15, and the 
study of van Nierop and colleagues7 has shown that psychotic experiences not validated 
by clinical interview (FP SPRE) were about 2 times more prevalent than confirmed psy-
chotic symptoms, it can be argued that the detection of some people who are genuinely 
at risk will be at the cost of valuable resources invested in a high amount of clinical 
interviews of individuals whom are not distressed by or seeking help for these experi-
ences in which it might trigger the development of self-perceived stigma. Taken togeth-
er, early identification and intervention of subclinical psychotic symptoms is important 
and screening with short screening instrument like the Prodromal Questionnaire106 or 
CAPE-15107 should be widely implemented in mental health care practice. In the Nether-
lands, the EDIE-NL project108 has resulted in implementation of the screening approach 
in all help-seeking patients in some of the large mental health services throughout the 
country. A positive score on the screening is followed by clinical interview to determine 
presence of CHR-P state or psychosis.
Clinical implications and directions for future research 
Early intervention can be enhanced by gaining more insight in mechanisms and factors 
that determine increasing levels of subclinical psychotic symptoms and the eventu-
al development of psychosis. Several studies of CHR-P patients have found low social 
functioning to be predictive for the development of psychosis. The study presented in 
chapter 2 further highlights the importance of targeting low social functioning in early 
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interventions as it showed that individuals who developed future psychotic symptoms 
were already characterised by deterioration in social functioning. Social skills training 
and family involvement to create a supportive environment can help to improve social 
functioning109 which in turn might prevent further development of psychotic symptoms. 
Chapter 2 furthermore showed that individuals with baseline FP SRPE who subsequent-
ly developed psychotic symptoms were characterised by the personality trait of high 
neuroticism, which is a tendency to show emotional instability, and react with increased 
anxiety, fear, and sadness110. In addition, high neuroticism was the strongest predictor 
for the continued self-report of psychotic experiences. Given that psychotic patients 
with high neuroticism tend to have more severe and distressing positive symptoms111 
and both psychotic and CHR-P patients often use ineffective coping styles under stress110, 
111 that can even enhance symptoms112, and use of adequate strategies has been found 
to improve psychotic symptoms113, interventions that help CHR patients to develop and 
apply adequate coping strategies are likely to be effective.
Increased emotional stress reactivity in daily life can be regarded as an expression of the 
high neuroticism trait and chapter 4 provided evidence that increased emotional stress 
reactivity in daily life not only characterizes psychotic disorder patients but is present in 
CHR-P patients. This effect was even stronger than in long-term psychotic disorder pa-
tients. In line with psychological models on psychosis development92, 94 and based on all 
findings we can conclude that increased emotional stress reactivity plays an important 
role in the development and maintenance of psychotic symptoms, particularly in the 
at-risk phase. Whether increased emotional stress reactivity is truly a causal mechanism 
underlying the affective pathway to psychosis remains to be examined. Future studies 
are needed to investigate whether CHR-P patients that convert are characterised by 
higher emotional stress reactivity than those who do not.
Finally, the ESM studies in chapter 4 and chapter 5 both provided evidence that (sub-
clinical) psychotic symptoms are distressing. Detailed analysis of the temporal dynamics 
of suspiciousness and hallucinations showed that both are associated with increases in 
anxiety, negative affect and a decrease in positive affect and self-esteem.  In the Dutch 
EDIE-NL early intervention protocol, CHR-P patients receive Cognitive Behavioural Ther-
apy (CBT) that focusses on broad psychoeducation on dopamine sensitization and the 
effects on perception and reasoning, exercises to become aware of cognitive biases and 
to correct these, behavioural experiments and homework task in addition to care as 
usual for other mental health problems. CBT targets appraisal processes that accompany 
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perceptual aberrations and suspiciousness to normalize these extraordinary experienc-
es in order to prevent delusion formation and avoidance behaviours that consolidate 
symptoms.
In contrast to this traditional CBT protocol in which treatment focusses directly on the 
presence and content of (subclinical) psychotic symptoms, the newest generation of 
contextual CBTs puts high emphasis on the context and includes Acceptance and Com-
mitment Therapy (ACT). ACT may be an effective treatment strategy as it encourages 
detached acceptance of unpleasant thoughts and experiences. Although more research 
is needed, results of pilot studies of ACT in psychotic disorder patients showed positive 
effects114-116. Furthermore, a recent feasibility study in a sample of general outpatient 
population showed that ACT in daily life was an acceptable and feasible mHealth inter-
vention, suitable for a broad range of mental health problems117. Currently, the effec-
tiveness of a newly developed ecological momentary intervention that targets elevated 
stress sensitivity, altered reward-experience, and psychological flexibility based on prin-
ciples of ACT in CHR-P patients is being evaluated. This ongoing ACT in daily life study 
extends standard ACT therapy with real life training and exercises through a dedicated 
device, thereby enhancing participants’ ACT-based skills and techniques. If found to be 
effective, ACT can serve as a valuable alternative for patients who benefit less from CBT.
Finally, as discussed previously, ESM can now be used as a diagnostic tool to examine 
the dynamics of psychotic symptoms, mood, self-esteem and social factors for each indi-
vidual patient. ESM can also be applied to monitor treatment progress, by investigating 
the effect on symptoms as well as mood, social functioning and quality of life. However, 
the studies in chapter 4 and chapter 5 used items to examine psychotic symptoms that 
were previously developed for psychotic disorder patients. Especially the item inves-
tigating auditory hallucinations needs refinement for the CHR-P population, as these 
are mostly characterised by subtle auditory alterations. The current item ‘I hear voices’ 
might have resulted in CHR-P patient not reporting other, more subtle forms of auditory 
disturbances, which implies that current results might reflect a underestimation of the 
prevalence of these experiences in individuals with subclinical symptoms. Refined items 
need to be developed and validated in both individuals with subclinical symptoms and 
psychotic disorder patients in order to improve not only ESM in psychosis research and 
clinical practice.
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SUMMARY
Better knowledge of the risk factors for and mechanisms and processes underlying the 
developmental pathway(s) from psychotic experiences to psychotic disorders is crucial 
for the development of more effective early treatment options. The current thesis titled 
‘Dissecting the psychosis continuum risk factors along the pathway from experiences to 
disorder’ examines potential mechanisms and risk factors for psychosis in the lower end 
of the psychosis continuum. The first part of this thesis focussed on psychotic experienc-
es (self)reported by in individuals from the general population, and by family members 
of psychotic patients who represent a group of individuals at elevated genetic high risk 
for psychosis (chapter 2 and 3). The second part of this thesis focussed on the examina-
tion of affective and psychotic symptomatology in the daily lives of individuals at clinical 
high risk for psychosis and first episode psychotic patients (chapters 4 and 5). 
Chapter 1 provides an overview on the epidemiology, aetiology and genetics of psychot-
ic disorders and the clinical high risk state. The proposed ‘affective pathway to psycho-
sis’ and findings of previous research with the Experience Sampling Method (ESM) are 
introduced. 
In chapter 2, two different, often used measures of psychotic experiences were admin-
istered in a large longitudinal general population study (NEMESIS-II): a self-report mea-
sure and a more extensive clinical interview. For those individuals who had self-reported 
psychotic experiences that were subsequently assessed as “false-positive” after clinical 
interview (FP SRPE) at baseline the course and outcome 3-year follow-up was examined. 
We prospectively examined (1) the prevalence of remission and persistence of FP SRPE 
and transition to validated PE; (2) potential baseline psychopathological and psychoso-
cial predictors of persistence of FP SRPE and transition to validated PE, and (3) whether 
those individuals with persistent FP SRPE and validated PE at follow-up were already 
differed on psychopathology and psychosocial factors at baseline compared to individ-
uals who did not report new SRPE during the follow-up period. Results indicated that 
those individuals with baseline FP SRPE were significantly more likely to report SRPE and 
validated PE at follow-up. Baseline FP SRPE also predicted presence of mood and anxiety 
disorders, reduced functioning and help-seeking at follow-up. Several baseline psycho-
pathological, psychosocial and PE characteristics were predictive for the persistence of 
SRPE. These baseline factors also differentiated groups with FP SRPE or validated PE from 
those with remitted FP SRPE at follow-up. 
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In chapter 3, the association between self-report and interview based assessments of 
psychotic symptoms and the Polygenic Risk Score (PRS) as an index for genetic risk for 
psychosis was examined in non-psychotic sibling and parent of patients with a psychotic 
disorder, a group with elevated genetic risk for psychosis and (non-psychotic) controls 
who are at an average genetic risk for psychosis. This study uncovered that PRS as an 
index for genetic risk for psychosis was associated with positive psychotic symptoms 
obtained via clinical interview but not with the self-report measure. These results thus 
suggest that studies of gene-environment relationships in psychosis are more likely to 
be informative when objective interview measures of subclinical psychotic symptoms 
are used. PRS was also associated with presence of affective episodes (depression and/
or mania), suggesting that the association between genetic risk and psychosis proneness 
is not only mediated by positive symptomatology, but also by measures of affective dys-
regulation.
In the study presented in Chapter 4 affective and psychotic stress reactivity for small 
daily life stressors were examined in individuals at clinical high risk (CHR-P), chronic psy-
chotic patients and healthy controls. Previous research has shown that psychotic disor-
der patients and their first-degree relatives are characterised by increased affective and 
psychotic stress reactivity. Early stress sensitisation might be an underlying mechanism 
in CHR-P patients for the transition from subclinical psychotic symptoms to full-blown 
psychosis. In chapter 4, the association between small daily life stressors and negative 
affect (NA) and psychotic experiences measured with the Experience Sampling Method 
(ESM) was studied. Additionally, we assessed if psychotic experiences were experienced 
as stressful by examining the association between psychotic experiences and NA. We 
found that stress sensitization seems to play a role particularly in the early phase of psy-
chosis development as results showed that CHR-P patients were more sensitive to daily 
life stressors than chronic psychotic patients. In this early phase, psychotic experiences 
also contributed to the experience of stress.
In Chapter 5, a study of the phenomenology of hallucinations and persecutory delusions 
in the realm of daily life is presented. Hallucinations and persecutory delusions are core 
features of (subclinical) psychosis, often causing considerable distress. The phenom-
enology of auditory and visual hallucinations and suspiciousness has previously been 
investigated in the realm of daily life in psychosis spectrum patients and we aimed to 
extend this investigation to patients with a first psychotic episode (FEP) and individuals 
at clinical high risk for psychosis (CHR-P), using ESM over a 6-day period. The prevalence, 
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course and the co-occurrence of hallucinations and feelings of suspiciousness in daily 
life as well as the temporal relationship of these experiences with emotions, anxiety and 
self-esteem were examined. We found that hallucinations and suspiciousness are com-
mon in CHR-P and FEP and regularly occur together, although group differences were 
apparent. Furthermore, individuals with hallucinations reported more NA, anxiety and 
delusional intensity and lower self-esteem than those without, suggesting that presence 
of hallucinations reflects a more severe illness state. Finally, the results have clinical val-
ue as they provide information about changes in mood, and self-esteem preceding and 
during suspicious and hallucinatory episodes which can serve as targets for (person-
alised) treatment.
Finally, chapter 6 summarizes the results of the research presented in this thesis. Mech-
anisms and risk factors for the developmental pathway from psychotic experiences to 
psychotic disorder are discussed and integrated. Additionally, methodological consid-
erations, implications for clinical practice and recommendations for future research are 
also provided. 
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SAMENVATTING
Het vergroten van de kennis over de risicofactoren en de onderliggende mechanismen 
betrokken bij de ontwikkeling van psychotische ervaringen tot psychotische stoornissen is 
belangrijk. Deze kennis kan gebruikt worden om interventies die gericht zijn op preventie 
van psychose te verbeteren. Dit proefschrift getiteld ‘Dissecting the psychosis continuum 
risk factors along the pathway from experiences to disorder’ onderzoekt potentiële onder-
liggende mechanismen en risicofactoren voor de ontwikkeling van psychotische stoornis-
sen aan de onderkant van het psychose continuüm. In het eerste deel van dit proefschrift 
worden psychotische ervaringen onderzocht die (zelf)gerapporteerd worden door indivi-
duen uit de algemene bevolking. Ook worden psychotische ervaringen van familieleden 
van patiënten met een psychotische stoornis onderzocht, een groep mensen met een ver-
hoogd genetische risico op het ontwikkelen van een psychotische stoornis (hoofdstuk 2 en 
hoofdstuk 3). Het tweede deel van dit proefschrift omvat onderzoeken naar veranderingen 
in stemming en psychotische ervaringen in het dagelijks leven van individuen met ver-
hoogd risico op psychose (clinical high risk, CHR) en patiënten die hun eerste psychotische 
episode doormaken (hoofdstuk 4 en hoofdstuk 5). 
Hoofdstuk 1 geeft een overzicht van de epidemiologische kenmerken, etiologie en ge-
netica van psychotische stoornissen en de CHR groep. De zogenaamde ‘affectieve weg 
naar psychose’ en eerdere resultaten van onderzoeken met de Experience Sampling 
Methode (ESM) worden geïntroduceerd. 
In hoofdstuk 2, werden twee vaak toegepaste meetinstrumenten voor psychotische er-
varingen gebruikt in een groot longitudinaal onderzoek bij individuen van de algemene 
bevolking: een zelf-rapportage vragenlijst en een klinisch interview. De ontwikkeling en 
beloop van de psychotische ervaringen na drie jaar werd onderzocht bij de groep van 
individuen waarvan de zelf-gerapporteerde psychotische ervaringen op baseline met 
het klinisch interview als ‘vals-positief’ (FP SRPE) werden beoordeeld. We onderzocht-
en (1) de prevalentie van a) remissie en b) persistentie van FP SPRE en c) transitie naar 
gevalideerde psychotische symptomen; (2) de voorspellende waarde van psychopa-
thologische en psychosociale kenmerken gemeten op baseline voor de persistentie van 
FP SRPE en transitie naar gevalideerde psychotische symptomen; en (3) of de groep-
en (a, b en c) op baseline al verschilden van elkaar op gebied van psychopathologische 
en psychosociale factoren.  Er werd gevonden dat individuen met FP SRPE bij baseline 
een hogere kans hadden op het rapporteren van psychotische ervaringen bij follow-up 
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dan degenen die niet eerder psychotische ervaringen rapporteerden. De aanwezigheid 
van baseline FP SRPE was voorspellend voor de aanwezigheid van een stemming en/of 
angststoornis, verminderd functioneren en het zoeken van hulp voor klachten bij fol-
low-up. Het aanhouden van (zelf-gerapporteerde) psychotische ervaringen werd voor-
speld door de aanwezigheid van ander psychische problemen en het aantal en de fre-
quentie van zelf-gerapporteerde psychotische ervaringen bij baseline. De individuen met 
persistente vals-positieve psychotische ervaringen alsook individuen gevalideerde psy-
chotische symptomen verschilden op deze baseline factoren van de individuen die geen 
psychotische ervaringen meer hadden gedurende de follow-up periode (remissiegroep). 
In hoofdstuk 3 werd de associatie tussen psychotische ervaringen en de ‘Polygenic Risk 
Score’ (PRS), een index voor genetisch risico voor psychose, onderzocht. Psychotische 
ervaringen werden gemeten met een zelf-rapportage lijst en een interview. Dit werd 
gedaan in een groep van niet-psychotische eerstegraads familieleden (broers/zussen en 
ouders) van psychotische patiënten die een verhoogd genetisch risico hebben voor het 
ontwikkelen van een psychose en (niet-psychotische) controles, die een gemiddeld risico 
lopen. Deze studie toonde aan dat de PRS geassocieerd was met subklinische positi-
eve psychotische symptomen die naar voren kwamen tijdens het interview. Deze relat-
ie werd niet gevonden met zelf-gerapporteerde symptomen. De resultaten suggereren 
dat onderzoek naar gen-omgevingsrelaties bij psychose informatiever zal zijn wanneer 
een objectief interview wordt gebruikt om aanwezigheid van subklinische psychotische 
symptomen te bepalen. De PRS was ook geassocieerd met de aanwezigheid van affec-
tieve episodes (depressie en/of manie). Dit resultaat suggereert dat de associatie tus-
sen genetisch risico en psychosegevoeligheid niet alleen beïnvloed wordt door positieve 
symptomen, maar ook door de aanwezigheid van affectieve disregulatie. 
In de studie gepresenteerd in hoofdstuk 4 werd affectieve en psychotische stress reac-
tiviteit voor kleine stressoren in het dagelijks leven onderzocht in individuen met ver-
hoogd psychoserisico (CHR-P), chronische psychotische patiënten en gezonde controles. 
Eerder onderzoek toonde aan dat patiënten met een psychotische stoornis en hun 
eerstegraads familieleden gekenmerkt worden door hogere affectieve en psychotische 
stress reactiviteit ten opzichte van controles. Vroege stress sensitisatie is mogelijk een 
mechanisme betrokken bij de transitie van subklinische psychotische symptomen naar 
psychose. In hoofdstuk 4 werd de associatie tussen dagelijkse stressoren en negatief af-
fect (NA) en psychotische ervaringen onderzocht, gemeten met de Experience Sampling 
Methode (ESM). Daarnaast werd onderzocht of psychotische ervaringen als stressvol 
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ervaren werden door de associatie tussen psychotische ervaringen en NA te onderzoek-
en. Uit deze studie blijkt dat stress sensitisatie een belangrijke rol in de vroege fase van 
het psychose ontwikkelingsproces speelt. CHR-P patiënten waren gevoeliger voor dage-
lijkse stressoren dan chronisch psychotische patiënten. In deze vroege fase blijken psy-
chotische ervaringen zelf ook een bron van stress te zijn. 
In hoofdstuk 5 werd een studie van de fenomenologie van hallucinaties en achterdocht-
wanen in het dagelijks leven gepresenteerd. Deze kernsymptomen van (subklinische) 
psychose veroorzaken vaak veel leed. De fenomenologie van auditieve en visuele hallu-
cinaties en achterdocht is eerder onderzocht in het dagelijks leven in psychose spectrum 
patiënten. De huidige studie had als doel dit in kaart te brengen voor eerste psychose 
patiënten (FEP) en individuen met verhoogd risico op psychose (CHR-P) met behulp van 
ESM gedurende een zesdaagse periode. De prevalentie, het verloop en het tegelijk op-
treden van hallucinaties en gevoelens van achterdocht, maar ook de temporele relat-
ies van deze ervaringen met emoties, angst en zelfvertrouwen werden onderzocht. Er 
werd gevonden dat hallucinaties en achterdocht vaak en geregeld samen voorkomen bij 
CHR-P en FEP patiënten, hoewel er ook groepsverschillen gevonden werden. Daarnaast 
rapporteerden individuen met hallucinaties meer NA, angst en hogere intensiteit van 
waanideeën en minder zelfvertrouwen dan individuen die geen hallucinaties ervaarden. 
Dit suggereert dat de aanwezigheid van hallucinaties een ernstiger ziekteproces reflect-
eert. De resultaten brengen veranderingen in stemming en zelfvertrouwen voorafgaand 
en tijdens episodes met achterdocht en hallucinaties in beeld. Deze informatie kan geb-
ruikt worden om (gepersonaliseerde) zorg te optimaliseren. 
Tot slot wordt in hoofdstuk 6 een samenvatting gegeven van de resultaten van het 
onderzoek gepresenteerd in dit proefschrift. Mechanismen en risico factoren onderlig-
gend aan de ontwikkeling van psychotische ervaringen tot psychotische stoornis worden 
besproken. Daarnaast worden methodologische aandachtspunten, implicaties voor de 
klinische praktijk en aanbevelingen voor toekomstig onderzoek beschreven.
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VALORISATION
Societal relevance
Psychotic disorders are associated with high burden for patients themselves as well as 
for their family members and friends, although prevalence is relatively low (0.5-1% for 
schizophrenia, 2.5-3.5% for psychotic disorders1). This is directly due to significant im-
pairments in academic performance and occupational functioning, difficulties with inter-
personal relationships and experiences of stigmatisation and discrimination, all resulting 
in substantially reduction in quality of life. Additionally, expenses for mental disorders 
and psychotic disorders in particular are among the highest of all healthcare expenses in 
the Netherlands2. The total costs for mental disorders including psychotic disorders are 
the combination of direct healthcare costs, non-medical costs including extra resources 
for social service and education, and indirect costs due to work absence or early retire-
ment. These indirect costs may emerge from impairments, disability, premature death, 
and legal problems due to loss of productivity3, and form the largest proportion of all 
costs for psychotic patients4. Overall, it can be concluded that psychotic disorders are a 
substantial burden for the affected individual, his/her social circle, those involved in the 
life and treatment of these patients and for society as a whole. Therefore, early diagno-
sis, intervention and preferably prevention are needed. A better understanding of the 
phenomenology, underlying mechanisms and psychological processes involved in the 
transition of subclinical symptoms towards disorder will help to reach that goal. 
In order to elucidate the complex and multi-factorial aetiology of psychotic disorders 
and to improve prevention and intervention strategies focus of research has shifted from 
the population of psychotic disorder patients, especially schizophrenic patients, to first 
episode psychosis patients and at the lower end of the psychosis continuum to individu-
als with subclinical psychotic symptoms at clinical high risk for psychosis (CHR-P) as well 
as (non-help seeking) individuals in the general population with psychotic-like experi-
ences. The current thesis investigated potential mechanisms and risk factors involved 
in the development from incidental psychotic-like experiences and subclinical psychotic 
symptoms to a first psychotic episode. The epidemiology and phenomenology of these 
experiences and associated factors was examined in both in longitudinal studies and 
Experiences Sampling Method (ESM) studies in daily life. 
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Target audience
The findings of this thesis are relevant for individuals with subclinical psychotic symp-
toms, psychotic patients, health care professionals and policy makers.
The results of chapter 2 and chapter 3 provide important information for both health 
care professionals as well as policy makers. Self-report measures for psychotic experi-
ences are effective as screening instruments for the presence of potential (subclinical) 
psychotic symptoms, which should then be examined in detail by clinical interview. The 
use of a semi-structured psychosis risk assessment interview like the CAARMS or the 
SIPS is advised as it allows validation of an experience as a true subclinical symptom 
while also obtaining detailed information about the frequency of a symptoms and deter-
mination of CHR-P or psychosis status. Importantly,  it has been suggested that clinical 
early detection teams may need to further extend their services into the community so 
that these individuals have better access to specialized mental health care5. However, in 
chapter 2 it was found that (false-positive) self-reported psychotic experiences by indi-
viduals from the general population were mostly transitory in nature and only a small 
subsample of individuals developed true psychotic symptoms. This finding supports the 
recommendation that screening with self-report measures and subsequent assessment 
of CHR-P state should be primarily offered to selected samples of subjects who are al-
ready distressed by mental problems and seeking help for them6. Use for prevention 
in non-help-seeking subjects in the general population should be discouraged7, as this 
strategy is not cost-effective due to false-positive rates. 
The results of chapter 2 highlight the importance of targeting low social functioning in 
early interventions as individuals who developed future psychotic symptoms were al-
ready characterised by deterioration in social functioning. Social skills training and family 
involvement to create a supportive environment can help to improve social functioning8 
which in turn might prevent further development of psychotic symptoms. 
Chapter 2 furthermore showed high neuroticism (i.e. a tendency to show emotional 
instability, and react with increased anxiety, fear, and sadness9) is an important predictor 
of persistence and further development of psychotic symptoms. The results of chapter 
4 further highlight the close relationship between stress, symptoms and low mood. In-
creased emotional reactivity for small daily life stressors in individuals at clinical high 
risk for psychosis may be an important underlying mechanism in the process towards 
transition to psychotic disorder. Furthermore, (subclinical) psychotic symptoms can be 
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regarded as an additional source of distress. So both CHR-P and first episode psychosis 
patients are thus likely to benefit from psychoeducation and non-specific early interven-
tions aimed at stress-reduction and enhancement of effective coping skills.
Results of chapter 5 stress the need for thorough investigation of the exact nature of 
subclinical psychotic symptoms. Results tentatively suggest that severity of symptoms 
and risk for transition are likely to be higher for individuals reporting both feelings of 
suspiciousness as well as hallucinations, although this should be examined more careful-
ly in a longitudinal study. Health care professionals need to be aware of the central role 
of emotion-related processes, anxiety and self-esteem for the occurrence of hallucina-
tions and suspiciousness in daily life. Use of ESM can help bridge the gap between the 
professional’s office and the patient’s daily life. It can help to unravel symptomatic and 
behavioural patterns as it supplies both the individual patient and clinician with large 
amount of detailed, reliable and ecologically valid information about symptoms and 
their relationships with mood, anxiety, self-esteem all in the social context of daily life. 
Innovation and implementation
Recently, studies have started to investigate the application of ESM interventions. Cur-
rently, the effectiveness of a newly developed ecological momentary intervention that 
targets elevated stress sensitivity, altered reward-experience, and psychological flexibili-
ty based on principles of Acceptance and Commitment Therapy (ACT) in CHR-P and first 
episode psychosis patients is being evaluated in the INTERACT study. The effectiveness 
of ACT is compared with a treatment as usual control group, of which some receive par-
ticipants receive CBT specifically developed to treat (subclinical) psychotic symptoms. 
This ongoing ACT in daily life study extends standard ACT therapy with real life training 
and exercises through a dedicated device, thereby enhancing participants’ ACT-based 
skills and techniques. Furthermore, a new study will use ESM as a monitoring and de-
tection tool for changes in affective and psychotic symptomatology that could serve as 
warning signs for relapse in psychotic patients who are in symptomatic remission and 
want to gradually reduce and stop their anti-psychotic medication use. 
The use of ESM in clinical practice and psychosis care specifically is still limited, but has 
great potential to improve personalized treatment as ESM is now available via mobile 
phone applications. Recent development and availability of web-based feedback sys-
tems offers patients and health care professionals access to real-life data on emotional 
en symptomatic dynamics. ESM can help to refine the diagnostic process and monitor af-
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fective and psychotic symptomatology in daily life. As mood and symptoms are assessed 
‘in the moment’ and in the context of daily life, they are not influenced by memory bias-
es hampering traditional retrospective clinical interviews and questionnaires assessing 
longer time periods. ESM allows patients to accurately report changes in their emotions 
and behavioural pattern and reveals which emotional and/or behavioural patterns are 
in need of change. The implementation of ESM in clinical practice does require that pro-
fessionals are trained in how gain access to, and then interpret and use ESM data in a 
therapeutic fashion. 
As part of my activities as a psychologist at the mental healthcare institute GGzE Eind-
hoven, division Early Psychosis, I am involved in the implementation of ESM as a diag-
nostic and monitoring tool as part of regular care for first episode psychosis patients. In 
this fashion I can implement the knowledge of ESM that I gained during my PhD track in 
clinical practice. Furthermore, I am able to contribute to both of the above mentioned 
ESM studies as a research practitioner. 
Knowledge dissemination
The present research was and will be published in peer-reviewed journals and present-
ed at national and international research conferences. In this way, research results and 
methodological developments can be discussed with other scientists, what in turn stim-
ulates development and refinement of knowledge and theories about the development 
of psychotic disorders. Furthermore, the results were and will be made public at more 
clinically oriented conferences to inform health care professionals and policy makers. By 
involving health care professionals in research projects, especially those focussed on the 
development and refinement of treatment options, valuable information can be gained 
on flaws of current options and feasibility of proposed solutions. By working together, 
scientists and health care professionals can greatly impact on the lives of patients and 
their families and society as a whole by developing and implementing more efficient 
treatment options. Finally, results were and will be made public conferences and sympo-
sia, magazines and websites managed by patient organisations that are easily accessible 
to the general population including patients and their families. It is the responsibility 
of the scientific community to actively involve patients and their families in scientific 
research. They can provide valuable insights on challenges they are facing, provide feed-
back on interventions and when relevant, on the usability of (proposed) technological 
tools. Adequate dissemination of knowledge will help to reduce stigmatisation in profes-
sionals, patients and the general population. 
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DANKWOORD
De laatste punt is gezet, met dit boekje sluit ik mijn promotietraject af. Hoewel mijn 
naam op de cover staat heb ik dit traject niet alleen afgelegd en in dit hoofdstuk wil ik 
graag iedereen bedanken die in welk opzicht dan ook een bijdrage heeft geleverd aan de 
totstandkoming van dit proefschrift. 
Allereerst wil ik alle deelnemers bedanken die hebben deelgenomen aan de ‘iThink’ 
studie en de andere studies beschreven in dit proefschrift. Dank jullie voor het delen 
van jullie verhalen en ervaringen en het mogen meekijken in jullie dagelijkse leven. De 
bijdrage die jullie geleverd om de kennis over psychiatrische aandoeningen en psychose 
in het bijzonder te vergroten is onmisbaar.
Dan wil ik mijn promotieteam bedanken: Inez, dank je wel dat je me hebt meegenomen 
in de interessante en bijzondere wereld van (ESM) psychose onderzoek. Ik heb veel van 
je geleerd en wil je bedanken voor de ondersteuning die geleid heeft tot mooie ervar-
ingen en artikelen alsook tijdens de uitdagende perioden binnen dit traject. Ruud, be-
dankt voor je begeleiding bij het schrijven van de artikelen, ik kon zelfs bij je thuis terecht 
voor afspraken toen de blessure aan jouw enkel je belemmerde om naar het werk af te 
reizen! Ook heb ik veel geleerd van jouw dubbele rol als onderzoeker en clinicus. Tineke, 
dank je wel voor een heel fijn eerste jaar als PhD student! Bedankt voor de structuur en 
regelmaat die je bood die zo ontzettend belangrijk zijn om orde te scheppen in dit chao-
tische bestaan. Bij jou was er altijd ruimte voor een lach en een traan. 
Ik wil graag mijn iThink teamleden bedanken: Feikje, Debora, Ilse, Nele S en Patrick. 
Zonder jullie was het gelukt!
Lieve mede (ex)promovendi op Vijverdal: Annelie, Hennie, Thomas, Iris, Jindra, Esther, 
Eshan, Silvia, Ozan, Sophie, Stijn, Christian, Zuzana, Martine, Tim, Mayke, Suzanne, 
Dennis en Nicole. Ik wil jullie allemaal bedanken voor jullie gezelligheid tijdens en na 
werktijd bij lunches, pizza avonden met natuurlijk een potje weerwolven, borrels, bbq’s, 
etentjes en feestjes, alsook voor het delen van alle tips, tricks en kennis over allerlei 
zaken in de onderzoekswereld. 
Annelie, mijn kamergenootje! Ontelbare uren hebben we samen doorgebracht op ons 
kantoor, waarvan we ook regelmatig de opstelling van bureaus veranderden in de hoop 
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dat dat de productiviteit zou kunnen beïnvloeden ;) Naast het kunnen bespreken van alle 
ups en downs die bij het leven als promovendus horen hebben samen ook veel gezel-
ligheid en levenservaringen gedeeld. Ik mis jouw gezelschap op kantoor nu al. Het is dat 
het wondertje dat op dit moment nog in je buik verblijft ten tijde van mijn verdediging 
al je tijd en aandacht zal opeisen, maar ik hoop dat je in gedachte die dag achter me zal 
staan!
Rosalie, ESM buddy van divisie 1, wat ontzettend leuk dat ik jou heb leren kennen!
Heel erg bedankt mijn lieve paranimfen, Sanne en Tirza. Sanne, ik ben ontzettend blij 
dat we collega’s waren en vriendinnen zijn! Ondanks dat we in verschillende fases van 
ons promotietraject zaten en totaal verschillende onderwerpen hadden klikte het vanaf 
het eerste moment. Ik kan met jou over alles praten en we hebben samen frustraties 
gedeeld en gehuild maar vooral gelachen en plezier gemaakt. Tirza, als ervaringsdeskun-
dige partner van een gepromoveerde arts weet jij als geen ander hoeveel tijd en energie 
er gaat zitten in een promotietraject. Dank je wel dat je er altijd bent om te luisteren en 
meedenken. Als werkende moeder van 3 kinderen weet je als geen ander hoe belangrijk 
het is om de basis thuis in orde te hebben en je bent daarin een voorbeeld waar ik veel 
van geleerd heb. Fijn dat je ook straks tijdens de verdediging weer achter me staat. 
Truda, Wendy en Debora, jullie waren mijn rotsen in de branding! Van onderzoeks-
perikelen tot persoonlijke fijne momenten en struggles , ik vond bij jullie voor van alles 
een luisterend oor en bruikbaar advies. 
Ik wil ook iedereen bedanken die betrokken was bij het INTERACT project en in het bi-
jzonder Silke, Uli, Nele V, Davinia, Evelyne en Lore. Tim, supertof dat ik bij jou de ACT 
cursus en heb kunnen volgen, ik maak er nu gebruik van!
Daarnaast wil ik mijn lieve collega’s Karlijn, Aki, Rob, Aleks, Hugo, Maude, Robin, Mar-
tien en Hugo van het CCP in Leuven bedanken. Jullie maakten het altijd gezellig ook al 
was ik niet zo vaak aanwezig of St. Raf.
Ron bedankt voor alle technische ondersteuning op gebied van laptops, programma’s 
en Psymates! Daphne, dank voor alle uren die je hebt besteed aan het invoeren van alle 
verzamelde data. Trees, Ine en Jolanda, bedankt voor jullie werk op de achtergrond! 
Verder wil ik ook alle andere collega’s van Vijverdal bedanken!
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Ook wil ik graag alle leden van de beoordelingscommissie bedanken voor het beoor-
delen van mijn manuscript, en de coauteurs voor de prettige samenwerking en bijdrage 
aan de artikelen. 
Suzanne, Carolien en Koos, Joost en Carlijn: bedankt voor jullie interesse en steun vanaf 
de zijlijn tijdens de oh zo belangrijke momenten van ontspanning buiten het werk. 
Johan, bedankt voor alle hulp bij het ontwerpen van de kaft, misschien wel het belangri-
jkste onderdeel van dit proefschrift ;)
EDI & ACT teamleden van GGzE en in het bijzonder Elise, Jeu en Machteld: Ik ben heel 
blij dat ik ruim 3 jaar met jullie heb samen kunnen werken in het vroegdetectie team 
alsook jullie hulp bij het werven van deelnemers voor mijn onderzoek. Door jullie en 
de overige teamleden heb ik daarnaast ook veel geleerd over de psychosezorg. Ik ben 
erg blij dat we de samenwerking na mijn promotie hebben voortgezet als collega’s zijn 
binnen de vroege psychosezorg bij GGzE! 
Pap en mam, jullie steun is altijd onvoorwaardelijk en onmisbaar geweest tijdens dit 
promotietraject. Van opbeurende woorden in moeilijke tijden tot oppasbeurten sinds de 
komst van Iris. Zonder jullie had ik het niet kunnen redden. 
Harry en Renée, ook jullie stonden altijd klaar met een luisterend oor, advies of gewillige 
slachtoffers voor een oppasbeurt wanneer ik mijn vrije dag toch moest besteden aan het 
afronden van dit proefschrift. 
Nadine en Matthijn, Roel en Tirza, Guido en Nadine, Patrick en Pascalle, Selma en nat-
uurlijk Dominic, jullie toonden altijd interesse in mijn onderzoek ondanks dat het voor 
jullie misschien niet altijd helemaal duidelijk was wat het precies inhield. 
Lieve Mark, echtgenoot en mijn grootste steun. Bedankt dat je er altijd voor me bent en 
in mij gelooft! Het zijn drukke en roerige jaren geweest met moeilijkere periodes maar 
vooral vele hele mooie hoogtepunten! Zonder jou had ik het nooit gered. Ik hou van je!
Lieve Iris, jouw komst zette alles in perspectief. 
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CURRICULUM VITAE
Yori van der Steen werd geboren op 26 juli 1986 te Roermond. In 2004 behaalde zij haar 
VWO diploma aan het Bisschoppelijk College Schöndeln te Roermond. Hierna behaalde 
zij in 2008 haar Bachelor Cognitieve Psychologie aan de Universiteit Maastricht. In 2008 
behaalde ze tevens haar Master Rechtspsychologie aan de Universiteit Maastricht. In 
2010 vervolgde zij haar studies met de premaster en vervolgens Master Neuropsychol-
ogie aan de Universiteit Utrecht, waarvoor ze haar klinische en wetenschappelijke stage 
liep op de afdeling Psychiatrie van het Universitair Medisch Centrum Utrecht. Hier kwam 
ze voor het eerst in aanraking met patiëntenzorg en onderzoek binnen het spectrum van 
psychotisch stoornissen. In april 2012 behaalde zij hiervoor haar diploma. In juli 2013 
startte zij haar promotietraject bij de afdeling Psychiatrie en Neuropsychologie van de 
Universiteit Utrecht in het team van Prof. Myin-Germeys. In 2015 startte ze ook met 
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assessment of patients with Alzheimer’s Disease and related disorders. Supervisors: 
prof.dr. F. Verhey; prof.dr. Ph. Robert, Nice, Fr; Co-supervisors: dr. P. Aalten; dr. R. David, 
Nice. Fr.
Michelene Chenault: Assessing Readiness for Hearing Rehabilitation. Supervisors: prof.
dr. M.P.F. Berger; prof.dr. B. Kremer; Co-supervisor: dr. L.J.C. Anteunis.
Anand Vinekar: Retinopathy of Prematurity. Recent advances in tele-medicine screen-
ing, risk factors and spectral domain optical coherence tomography imaging.  Supervi-
sor: prof.dr. C.A.B. Webers; Co-supervisor: dr. N.J. Bauer
Fleur van Dooren: Diabetes and Depression: exploring the Interface between Patho-
physiological and Psychological factors. Supervisors: prof.dr. F.R.J. Verhey; prof.dr. J.K.L. 
Denollet, UvT; prof.dr. F. Pouwer, UvT; Co-supervisor: dr. M.T. Schram.
Gabriëlla Pons van Dijk: Taekwondo and physical fitness components in middle-aged 
healthy volunteers; the Sekwondo study. Supervisors: prof.dr. J. Lodder; prof.dr. H. King-
ma; Co-supervisor: dr. A.F. Lenssen.
Yara Pujol López: Development and psychoneuroimmunological mechanisms in de-
pression. Supervisor: prof.dr. H.W.M. Steinbusch; Co-supervisors: Dr. G. Kenis; Dr. D. van 
den Hove; Dr. Aye Mu Myint, München.
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Romina Gentier: UBB+1; an important switch in the onset of Alzheimer’s disease. Super-
visors: Prof. H. Steinbusch; Prof. D. Hopkins; Co-supervisor: Dr. F. van Leeuwen.
Sanne Smeets: Insights into insight: studies on awareness of deficits after acquired brain 
injury. Supervisor: Prof. C. van Heugten; Prof. R. Ponds; Co-supervisor: Dr. I. Winkens
Kim Beerhorst: Bone disease in chronic epilepsy: fit for a fracture. Supervisor: Prof. A. 
Aldenkamp; Prof. R. van Oostenbrugge; Co-supervisor: Dr. P. Verschuure.
Alex Zwanenburg: Cerebral and cardiac signal monitoring in fetal sheep with hypox-
ic-ischemic encephalopathy. Supervisor: Prof. T. Delhaas; Prof. B. Kramer; Co-supervi-
sors: Dr. T. Wolfs; Dr. P. Andriessen, MMC.
Ismail Sinan Guloksuz: Biological mechanisms of environmental stressors in psychiatry. 
Supervisor: Prof. J. van Os; Co-supervisors: Dr. B. Rutten; Dr. M. Drukker.
Seyed Ehsan Pishva MD: Environmental Epigenetics in mental health and illness. Super-
visor: Prof.dr. J. van Os; Co-supervisors: Dr. B.P.F. Rutten; Dr. G. Kenis.
Ankie Hamaekers: Rescue ventilation using expiratory ventilation assistance; innovat-
ing while clutching at straws. Supervisors: Prof.dr. W.F. Buhre; Prof.dr. M. van Kleef.
Rens Evers. 22q11.2 deletion syndrome: intelligence, psychopathology and neuro-
chemistry at adult age. Supervisors: Prof.dr. L.M.G. Curfs; Prof.dr. T. v. Amelsvoort.
Sarah-Anna Hescham. Novel insights towards memory restoration. Supervisor: Prof.dr. 
Y. Temel; Co-supervisor: Dr. A. Blokland; Dr. A. Jahanshahi.
João P. da Costa Alvares Viegas Nunes. Insulin receptor sensitization improves affective 
pathology in various mouse models. Supervisor: Prof.dr. H.W.M. Steinbusch; Co-super-
visors: Dr. K-P. Lesch; Dr. T. Strekalova; Dr.B.H. Cline, Oxford.
Yanny Ying-Yee Cheng. Clinical Outcomes After Innovative Lamellar Corneal Transplan-
tation Surgery. Supervisor: Prof.dr. R.M.M.A. Nuijts; Co-supervisor: Dr. J.S.A.G. Schouten.
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Oliver Gerlach. Parkinson’s disease, deterioration during hospitalization. Supervisor: 
Prof.dr. R. van Oostenbrugge; Co-supervisor: Dr. W. Weber.
Remo Arts. Intracochlear electrical stimulation to suppress tinnitus. Supervisor: Prof.dr. 
R.J. Stokroos; Co-supervisor: Dr. E.L.J. Georg. 
Mitchel van Eeden. The €- Restore4stroke study: Economic evaluation of stroke care in 
the Netherlands. Supervisors: Prof.dr.mr. S.M.A.A. Evers; Prof.dr. C.M. v. Heugten; Co-su-
pervisor: dr. G.A.P. van Mastrigt. 
Pim Klarenbeek. Blood pressure and cerebral small vessel disease. Supervisor: Prof.dr. 
R.J. van Oostenbrugge; Co-supervisor: Dr. J. Staals. 
Ramona Hohnen. Peripheral pharmacological targets to modify bladder contractility. 
Supervisor: Prof.dr. Ph.E.V. van Kerrebroeck; Co-supervisors: Dr. G.A. van Koeveringe; Dr. 
M.A. Sahnama’i; Dr. C. Meriaux. 
Ersoy Kocabicak. Deep brain stimulation of the subthalamic nucleus: Clinical and sci-
entific aspects. Supervisors: Prof.dr. Y. Temel; Prof.dr. K. van Overbeeke; Co-supervisor: 
Dr. A. Jahanshahi.
Sven Akkerman. Temporal aspects of cyclic messenger signaling in object recognition 
memory; a pharmalogical approach. Supervisor: Prof.dr. H.W.M. Steinbusch; Co-super-
visors: dr. J. Prickaerts; dr. A. Blokland.
Anja Moonen. Emotion and Cognition in Parkinson’s disease; etiology and neurobiolog-
ical mechanisms. Supervisor: Prof.dr. F.R.J. Verhey; Co-supervisor: dr. A.F.G. Leentjens. 
Anna Schüth. Three-dimensional bladder tissue morphology. Supervisors: Prof.dr. G.A. 
van Koeveringe; Prof.dr. M. v. Zandvoort, Aachen; Prof.dr. Ph. V. Kerrebroeck.
Elisabeth van der Ven. Ethnic minority position as risk indicator for autism-Spectrum 
and psychotic disorders. Supervisors: Prof.dr. J.P. Selten; Prof.dr. J. van Os.
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Zuzana Kasanova. Environmental reactivity for better or worse; The impact of stress 
and reward on neurochemistry, affect and behavior across the psychosis continuum. 
Supervisor: Prof.dr. I. Myin-Germeys, KU Leuven/UM; Co-supervisor: dr. D. Collip.
Danielle Lambrechts. Ketogenic diet therapies; treatment for children and adults with 
refractory epilepsy. Supervisors: Prof.dr. H.J.M. Majoie; Prof.dr. J.S.H. Vles; Prof.dr. A.P. 
Aldenkamp; Co-supervisor: dr. A.J.A. de Louw, Kempenhaghe, Heeze.
Frank van Bussel. Advanced MRI in diabetes; cerebral biomarkers of cognitive decre-
ments. Supervisors: Prof.dr.ir. W.H. Backes; Prof.dr. P.A.M. Hofman; Co-supervisor: dr. 
J.F.A. Jansen.
Lisa Schönfeldt. Neurostimulation to treat brain injury? Supervisors: Prof.dr. Y. Temel; 
Prof.dr. S. Hendrikx, Hasselt; Co-supervisor: dr. A. Jahanshahi.
Rianne Geerlings. Transition in patients with childhood-onset epilepsy; a long way to 
adulthood. Supervisor: Prof.dr. A.P. Aldenkamp; Co-supervisors:dr. A.J.A. de Louw, dr. 
L.M.C. Gottmer, Kempenhaeghe.
Nele Claes. B cells as multifactorial players in multiple sclerosis pathogenesis: insights 
from therapeutics. Supervisors: Prof.dr. V. Somers, Hasselt; Prof.dr. R. Hupperts Co-su-
pervisors: Prof.dr. P. Stinissen, dr. J. Fraussen, Hasselt.
Olaf Schijns. Epilepsy surgery and biomarkers from history to molecular imaging. Su-
pervisors: Prof.dr. J.J. van Overbeeke; Prof.dr. H. Clustermann, Aachen; Co-supervisors: 
dr. G. Hoogland; dr. M.J.P. v. Kroonenburgh.
Lizzy Boots. Balanced and Prepared; development and evaluation of a supportive 
e-health intervention for caregivers of people with early-stage dementia. Supervisors: 
Prof.dr. F.R.J. Verhey; Prof.dr. G.I.J.M. Kempen; Co-supervisor: dr. M.E. de Vugt.
Wouter Donders. Towards patient-specific (cerebro-) vascular model applications. Su-
pervisors: Prof.dr. T. Delhaas; Prof.dr.ir. F.N. van de Vosse, TUE; Co-supervisor: dr.ir. W. 
Huberts.
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Sizzle Vanterpool. The implications of intrauterine invasion by microbes for placental 
Pathology and the occurrence of adverse pregnancy outcomes. Supervisor: Prof.dr. 
B.W. Kramer. Co-supervisors:  dr. J.V. Been, Erasmus MC Rotterdam, dr. U von Rango.
Manuela Heins. The Relationship between Social Adversity, Psychosis, and Depression 
across an Individual’s Life Span. Supervisor: Prof.dr. I. Myin-Germeys.
Christianus van Ganzewinkel. NEONATAL PAIN; Out of Sight, Out of Mind? Supervisor: 
Prof.dr. B.W.W. Kramer; Co-supervisor: dr. P. Andriessen, MMC Veldhoven.
Anne-Hilde Muris. Hype or hope? Vitamin D in multiple sclerosis; A clinical and immu-
nological perspective. Supervisor: Prof.dr. R.M.M. Hupperts; Co-supervisor: dr. J.G.M.C. 
Damoiseaux.
Gerard Bode. The link between ceramide transporters, innate Immunity and Alzhei-
mer’s disease. Supervisor: Prof.dr. M.H.V. de Baets; Co-supervisors: dr. P. Martinez, dr. 
M. Losen. 
Jo Stevens. Advanced diagnostics and therapeutics for Alzheimer’s disease. Supervisor: 
Prof.dr. M. de Baets; Co-supervisors: dr. M. Losen, dr. P. Martinez-Martinez.
Rosan Luijcks. Stress and pain in muscles and brain; developing psychophysiological 
paradigms to examine stress and pain interactions. Supervisors: Prof.dr. J.J. van Os; 
Prof.dr.ir. H.J. Hermens, UT; Co-supervisor: dr. R. Lousberg.
M.C. Haanschoten. Towards efficient cardiac surgery – the integrating role of anes-
thesiology and intensive care. Supervisors: Prof. dr. W. Buhre; Prof. dr. A. van Zundert 
(Queensland); Co-supervisors: Dr. M.A. Soliman Hamad; Dr. A. van Straten (Catharina 
zkhs.)
Harmen Jan van de Haar. Microvascular and blood-brain barrier dysfunction in Alzhei-
mer’s disease. Supervisor: Prof.dr.ir. W. Backes; Prof.dr. F. Verhey; Co-supervisor: Dr. J. 
Jansen; Dr.ir. M. v. Osch, LUMC.
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Coenraad Itz. Chronic low back pain, considerations about: Natural Course, Diagnosis, 
Interventional Treatment and Costs. Supervisor: Prof.dr. M. van Kleef; Prof.dr. F. Huygen, 
EUR; Co-supervisor: Dr. B. Ramaekers.
Willemijn Jansen. The Path of Alzheimer’s disease: from neuropathology to clinic. Su-
pervisor: Prof.dr. F. Verhey; Co-supervisors: Dr. P.J. Visser; Dr. I. Ramakers.
Ligia dos Santos Mendes Lemes Soares. Phosphodiesterase inhibitors: a potential ther-
apeutic approach for ischemic cerebral injury. Supervisor: Prof.dr. H.W.M. Steinbusch; 
Co-supervisors: Dr. R.M. Weffort de Oliveira, Brazil; Dr. J. Prickaerts
Martijn Broen. Anxiety and depression in Parkinson’s disease. Supervisor: Prof.dr. R.J. 
van Oostenbrugge; Co-supervisors: Dr. A.F.G. Leentjens; Dr. M.L. Kuijf.
Sandra Schipper. Extrasynaptic receptors as a treatment target in epilepsy. Supervisor: 
Prof.dr. J.H.S. Vles; Co-supervisors: Dr. G. Hoogland; Dr. S. Klinkenberg; Dr. M.W. Aalbers, 
RUG.
João Casaca Carreira. Making sense of Antisense Oligonucleotides Therapy in Experi-
mental Huntington’s disease. Supervisor: Prof.dr. Y. Temel; Co-supervisors: Dr. A. Jahan-
shahi; Dr. W. van Roon-Mom, LUMC.
Dominique IJff. Trick or Treat? Cognitive side-effects of antiepileptic treatment. Super-
visors: Prof.dr. A.P. Aldenkamp; Prof.dr. M. Majoie; Co-supervisors: Dr. J. Jansen; Dr. R. 
Lazeron, Kempenhaeghe.
Alfredo Ramirez. Neurogenetic approach in neurodegenerative disorders. Supervisors: 
Prof.dr. B.P.F. Rutten; Prof.dr. H.W.M. Steinbusch; Prof.dr. M.M. Nöthen, University of 
Bonn. 
Nienke Visser. Toric Intraocular lenses in cataract surgery. Supervisor: Prof.dr. R.M.M.A. 
Nuijts; Co-supervisor: Dr. N.J.C. Bauer.
Jakob Burgstaller. Prognostic indicators for patients with degenerative lumbar spinal 
stenosis. Supervisor: Prof.dr. M. van Kleef; Co-supervisors: Dr. M.M. Wertli, University of 
Zurich; Dr. H.F. Gramke.
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Mark van den Hurk. Neuronal Identity and Maturation: Insights from the Single-Cell 
Transcriptome. Supervisors: Prof.dr. H.W.M. Steinbusch; Prof.dr. B.P.F. Rutten; Co-super-
visors: Dr. G. Kenis; Dr. C. Bardy, Adelaide.
Maria Nikiforou. Prenatal stress and the fetal gut. Potential interventions to prevent 
adverse outcomes. Supervisors: Prof.dr. B.W. Kramer; Prof.dr. H.W. Steinbusch; Co-su-
pervisor: Dr. T.G. Wolfs.
Janneke Peijnenborgh. Assessment of cognition, time perception, and motivation in 
children. Supervisors: Prof.dr. J.S.H. Vles; Prof.dr. A.P. Aldenkamp; Co-supervisors: Dr. J. 
Hendriksen; Dr. P. Hurks.
Joany Millenaar. Young onset dementia; towards a better understanding of care needs 
and experiences. Supervisors: Prof.dr. F. Verhey; Prof.dr. R. Koopmans, RUN; Co-supervi-
sors: Dr. M. de Vugt; Dr. C. Bakker, RUN.
2017
Adriana Smits. Perinatal factors and hearing outcome. Supervisors: Prof.dr. R.J. Stokroos; 
Prof.dr. B.W. Kramer; Prof.dr. B. Kremer.
Angela Bouwmans. Transcranial sonography in parkinsonian disorders: clear window 
or blurred vision. Supervisor: Prof.dr. W.H. Mess; Co-promotores: Dr. W.E.J. Weber; Dr. 
A.F.G. Leentjens.
Björn K. Stessel. Patient centred care after day surgery: scope for improvement. Super-
visors: Prof.dr. W. Buhre; Prof.dr. B. Joosten. Co-supervisor: Dr. A.H. Gramke.
Jan Guy Bogaarts. Quantitative EEG and machine learning methods for the detection of 
epileptic seizures and cerebral asymmetry. Supervisor: Prof.dr. W.M. Mess; Co-supervi-
sor: Dr.ir. J.P.H. Reulen; Dr.ir. E.D. Gommer.
Martin M. Müller. Pregnancy derived products for treatment of perinatal brain injuries. 
Supervisors: Prof.dr. B.W.W. Kramer; Prof.dr. D. Surbek, Bern; Co-supervisors: Dr. T. Wolfs; 
Dr. G. Gavilanes.
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Daan Ophelders. Novel treatment strategies for the protection of the preterm brain; 
Re-balancing inflammation and regeneration. Supervisor: Prof.dr. B. Kramer; Co-super-
visor: Dr. T. Wolfs; Dr. R. Jellema.
Rosalie van Knippenberg. Experience sampling in dementia care; an innovative inter-
vention to support caregivers in daily life. Supervisors: Prof.dr. F. Verhey; Prof.dr. R. 
Ponds; Prof.dr. I. Myin-Germeys, KU Leuven; Co-supervisor: Dr. M. de Vugt.
Claudia Vingerhoets. Investigating neurobiological mechanisms underlying comor-
bid cognitive symptoms in psychosis and substance use. Supervisors: Prof.dr. T. van 
Amelsvoort; Prof.dr. J. Booij, UvA; Co-supervisor: Dr. O. Bloemen
Dennis Oerlemans. Evolution of Neuromodulation for Lower Urinary Tract Dysfunction; 
Past, Present and Future. Supervisors: Prof.dr. Ph. van Kerrebroeck; Prof.dr. G. van Koev-
eringe. Co-supervisors: Dr. E. Weil; Dr. T. Marcelissen.
Marion Levy. Evaluation of BDNF/TrkB signaling as a common target in the treatment 
of major depression and Alzheimer’s disease. Supervisors: Prof.dr. H. Steinbusch; Prof. 
L. Lanfumey, Université Paris Descartes, France. Co-supervisors: Dr. G. Kenis; Dr. D. van 
den Hove.
Patrick Domen. Stay connected: a family-based diffusion imaging study in psychotic 
disorder. Supervisor: Prof.dr. J. van Os. Co-supervisor: Dr. M. Marcelis
Geor Bakker. Innovative Approaches to Understanding the Neurobiology of Psychosis. 
Supervisors: Prof.dr. T. van Amelsfoort; Prof.dr. J. Booij, UvA. Co-supervisor: dr. M. Caan, 
UvA; dr. O. Bloemen.
Wilma Boevink. HEE! Over Herstel, Empowerment en Ervaringsdeskundigheid in de 
psychiatrie. Supervisors: Prof.dr. J. van Os; Prof.dr. Ph. Delespaul. Co-supervisor: dr. H. 
Kroon.
Nataliia Markova . Modified swim test as a mouse depression paradigm of enhanced 
Cognitive processing: the role of GSK3β. Supervisor: Prof.dr. H. Steinbusch; Prof.dr. K-P. 
Lesch, University of Wuerzburg. Co-supervisor: Dr. T. Strekalova.
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Merijn van de Laar. Individual differences in insomnia; implications of Psychological 
factors for diagnosis and treatment. Supervisor: Prof.dr. A. Aldenkamp; Prof.dr. D. Pever-
nagie, Universiteit Gent. Co-supervisor: Dr. S. Overeem, TUE.
Willem Buskermolen. If only I could tell …; Measuring predictors for challenging be-
haviour in people with both intellectual disability and hearing impairment. Supervisor: 
Prof.dr. A. Aldenkamp. Co-supervisor: Dr. J. Hoekman, UL.
Kay Deckers. The role of lifestyle factors in primary prevention of dementia; an epide-
miological perspective. Supervisor: Prof.dr. F. Verhey. Co-supervisor: Dr. M.  van Boxtel; 
Dr.S. Köhler.
Brechje Dandachi-FitzGerald. Symptom validity in clinical assessments. Supervisors: 
Prof.dr. R. Ponds; Prof.dr. F. Verhey.
Maurice Theunissen. Understanding factors affecting postoperative Quality of Life.Su-
pervisors: Prof.dr. M. Peters, Prof.dr. M. Marcus. Co-supervisor: Dr. H. Gramke.
Anna Cleutjens. COgnitive-Pulmonary Disease? Neuropsychological functioning in pa-
tients with COPD. Supervisors: Prof.dr. E. Wouters, Prof.dr. R. Ponds. Co-supervisors: Dr. 
D. Janssen, Horn, Dr. J. Dijkstra.
Laura Serpero. Next Generaton Biomarkers in Perinatal Medicine: S100B Protein. Su-
pervisors: Prof.dr. D. Gazzalo, Alessandria, Italy; Prof.dr. B..W.W. Kramer. Co-supervisor: 
Dr. A.W.D. Gavilanes. 
Alessandro Varrica. S100B Protein and Congential Heart Diseases: Brain Aspects. Su-
pervisors: Prof.dr. D. Gazzalo, Alessandria, Italy; Prof.dr. J.S.H. Vles; Prof.dr. L.J.I. Zimmer-
mann. Co-supervisor: Dr. A.W.D. Gavilanes. 
Pim R.A. Heckman. Targeting phosphodiesterase type 4 for improving cognitive fron-
to-striatal function: a translational approach. Supervisor: Prof.dr. J.G. Ramaekers. 
Co-supervisors: Dr. J.H.H.J.. Prickaerts; Dr. A. Blokland. 
200  |  Epilogue
Sven van Poucke. Platelets, form sample to big data; exploring granularity in platelet 
research. Supervisors: Prof.dr. M.A.E. Marcus; Prof.dr. W. Buhre. Co-supervisor: Dr. M. 
Lancé.
Désirée M.J. Vrijens. Dysfunctions of the Lower Urinary Tract and Affective Symptoms. 
Supervisors: Prof.dr. Ph.E.V. van Kerrebroeck; Prof.dr. G.A. van Koeveringe. Co-supervi-
sors: Dr. C. Leue.
Tamar van Veenendaal. Neurotransmitters & Networks. An MR view on epilepsy and 
antiepileptic drugs. Supervisors: Prof.dr.ir. W.H. Backes; Prof.dr. A.P. Aldenkamp. Co-su-
pervisor: Dr. J.F.A. Jansen.
Evelien M. Barendse. Autism Spectrum Disorders in High functioning Adolescents; Di-
agnostic considerations (AHA). Supervisors: Prof.dr. A.P. Aldenkamp; Prof.dr. R.P.C. Kes-
sels, Radboud University.
Roy Lardenoije. A venture into the epigenetics of aging and Alzheimer’s Disease. Super-
visors: Prof.dr. B.P.F. Rutten; Prof.dr. H.W.M. Steinbusch. Co-supervisors: Dr. D. van den 
Hove; Dr. C.A. Lemere, USA.
Charlotte L. Mentzel. The course recognition and treatment of movement disorders in 
severe mental illness. Supervisors: Prof.dr. P.N. van Harten; Prof.dr. M.A.J. de Koning-Ti-
jssen, UMCG. Co-supervisor: Dr. P.R. Bakker. 
Tim Batink. Third Wave Behaviour Therapy: Process Measures and Contextual Inter-
ventions. Supervisors: Prof.dr. F.P.M.L. Peeters; Prof.dr. J.J. van Os; Prof.dr. M.C. Wichers, 
UMC Groningen. 
Kevin L.J. Rademakers. Detrusor Underactivity: From Theory To Clinical Assessment. 
Supervisors: Prof.dr. G.A. van Koeveringe; Prof.dr. Ph.E.V. van Kerrebroeck. Co-supervi-
sor: Dr. M. Oelke.
Iris M.J. Lange. Should I stay or should I go ? Brain mechanisms underlying fear and 
safety learning, and explosure therapy outcome. Supervisors: Prof.dr. K.R.J. Schruers;-
Prof.dr. T.A.M.J. van Amelsfoort. Co-supervisor: Dr. L. Goossens.
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Ruben G.F. Hendriksen. Evidence for a dystrophin-associated encephalopathy in 
Duchenne Muscular Dystrophy. Supervisor: Prof.dr. J.S.H. Vles. Co-supervisors: Dr. G. 
Hoogland; Dr. M.W. Aalbers, UMC Groningen.
Michael Gofeld. Strengths and limitations of the lumbar spine ultrasound-guided inter-
ventions. Supervisor: Prof.dr. M. van Kleef. Co-supervisor: Dr. M. Sommer.
Willem A.R. Zwaans. Strategies for chronic inguinal pain. Supervisor: Prof.dr. M. van 
Kleef. Co-supervisors: Dr. R.H.M. Roumen; Dr. M.R.M. Scheltinga, MMC Veldhoven.
Linda M. Rolf. Mapping the effects of vitamin D in multiple sclerosis A 3D Perspec-
tive. Supervisor: Prof.dr. R.M.M. Hupperts. Co-supervisors: Dr. J.G.M.C. Damoiseaux; Dr. 
J.J.F.M. Smolders, CWZ Nijmegen. 
Maarten van Beek. Spinal Cord Stimulation in Clinical and Experimental Painful Diabet-
ic Polyneuropathy. Supervisors: Prof.dr. E.A. Joosten; Prof.dr. M. van Kleef. Co-supervi-
sor: Dr. S.M.J. van Kuijk.
Melina Barkhuizen. Genetic and perinatal risk factors for movement disorders. Super-
visors: prof.dr. B.W.W. Kramer, prof.dr. H.W.M. Steinbusch, Prof.dr. A.F. Grobler. Co-super-
visor: dr. A.W.D.Gavilanes-Jimenez.
Renske Uiterwijk. Cognitive function and cerebral small vessel disease in hypertension. 
Supervisor: prof.dr. R.J. van Oostenbrugge. Co-supervisor: Dr. J.E.A. Staals.
Elles Douven. Depression and apathy after stroke. Supervisor: prof.dr. F.R.J. Verhey. 
Co-supervisors: Dr. P. Aalten, dr. J. Staals.
Mauro Pessia. Brain K+ Channels: from molecular and physiological  features to autism 
spectrum disorder and intellectual disability. Supervisors: prof.dr. H.W.M. Steinbusch, 
prof.dr. M.B. Donati, It. 
Carsten Leue. Hyperarousal in the Hospital and what to do about it: the MED-PSYCH-
NET - a transitional network approach fostering personalized care in psychosomatic 
medicine. Supervisors: Prof.dr. J. van Os, Prof.dr. A. Masclee. Co-supervisors: Dr. J. Strik, 
Dr. J. Kruimel
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Andrea S. Herrera Soto. Aminochrome, an endotoxin for inducing a new rat model of 
Parkinson’s Disease. Supervisor: prof.dr. H.W.M. Steinbusch. Co-supervisors: Prof.dr. 
Juan Segura-Aquilar; prof. G. Diaz-Veliz, Santiago of Chile
Eline E.B. de Clerck. Ocular neurodegenerative changes and macular  cysts in prediabe-
tes and type 2 diabetes. Supervisors: Prof.dr. C.A.B. Webers, Prof.dr. C.D.A. Stehouwer. 
Co-supervisor: Dr. J.S.A.G. Schouten
Steven T.H. Honings. Exploring psychosis and multidirectional violence:  a prospective 
study in the general population. Supervisor: Prof.dr. J. van Os. Co-supervisor: Dr. M. 
Drukker
2018
Sau May Wong. Advances in Microvasculair MRI Techniques: Breaking the Pathophys-
iological Barriers in Cerebral Small Vessel Disease. Supervisor: Prof.drir. W.H. Backes, 
Porf.dr. R.J. van Oostenbrugge. Co-supervisor: Dr. J.F.A. Jansen
Mark B.N. van Winkel. Lonely at heart and stressed in company of others; the influ-
ence of daily life social experiences and emotions on depression. Supervisors: prof.dr. F. 
Peeters; prof.dr. I. Myin-Germeys, KU Leuven/UM; prof.dr. M. Wichers, UMC Groningen
Harsha Birur Laxmana Rao. Revisiting the vascular theory of glaucoma using optical 
coherence tomography angiography. Supervisors: prof.dr. C.A.B. Webers; prof.dr. R.N. 
Weinreb, University of California, San Diego
Babette L.R. Reijs. Cognitive correlates of cerebrospinal fluid biomarkers for Alzhei-
mer’s disease. Supervisor: prof.dr. F.R.J. Verhey. Co-supervisors: Dr. P.J. Visser; dr. I.H.G.B. 
Ramakers
Rachel Slangen. Spinal cord stimulation in painful diabetic peripheral Neuropathy. Clin-
ical- and cost-effectiveness. Supervisors: prof.dr. M. van Kleef; Prof.dr. C. Dirksen; prof.
dr. C. Faber
Ganne Chaitanya. Epilepsy: A network disorder. Supervisors: prof.dr. A.P. Aldenkamp; 
prof. P. Satishchandra, NIMHANS, Bangalore, India. Co-supervisors: Dr. J.F.A. Jansen; Dr. 
S. Zinger, TUE
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Sumitha Rajendrarao. New Insight into the Multifaceted Pathogenic Mechanisms of 
Sporadic Amyotrophic Lateral Sclerosis. Supervisors: prof.dr. B.W. Kamer; prof.dr. H.W. 
Steinbusch. Co-supervisor: prof. T.R. Raju, NIMHANS, Bangalore, India
Suzanne Roggeveen. Interference of mobile phone with electrophysiology and emo-
tions; results from short-term experimental studies. Supervisor: Prof.dr. J. van Os. 
Co-supervisor: Dr. R. Lousberg. 
Matthias Walter. Multi-methodological approaches to investigate lower urinary tract 
function in health and disease. Supervisors: Prof.dr. Ph.E.V.A. van Kerrebroek; Prof.dr. 
G.A. van Koeveringe; Prof.dr. A. Curt, Zürich, CH.
Lalit Gupta. Inhomogeneities in spontaneous brain fluctuations. Supervisors: Prof.dr.ir. 
WH. Backes; Prof.dr. P.A.M. Hofman. Co-supervisor: Dr. J.F.A. Jansen.
Chaitra Jayadev. Impact of imaging the pediatric retina. Supervisor: Prof.dr. C.A.B. We-
bers. Co-supervisor: Dr. N.J.C. Bauer; Dr. A. Vinekar. 
Annelie Klippel. Navigating through complexity; processes and mechanisms underlying 
the development of psychosis. Supervisors: Prof.dr. I. Myin-Germeys, KU-Leuven; Prof.
dr. M.C. Wichers, UMC Groningen. Co-supervisor: Dr. U. Reininghaus. 
Kürşat Altinbaş. Reconstructing The Diagnostic Framework of Bipolarity. Supervisor: 
Prof.dr. J. van Os. Co-supervisor: Dr. I.S. Gülöksüz.
Andrea J.R. Balthasar. Eyes of the needle; Spectral tissue sensing, an innovative tech-
nology for detecting various tissue types during percutaneous needle-based proce-
dures in locoregional anesthesia and pain medicine. Supervisor: Prof.dr. M. van Kleef. 
Co-supervisor: Dr. G-J. van Geffen, Radboud UMC Nijmegen.
Walmari Pilz. Shedding light on oropharyngeal dysphagia in myotonic dystrophy type 
1. Supervisor: Prof.dr. B. Kremer. Co-supervisors: Dr. L.W.J. Baijens; Dr. V. Lima Passos.
Nynke J. van den Hoogen. Repetitive painful procedures in the neonate: Treatment and 
adult pain sensitivity. Supervisors: Prof.dr. E.A.J. Joosten, Prof.dr. D. Tibboel, Erasmus 
MC-Sophia, Rotterdam. Co-supervisor: Dr. J. Patijn.
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Carlota Mestres Gonzalvo. Medication optimisation; Methodological aspects and new 
strategies. Supervisors: Prof.dr. F.R.J. Verhey, Prof.dr. P.H.M. van der Kuy, Erasmus MC 
Rotterdam. Co-supervisors: Dr. R. Janknegt, Zuyderland MC.
Carolin Hoffmann. The Brain under Attack: Autoantibodies in Psychotic Disorders. Su-
pervisors: Prof.dr. P. Martinez, Prof.dr. B. Rutten, Prof.dr. J. van Os, UU/UM.
Jindra M. Bakker. On the bumpy road of happiness: Mechanisms of daily life reward 
processing and how it can be changed. Supervisors: Prof.dr. M. Wichers, UMC Gronin-
gen, Prof.dr. I. Myin-Germeys, KU Leuven/UM. Co-supervisor: Dr. L. Goossens. 
